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The commissioning and management of
community drug treatment services for adults
changing
The Audit Commission promotes the best use of
public money by ensuring the proper stewardship of public
finances and by helping those responsible for public services to
achieve economy, efficiency and effectiveness.
The Commission was established in 1983 to appoint and regulate the
external auditors of local authorities in England and Wales. In 1990 its role
was extended to include the NHS. In April 2000, the Commission was given
additional responsibility for carrying out best value inspections of certain
local government services and functions. Today its remit covers more than
13,000 bodies which between them spend nearly £100 billion of public
money annually. The Commission operates independently and derives most
of its income from the fees charged to audited bodies.
Auditors are appointed from District Audit and private accountancy firms
to monitor public expenditure. Auditors were first appointed in the 1840s
to inspect the accounts of authorities administering the Poor Law. Audits
ensured that safeguards were in place against fraud and corruption and
that local rates were being used for the purposes intended. These founding
principles remain as relevant today as they were 150 years ago. 
Public funds need to be used wisely as well as in accordance with the law,
so today’s auditors have to assess expenditure not just for probity and
regularity, but also for value for money. The Commission’s value-for-money
studies examine public services objectively, often from the users’
perspective. Its findings and recommendations are communicated through
a wide range of publications and events.
For more information on the work of the Commission, please contact:
Andrew Foster, Controller, The Audit Commission, 
1 Vincent Square, London SW1P 2PN, Tel: 020 7828 1212
Website: www.audit-commission.gov.uk
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Preface
Drug treatment services exist, above all, to support drug misusers –
helping them to minimise the harm they do to themselves, to reduce their
use of illicit drugs and to rebuild their lives. But tackling drug misuse also
delivers important benefits to the wider community. As drug problems
often fuel crime, social exclusion and anti-social behaviour, effective
treatment services can potentially improve all citizens’ quality of life and
play an important role in wider community renewal and regeneration
strategies.
With growing evidence that a range of treatment interventions ‘work’, the
Government has sought to increase the capacity of drug treatment
services and has allocated new resources to realise this objective.
Changing patterns of drug misuse and recent national initiatives – such as
the establishment of a National Treatment Agency for England and new
arrangements for the delivery of primary care – will also affect how local
services are commissioned and provided. In response to these
developments, the Audit Commission decided to undertake a study that
would review the current provision of community-based drug treatment
services for adults, identify any problems, and suggest how these could be
overcome.
Although the nature and scale of drug misuse varies from area to area,
most localities face the challenge of increasing the scale of treatment
provision and getting best value from existing resources. This report
therefore sets out practical recommendations that will enable drug action
teams (drug and alcohol action teams in Wales), local commissioners and
service providers to review their specialist services and joint
commissioning arrangements. The report also highlights the steps that
should be taken to strengthen the national framework of funding and
policy guidance in order to support local efforts more effectively. 
The study on which this report is based was carried out by Sára Kulay,
David Bird and Charlotte Brown from the Audit Commission’s Public
Services Research Directorate, under the direction of David Browning. A
paper summarising the evidence base for drug treatment prepared by Dr
John Marsden and Dr Michael Farrell at the National Addiction Centre
supplemented this work (Appendix 5). The study team also benefited
enormously from the co-operation of staff in the 11 fieldwork sites visited
and is grateful to all GPs and service users who gave their time to
complete a questionnaire or to be interviewed. An advisory group of
practitioners and other interested parties provided further assistance and
insight (Appendix 3). The conclusions of the report are, however, the
responsibility of the Audit Commission alone.
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Drug Misuse and Dependence
Over the last 40 years, drug misuse has increased and become
more closely associated with social disadvantage. Serious drug
problems can wreck lives, fuel crime and have a high
economic cost. The policy agenda for tackling drug misuse has
developed rapidly in recent years and led to a stronger
emphasis on drug treatment services. Increased levels of
Government investment offer new opportunities to expand
and improve the quality of local services.
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Widespread public concern about illicit drugs in Britain is a relatively
recent phenomenon. The rise of youth culture in the 1950s and 1960s
saw the ‘recreational’ use of drugs such as amphetamines, cannabis and
LSD spread among young people, and the number of young heroin
addicts began to grow, albeit slowly. Since then, the use of a wide range
of illicit drugs has become more common [APPENDIX 2, page 100]. Drug
problems have also increased and become more closely associated with
social disadvantage (Ref.1). Many deprived urban areas experienced a steep
increase in heroin misuse among teenagers and young adults during the
economic downturn in the early 1980s, leading to a sharp rise in the
number of addicts notified to the Home Office Addicts IndexI [EXHIBIT 1].
Further increases in drug-related problems were evident in the 1990s.
Between 1990 and 1996 addict notifications more than doubled and
drug-related deaths increased markedly (Refs.2,3). The number of people
found guilty or cautioned by the police for drug offencesII also rose from
44,922 in 1990 to 120,007 in 1999 (Ref.4).
EXHIBIT 1
Increases in notifications to the
Home Office Addicts Index, 1960 to
1996
Problem drug misuse remained
comparatively rare in the first part of
the 20th century but has grown
significantly over the last forty years.
Source: Home Office Addicts
Index/Corkery (unpublished) (Ref.2)
I From 1968 to April 1997 doctors had a statutory duty to notify the Home Office of patients
who, in their judgement, were addicted to one or more of a number of Class A drugs,
including cocaine, heroin and methadone. The numbers were serious underestimates of the
true position because many addicts did not seek treatment, and many of those who did were
not notified by their doctors.
II Offences involving controlled drugs under the Misuse of Drugs Act 1971 include unlawful
possession, unlawful production, unlawful supply, possession with an intent to supply
unlawfully and permitting premises to be used for unlawful purposes.
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The growth of drug problems has had a profound impact upon
individuals, communities and society as whole. Although many people in
England and Wales have taken drugs experimentally, a small minority has
developed a myriad of health, social and legal problems as a result of
their drug misuse or dependency. The impact of their drug problems often
spreads to local communities who face a rise in anti-social behaviour,
family breakdown and higher levels of crime. Deprived areas usually
suffer most, frequently becoming a focus for drug dealing that can fuel a
cycle of decline and lead to heightened levels of fear and intimidation
among local residents. Policing drug misuse and supporting those affected
by a drug habit also have a high economic cost. Recent Government
estimates put the total bill to the public purse at £3–4 billion in 2001/02
(Ref.5).
Against this backdrop, it is not surprising that combating drug misuse
has become a principal concern of government. The importance of drug
treatment services has also been increasingly recognised, as evidence of
their effectiveness has grown. The National Treatment Outcome Research
studyI (NTORs) tracking over 1,000 drug misusers in treatment in the
UK, for example, calculated a return of £3 due to savings in the criminal
justice system and lower levels of victim costs of crime for every £1 spent
on treatment (Ref.6). Improving the accessibility of drug treatment services
is therefore a crucial element of the Government’s current strategy,
supported by an ambitious target to double the number of drug misusers
in treatment between 1998 and 2008 (Ref.7). Providing effective
community-based drug treatment services is the primary focus of this
report.
Defining drug misuse and dependence
Views differ on how drug misuse should be defined (Ref.8). Some argue
that since the use of any illicit drug may result in harm or even death, the
term ‘misuse’ or ‘abuse’ should always apply. Others choose to distinguish
between ‘use’ and ‘misuse’, often to recognise that a significant number of
people who use drugs in an occasional or recreational context do not
develop drug-related problems. Clinical definitions in turn describe a
variety of distinct disorders related to the misuse of substances, including
intoxication, harmful use, dependence syndrome and withdrawal state.
For example, the World Health Organisation’s International Classification
of Disease (ICD-10) – the most commonly used diagnostic classification
in England – distinguishes between harmful use and dependence
syndrome:
I The National Treatment Outcome Research study is a longitudinal study of 1,075 drug
misusers entering 53 UK treatment services in 1995. The study was established as part of the
effectiveness review commissioned by the Department of Health in 1994.
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The scale and nature
of the problem
Policing drug misuse
and supporting those
affected by a drug
habit also have a high
economic cost.
• Harmful use is defined as a pattern of psychoactive substance use that
is causing damage to health…either physical or mental.
• Dependence syndrome is defined as a cluster of behavioural, cognitive
and physiological phenomena that develop after repeated substance
misuse and that typically include a strong desire to take the drug,
difficulties in controlling its use, persisting in use despite harmful
consequences, a higher priority given to drug use than other activities
and obligations, increased tolerance and sometimes a physical
withdrawal state (Ref.9).
Ongoing debate about terminology and the need for greater specificity
in a clinical setting inevitably mean that a number of different terms
continue to be used to describe drug-taking behaviour. However, for the
purposes of this report, the terms ‘drug use’ and ‘drug misuse’ will be
used throughout, adapted from previous definitions adopted by the
Health Advisory Service (HAS) (Ref.10) and Advisory Council on the
Misuse of Drugs (ACMD) (Ref.11):
• Drug use will be used to describe illegal and illicit drug taking that
does not cause any perceived immediate harm – even though it may
carry some risk of harm, such as health problems.
• Drug misuse will be used to describe illegal and illicit drug taking
which leads a person to experience social, psychological, physical or
legal problems related to intoxication and/or regular excessive
consumption and/or dependence.
Although a number of illicit drugs may lead to harm, drug misuse often
involves the use of opiates, particularly heroin, as well as crack cocaine or
other stimulants, often taken by the same people as a pattern of
‘polydrug’ use.
Estimating the extent of drug misuse
As drug taking is an illicit activity, reliable data on prevalence are
hard to obtain. The results of self-report surveys may be questionable, as
some respondents may not admit to the use of more heavily stigmatised
drugs such as heroin and crack cocaine or conceal their drug taking
because of the punitive legal framework [APPENDIX 4, page 103]. Surveys are
also likely to under-represent drug misusers who are more difficult to
capture, including those with chaotic lifestyles, homeless people and
people resident in institutions. Moreover, studies that simply focus on
lifetime prevalence do not provide useful information about current
behaviour. As a recent report by the Police Foundation recognised: ‘The
important issues are whether people are using drugs regularly, and if so
how often and how recently’ (Ref.12).
6.
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The British Crime SurveyI (BCS) provides the best available guide to
changing patterns of drug use among the adult population in England and
Wales (Ref.13). This shows that in 2000, around a third of adults aged
16–59 had used illicit drugs at some time during their lives, 11 per cent
had used these substances within the past year, and almost 6 per cent
were regular users, defined as any use of these substances within the past
month. The use of ‘any drug’ in the last year remained relatively stable
between 1994 and 2000, though use of any illicit drug among 16–19 year
olds was significantly lower in 2000. While there were significant
increases in the use of both powder and crack cocaine, consumption of
more addictive drugs remains rare: only 1 per cent of the population
reported use of heroin and crack cocaine.
The nature and extent of drug use differs across the population. A
higher proportion of males than females reported drug use, with men
outstripping women by a ratio of three to two. Prevalence is also higher
among unemployed people (though cocaine use has the highest prevalence
among those who are working) and young people [EXHIBIT 2]. Ethnic
comparisons show that drug use is more prevalent among white people
than other ethnic groups. A third of white people reported lifetime use of
any drug in the BCS, compared to 28 per cent among Black respondents,
15 per cent of Indians and 10 per cent of Pakistanis and Bangladeshis.
Variations in drug use by region are also evident [EXHIBIT 3]. London has
consistently higher rates for use of ‘any drug’, cocaine and ecstasy, though
other regions, including the North, South and Midlands, report higher
rates of heroin use (Ref.13).
EXHIBIT 2
Consumption of any drug ever, in
the last year, or last month, by age
group
Drug use declines with age, probably
reflecting changing lifestyle options.
Source: British Crime Survey, 2000
(Ref.13)
I The British Crime Survey is designed to be representative of the population of England and
Wales. The 1994, 1996, 1998 and 2000 surveys all include the same self-report drugs
component, completed by between 9,500 and 13,000 people aged 16 to 59.
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EXHIBIT 3
Regional variations in drug use
among young people
Percentage of respondents aged 16 to
29 using any drugs in the last year and
month by Government Office Region.
Source: British Crime Survey, 2000 (Ref.13)
Estimating the number of people who experience serious problems or
dependence because of their drug use is difficult. Many drug misusers do
not contact local services until late in their drug-using career, and not all
medical practitioners report contacts to the National Drug Treatment
Monitoring SystemI (NDTMS). Attempts to gauge prevalence have
resulted in widely varying estimates. An Office of Population, Censuses
and Surveys (OPCS) national survey of psychiatric morbidity, which
obtained data on levels of dependent drug use in 10,000 adults in the UK
in 1992, estimated that 728,000 individuals were dependent on drugs
(Ref.14). However, a stricter definition of dependenceII or the exclusion of
cannabis could easily have halved this estimate (Ref.15). More recent work,
based on ‘capture-recapture’III research, suggests that there could be
around 266,000 problem drug misusers in Britain – about 0.5 per cent of
the population (Ref.16). Between 161,000 and 169,000 of these are
estimated to have injected drugs.
I The Department of Health’s National Drug Treatment Monitoring System (NDTMS) in England
and Wales collects information on drug misusers who present to treatment services.
II The survey used a broad definition of dependence, including all individuals who reported one
or more of the following over the previous 12 months: needing to use an increasing amount
of the drug over the last 12 months to achieve the desired effect; feeling dependent upon
one or more of the drugs used; having tried unsuccessfully to reduce their level of drug use;
and/or having experienced withdrawal symptoms. The survey covered a range of drugs and
solvents. Some prescribed drugs (such as valium) were included, but alcohol was excluded.
III Capture-recapture methods are based upon identifying the overlap between various statutory
and non-statutory agencies’ samples of drug misusers. The size of the overlap between
samples allows a statistical model to be created in which to estimate the wider drug-using
population (Ref.15).
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Drug misuse and deprivation
Although there is a common assumption that poor social conditions
and poverty exacerbate drug misuse problems, the relationship is far
from straightforward. Drug use per se is clearly not confined to any one
social group or type of neighbourhood. Results from the BCS, for
example, show that the highest levels of drug use tend to be at the two
extremes of the household income scale, and that the lowest prevalence is
in the middle income groups (Ref.13). An analysis of the findings by
residential neighbourhoods in turn reveals uniformly higher levels of drug
use among 16 to 29 year olds living in ‘affluent urban areas’ compared to
other neighbourhoods, including both council estates and low income
areas (Ref.13). The reasons why people develop problematic habits are
equally hard to determine, not least because the causes may be
‘biological, psychological and social and usually interact’ (Ref.8).
More problematic forms of drug misuse do appear to be related to
geographical and individual measures of deprivation (Ref.15). Results from
the BCS show that use of heroin – the drug most frequently associated
with dependency – was notably higher in the lowest income group and
less affluent areas (Ref.13). Several studies in the UK have also identified a
statistically significant relationship between problem drug misuse and
social deprivation, and found deprived areas to have significantly higher
rates of presentation at drug treatment services and drug-related hospital
admissions (Refs.17,18). Certain groups of young people – including those
‘looked after’ by authorities, truants, those excluded from school and
young offenders – are more vulnerable to drug problems. A recent review
of the UK evidence led the ACMD to conclude that: ‘on strong balance
of probability, deprivation is today in Britain likely often to make a
significant causal contribution to the cause, complications and
intractability of damaging kinds of drug misuse’ (Ref.15). A number of
factors may explain this relationship, though causality is difficult to
establish [BOX A].
11.
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More problematic
forms of drug misuse
do appear to be
related to geographical
and individual
measures of
deprivation.
Harms associated with drug misuse
Not all drug misusers are dependent and the severity and nature of an
individual’s problems often change over time. However, for many people,
drug misuse frequently becomes a chronic relapsing condition – recovery
occurs but it is followed at some later point by a reoccurrence of abuse or
dependence. Many also experience major health problems as a result of
their habit. Injecting heroin users face an increased risk of overdose,
respiratory failure and deep vein thrombosis. Mental health problems,
including anxiety and depressive disorders, are also common among some
heavy users, though it may be difficult to establish which came first. Some
of the problems experienced – like the heightened risk of acquiring
Hepatitis B and C and HIV – relate directly to high risk behaviours such
as needle sharing and unsafe sex (Refs.19,20). Heavy crack cocaine use can
lead to problems such as paranoia, weight loss and breathing difficulties
(Ref.21). Recent research based on 288 primary crack cocaine users in a
12.
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BOX A
Drug misuse and deprivation
Source: Adapted from ‘Drug Misuse and the Environment’, Advisory Council on the Misuse of Drugs, 1998 (Ref.15)
The Advisory Council on the Misuse of Drugs identified a number of factors that may explain the link between
drug misuse and deprivation.
Deprivation may weaken family and social bonding and cohesiveness. Those growing up in
these circumstances may be prone to ignore the expectations of a society they have little
attachment to.
Deprivation gives rise to personal distress and psychological discomfort that can lead to
depressive illnesses and mood disturbances. Mind acting drugs (and illicit drugs) can be used as
self-medication to relieve distress or act as a substitute source of excitement and good feelings.
A poor area with high levels of unemployment can provide an environment where drug dealing
becomes established as part of an alternative economy. Where unemployment is high and
young people are without a job-related role or structure, being a dealer or a drug taker can
confer status and/or provide a meaningful occupation.
Deprivation may make spontaneous or post-treatment recovery more difficult. Lack of access to
positive alternatives may provide little incentive to cease use.
Deprived areas may find it more difficult to deal with drug problems at community level.
Equally, a potentially vulnerable community may be deliberately targeted by drug dealers. In
such circumstances, an initially low prevalence drug problem will easily spread and become
endemic.
crisis intervention service found that 64 per cent had experienced suicidal
thoughts and 37 per cent had attempted suicide (Ref.21).
Poor health inevitably leads to high levels of contact with casualty
and general medical services. NTORs found that, in the two years prior
to starting the NTORs treatment episode, almost half the drug misusers
in their cohort had received treatment in an accident and emergency
department and a quarter had been admitted to a general hospital bed
(Ref.6). The study of crack misusers in a crisis intervention service found
that 30 per cent had previous contact with a statutory mental health
service. High levels of morbidity and chance of overdose increase the risk
of premature death among heroin users. A long-term follow-up study of
dependent heroin misusers recently estimated that the sample had a
twelvefold increased risk of mortality compared to the general
population (Ref.22). 
As the severity of drug misuse increases, many people struggle to hold
down jobs. They report difficulties in their personal relationships with
family and friends and face legal and financial problems. The high cost of
consumption on a regular basis also means that some users rely on
criminal activity to fund their habit. NTORs reported high rates of
criminal behaviour among their sample of drug misusers, with 61 per
cent reporting 70,728 separate crimes during the three months prior to
entering treatment (Ref.6) – an average of about one crime a day each.
Although shoplifting was the most commonly reported offence, more
serious crimes such as burglary and robbery were reported by 12 per cent
and 5 per cent. Recent research among 506 people arrested found that 69
per cent tested positive for drugs, of whom 29 per cent tested positive for
opiates (including heroin) and 20 per cent for cocaine (including crack)
(Ref.23). The relationship between drugs and crime is also manifest in the
prison population, with a recent survey finding that 51 per cent of male
remands and 54 per cent of female remands reported drug dependency
(Ref.24).
14.
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The high cost of
consumption...also
means that some users
rely on criminal
activity to fund their
habit.
The policy agenda for addressing drug misuse problems has been
developing rapidly in recent years and has led to stronger emphasis on
drug treatment services [BOX B, overleaf]. The Government has given a high
profile to its plans to tackle drug misuse, supported by the publication of
a ten-year strategy in 1998. At the local level, drug action teams (DATs)
in England and drug and alcohol action teams (DAATs) in WalesI are
responsible for ensuring co-ordination between key agencies and assessing
whether local spending plans and initiatives are aligned to key
Government targets on drugs. The teams are expected to include senior
representatives from local authorities, health authorities, the police, and
the prison and probation services. From April 2001, DAT boundaries in
England became coterminous with those of local authoritiesII to ensure
more effective co-ordination with services such as housing, social services
and education. Welsh DAATs are based on the five current Welsh health
authority boundaries.
I In Wales, there has been a long-standing policy of including alcohol within the substance
misuse strategy and Welsh DAATs address both drug and alcohol issues. A significant
proportion of DATs in England also address alcohol issues. For the purpose of this document,
the term DAT includes teams that address either drug or drug and alcohol issues.
II DAT boundaries are based on either county shire, unitary, metropolitan district or, in the case
of London, borough boundaries.
15.
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Recent
developments in
policy and practice
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BOX B
Some recent key developments in policy and practice
1995
The Government’s White Paper
Tackling Drugs Together set out
plans to tackle drug misuse over a
three-year period (Ref.25). Multi-
agency drug action teams (DATs)
were established at a local level
with the remit of taking an
overview of drugs-related issues,
co-ordinating service planning and
delivery and developing local action
plans. 
1996
The Welsh Office published Forward
Together, a substance misuse
strategy to combat drug and alcohol
misuse in Wales (Ref.26). Drug and
alcohol action teams (DAATs) were
established at a local level.
The National Treatment Outcome
Research study (NTORs) tracking
drug misusers in treatment reported
interim results showing substantial
reductions in the quantity and
frequency of drug misuse and
criminal behaviour (Ref.27).
The Task Force to Review Services
for Drug Misusers set up by the
Department of Health reported that
there was clear evidence that
treatment – embracing social care
and support as well as clinical
interventions – can be effective in
reducing harm to individuals and
society (Ref.8).
1997
The Department of Health issued
guidance for health authorities and
social services on the purchasing of
effective treatment and care for
drug misusers in England (Ref.28).
The Welsh Drug and Alcohol Unit
(WDAU) issued guidance on
purchasing treatment to Welsh
health authorities and social services
departments (Ref.29). Separate
guidance was also produced for
service providers managing drug
and alcohol services in Wales (Ref.30).
1998
The White Paper Tackling Drugs to
Build A Better Britain published in
May 1998 set out the Government’s
ten-year strategy for tackling drug
misuse (Ref.31). A key target aimed to
increase participation of drug
misusers in treatment by 66 per cent
by 2005 and by 100 per cent by
2008.
The Government allocated an extra
£217 million to tackle drug
problems, spread over three years.
The funding included new monies
for treatment services and
earmarked some funds to support
the expansion of schemes for drug
misusing offenders.
Drug services were identified for the
first time in NHS Priorities and
Planning Guidance.
A new Prison Service Drug Strategy
was published, giving a commitment
to set up a drug treatment service
framework and develop
rehabilitation programmes (Ref.32).
The Advisory Council on the Misuse
of Drugs (ACMD) report Drug
Misuse and the Environment
concluded that deprivation made a
significant causal contribution to the
cause and intractability of damaging
kinds of drug misuse (Ref.15).
1999
The Department of Health published
new guidelines on the clinical
management of drug misuse and
dependence (Ref.33).
New commissioning standards for
drug and alcohol treatment and
care were published by the
Substance Misuse Advisory Service
(SMAS) (Ref.34).
Drugscope and Alcohol Concern
published a joint publication,
Quality in Alcohol and Drug
Services, setting out quality
standards for alcohol and drug
treatment services (Ref.35).
In Wales, £4.5 million was made
available over three years, as part of
a package of measures included in a
Social Inclusion Fund, to support
drug and alcohol treatment services
and improve access to treatment.
2000
The National Assembly for Wales
published Tackling Substance Misuse
in Wales: A Partnership Approach, a
ten-year strategy covering the full
range of substances that are
misused in Wales, including alcohol
and over-the-counter drugs, and
volatile substances, such as solvents
and glue (Ref.36).
The Government’s Spending Review
announced a further £167 million
for drug treatment, spread over
three years.
The ACMD report on reducing drug
related deaths was published in
June 2000. The report covered areas
such as prescribing, drug services,
surveillance and Hepatitis C. An
action plan to monitor and reduce
drug-related deaths will follow
(Ref.3).
The changing organisation of primary care will also affect the
commissioning and delivery of drug treatment services. The formation of
Primary Care Trusts (PCTs) in England will be completed by April 2002,
and in some areas PCTs will assume responsibility for commissioning
drug treatment services. In others, this function may rest with Strategic
Health Authorities.I In Wales, local health groups (LHGs) will
commission drug treatment services. New initiatives such as the
introduction of salaried options for GPs in England, Local Development
Schemes, GP commissioning pilots, the NHS Act 1999,II the Health and
Social Care Act 2001,III and nurse prescribing also offer new ways of
delivering and managing drug treatment services.
I Around 30 Strategic Health Authorities will be established from 1 April 2002. These replace
the 95 existing health authorities in England, which will be abolished.
II The NHS Act 1999 allows pooled funds, ‘lead commissioning’ and integrated provision.
III The Health and Social Care Act 2001 contains clauses to introduce care trusts, which were
first proposed in the NHS Plan (Ref.42), and which will provide integrated health and social
care within one agency.
16.
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The United Kingdom Anti-Drugs
Co-ordination Unit issued guidance
on pooled treatment budgets to
DATs (Ref.37). In England, DATs are
required to prepare annual
Treatment Plans indicating how
money will be spent locally.
2001
A new National Treatment Agency
(NTA) for England was established
in April 2001. Set up as a special
health authority, the NTA will play a
lead role in setting and monitoring
drug treatment standards and
oversee a pooled national treatment
budget.
The Government announced an
extra £300 million to support their
Communities Against Drugs
strategy, spread over three years,
and issued a circular setting out
how these monies were to be used
(Ref.38). £15 million will be made
available to DATs to increase their
involvement with local communities.
The Department for Work and
Pensions allocated £40 million,
spread over three years, to help
drug misusers find employment in
31 pathfinder areas in England and
Wales.
Occupational and functional maps
of the drugs and alcohol sector
were developed by the National
Training Organisation, Healthwork
UK, the Qualifications and
Curriculum Authority and DoH
(Ref.39). These will form the basis for
new National Occupational
Standards for specialist drug and
alcohol workers to be developed by
2002.
A new Drugs Strategy Directorate
based at the Home Office assumed
responsibility for the previous UK
Anti-Drugs Co-ordination Unit. It is
now responsible for ensuring the
delivery of all aspects of the drugs
strategy in cooperation with other
Government departments and key
agencies.
A White Paper on police reform,
Policing a New Century, outlines
plans to bring together the work of
DATs and Crime and Disorder
Reduction Partnerships (CDRPs)
(Ref.40).
2002
A Models of Care project
commissioned by the Department of
Health will set out guidance on the
co-ordination of treatment and
effective care management across
substance misuse treatment services.
Costs and resources 
In 1998, the Government’s Comprehensive Spending Review (CSR)
estimated that around £3.5 billion pounds would be spent on the direct
and indirect costs of drug misuse in 2001/02, channelled through a large
number of Government departments [EXHIBIT 4]. Criminal justice system
costs, covering police, prosecution, prisons and the courts, and social
security payments to drug misusers who cannot work, account for a
significant proportion of the total expenditure. The amount of money
spent on interventions to reduce drug problems in the first place – notably
treatment, education and prevention initiatives – is relatively small,
accounting for less than 20 per cent of the total sum. A key objective of
the Government’s strategy is to reduce the amount of money spent
addressing the consequences of drugs and direct more resources towards
interventions that tackle the causes of drug problems.
The Government has allocated new resources to support the
introduction of the strategy. Following the Comprehensive Spending
Review in 1998, an additional £217 million was invested in the national
drugs strategy, spread over three years (Ref.41). Further spending plans for
the new Drug Treatment Budget and other anti-drug programmes were
published in July 2000 following HM Treasury Spending Review 2000.
There have been two main criteria for the allocation of resources –
evidence of effectiveness and unmet need. As a result, investment in
research and information, initiatives targeted at specific ‘at risk’ groups
and drug treatment, has been prioritised. Investment in treatment will
increase from £234m in 2000/01 to £401m in 2003/04 (Ref.41).
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The amount of money
spent on interventions
to reduce drug
problems in the first
place...is relatively
small...
EXHIBIT 4
Government anti-drugs expenditure
In 1998, the Government estimated that around £3.5 billion a year would be spent on the direct and indirect costs of drugs
in 2001/02. Of this expenditure, 80 per cent is classed as reactive – dealing with the consequences of drug misuse.
Source: Comprehensive Spending Review, 1998
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In view of the rapidly developing policy agenda, higher levels of
financial investment and growing emphasis on providing timely and
appropriate support to people with drug misuse problems, effective drug
treatment services are necessary at a local level. To this end, the Audit
Commission has carried out a study of adult treatment services in 11
areas of England and Wales, based on DAT boundaries in England and
DAAT boundaries in Wales. The report covers specialist community-based
drug services provided by NHS trusts, social services departments and the
independent sector. It also looks at the role that general practitioners play
in supporting drug misusers, often by prescribing substitute drugs in
partnership with a specialist service.
In addition to interviewing a wide range of staff, various techniques
were used to collect data and provide comparative information
[BOX C]. The study found wide variation in the availability of different
services, working practices within services and how effectively local
agencies worked together. Weak commissioning practices and the absence
of management information and effective performance monitoring
arrangements often contributed to the problems identified. In many cases,
it was evident that people with drug misuse problems often struggle to get
the help that they need, when they need it. The study describes how all
agencies providing care and support need to work together to:
• strengthen partnership working and commissioning;
• review the quality and range of service provision;
• promote better care co-ordination and joint working; 
• develop more flexible approaches to attract and support a wider
range of drug misusers; and
• improve support to primary care.
Chapter Two outlines the historical development of drug treatment
services, the current role and structure of community-based drug
treatment services, and the features of effective drug treatment. Chapter
Three explores how services currently respond to need and where and
why problems arise. Chapter Four looks at possible ways forward that
could help to improve the quality and delivery of local services at a local
level. It also considers the steps that the new National Treatment Agency
and other Government departments could take to promote improvements
in policy and practice.
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BOX C
Techniques used in this study
Resource mapping: This was a summary of all the funding available for
community-based drug treatment services, inpatient provision and
residential services from health authorities, social services, police, probation
and, where appropriate, Primary Care Trusts. Information about levels of
activity and sources and level of funding was also collected directly from
community-based services in both the statutory and independent sectors.
Case file analysis: This covered 52 individuals who had been referred to
community drug services 12 months earlier. It looked at assessments carried
out, the range of professions and agencies involved and the actions taken
to ensure effective care management and throughcare. In total, 52 files
were examined in 6 different service providers.
GP survey: This gauged GPs’ attitudes to working with illicit opiate
misusers, their views about local drug treatment services and the training
and support they received. The survey was sent to all GPs (3,653) in 10 study
sites. It was based on a national survey undertaken by the National
Addiction Centre. 1,574 GPs responded to the survey – a response rate of 43
per cent.
User research: One-to-one interviews were held with 18 drugs misusers to
gain qualitative information about their experiences of seeking and
receiving help and views of local services. Individuals were contacted
through independent community-based services. Three focus groups were
also run. The groups included clients recruited from both residential and
community-based services.
2
Drug Treatment Services
The current pattern of drug treatment services is complex and
variable, reflecting both uneven growth and different
philosophies of care. Although there are many gaps in
understanding what sort of treatment works best for whom
and why, there is growing evidence that a range of treatment
interventions reduce drug misuse and the criminal activity and
health risks associated with it. But failure to apply accepted
good practice can reduce the chance of a successful outcome.
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As the number of drug misusers has increased, a range of services and
agencies has evolved to meet their needs. These aim:
• to reduce the harm which individuals cause to themselves, and others,
including family and society;
• to stabilise and reduce the consumption of illicit drugs with the aim,
where appropriate and possible, of achieving abstinence; and
• to rehabilitate the misuser into society (Ref.5).
The current pattern of service is complex and highly variable. The
type of support available ranges from less intensive harm minimisation
interventions, such as needle exchange schemes and information and
advice, through to more structured community-based and specialist
residential programmes. This report defines all these services as ‘drug
treatment services’. This chapter explores:
• the historical development of drug treatment services;
• the structure of drug treatment services; and 
• the features of effective treatment. 
Until the 1960s, there were no specialist drug treatment services in the
UK. Since then, a range of specialist services has developed and some GPs
have continued to provide support in a primary care setting
[EXHIBIT 5, overleaf]. Shifting political concerns and priorities have prompted
different waves of service development. The growth of Drug Dependency
Units (DDUs), for example, was a response to both the increasing
numbers of drug misusers and concerns over the illicit trade of prescribed
drugs among a few London doctors (Ref.43). The development of harm
minimisation approaches, such as needle exchange schemes, was in turn
driven by a recognition that HIV could be spread from one injecting drug
user to another and further in to the wider community. This led to a
stronger emphasis on attracting injecting drug misusers who were not
engaged in treatment (Ref.44). Most recent service developments view
treatment as a way of breaking the link between drug misuse and crime,
reflecting the Government’s emphasis on crime reduction [BOX D, overleaf].
Contrasting approaches to the care of drug misusers are also evident,
often reflecting different views about how people can best be treated.
Many DDUs, for example, initially placed a strong emphasis on a medical
model of care, focusing largely on the health needs of drug misusers. In
contrast, Community Drug Teams (CDTs) attempted to promote a more
‘integrated’ approach (Ref.45), viewing drug misuse in a more social context
and seeking to enlist the support of generic services, including housing,
social services, GPs and criminal justice agencies. The service objectives of
different providers also vary. While most residential programmes and
self-help networks, such as Narcotics Anonymous, view abstinence from
drugs as the key objective, many community-based services recognise
‘intermediate’ goals, such as reductions in the sharing of equipment or
criminal behaviour, as equally valid (though abstinence often remains the
ultimate objective).
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The historical
development of
drug treatment
services – uneven
growth, different
philosophies of
care
EXHIBIT 5
Key developments in drug treatment provision
Specialist drug treatment services emerged in the 1960s, alongside primary care provision.
Source: Audit Commission
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The role that GPs play in treating drug misusers has changed over
time. Before specialist services were established, they prescribed drugs –
mainly heroin and cocaine – to those who could not be withdrawn
completely.I This role diminished as specialist services were established,
but both the Department of Health and the ACMD have increasingly
encouraged GPs to work with drug misusers and to participate in ‘shared
care’ schemes. These are schemes defined by the Department of Health as
‘the joint participation of specialists and GPs in the planned delivery of
care for patients with a drug misuse problem, informed by enhanced
information exchange, beyond routine discharge and referral letters’
(Ref.33).
I The practice of maintaining addicts on maintenance doses, often over a fairly lengthy period,
was known as ‘the British system’.
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BOX D
Criminal justice drug treatment initiatives
A number of initiatives have been
developed to extend drug treatment
to those committing drug-related
crime:
• Arrest referral schemes: are
commissioned by the police and
aim to encourage arrestees who
are problem drug misusers to
seek treatment. Arrest referral
workers based in police custody
suites refer people to
appropriate treatment services.
The national strategy aims to
achieve schemes in all areas by
2002 (Ref.46).
• Drug treatment and testing
orders (DTTOs): are designed to
break the cycle of reoffending
through rehabilitation.
Offenders convicted of an
imprisonable offence, and
deemed suitable for an order,
are given a community
sentence, provided they agree
to attend a drug treatment
course for a minimum of 20
hours per week for between 6
months and 3 years, and to
undergo regular drug testing.
Courts regularly review
offenders’ progress. It was
estimated that 3,425 orders
would be made by 2001 (Ref. 47).
• Drug abstinence orders (DAOs):
Under a new pilot scheme in
Hackney, Nottingham and
Staffordshire, courts are able to
impose a new community
sentence, the Drug Abstinence
Order, and attach a Drug
Abstinence Requirement (DAR)
to existing sentences. New drug
testing powers allow persons
aged 18 and over who have
been charged with a range of
trigger offences, as well as those
under probation supervision, to
be tested for specific Class A
drugs, to identify those misusing
drugs and to monitor their
progress. Prisoners who are
released can also have a
condition inserted into their
licence requiring them to be
drug-tested by the probation
service.
• CARATs: every prison in England
and Wales now provides
counselling, assessment, referral,
advice and throughcare
(CARATs) for prisoners. By 2002,
the Government aims to
increase the CARATs caseload to
20,000, to establish 30 new
prison-based rehabilitation
programmes and put 5,000
prisoners a year through
treatment programmes (Ref.46).
The absence of any agreed service model for drug treatment provision
and variations in the scale and pattern of drug misuse from area to area
mean that different localities have evolved different combinations of
services, often including both independent and statutory provision.
Similar services may offer different types of treatment. Some street
agencies focus solely on drop-in services and information and advice,
whereas others also offer structured interventions such as daycare and
counselling programmes. The range of support offered by different types
of services, such as community drug teams and street agencies, often
overlaps [EXHIBIT 6].
Community-based drug services
A community drug service or ‘addictions service’ is usually provided
by a local NHS Trust and may offer a range of support, including:
• general healthcare;
• counselling;
• alternative or complementary therapies;
• substitute prescribing, usually oral methadone for opiate dependent
drug users;
• detoxification – as an inpatient and in the community;
• structured day care programmes; and
• relapse prevention programmes.
Each of the 11 areas visited in this study offered access to a
community drug team (CDT) or ‘addictions service’, with some having as
many as three separate services in their area. While most of these services
were based in NHS Trusts, this was not universal. In one site, the health
authority had commissioned an independent agency to provide drug
treatment services. In another, a small social services substance misuse
team had evolved into the main specialist service and was now
commissioned by the health authority to provide a city-wide service. In
both cases, medical staff were based within the teams. Out of the 16
CDTs covering DAT areas, 11 provided services for people with alcohol
problems as well as drug problems. Around two-thirds of CDT
expenditure in study sites was met by local health authorities.
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The current
structure of
community-based
drug treatment
services
...different localities
have evolved different
combinations of
services, often
including both
independent and
statutory provision.
EXHIBIT 6
Different types of drug treatment interventions
Most interventions are provided by the NHS and the independent sector.
Source: Audit Commission
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Street agencies often operate alongside CDTs and tend to offer low
threshold, open access interventions, including drop-in services,
information and advice, needle exchange services, counselling and support
for the family and friends of drug misusers. These are generally run by the
independent sector and have traditionally played an important role at the
‘front line’ in engaging drug misusers who are beginning to have major
problems but who may not yet be ready to commit to more structured
forms of treatment. They also have a key role in developing new
approaches to emerging drug problems and are an important source of
onward referral to other specialist treatment services.
In most cases, a rich mixture of funds is involved in supporting
individual street agencies: charitable contributions are mixed with
resources from local authorities and health authorities and funds from the
Single Regeneration Budget (SRB), National Lottery and European
funding schemes [EXHIBIT 7]. Many agencies have expanded in recent years
after securing new funding. The total funding across the 22 street agencies
covered by the Audit Commission study sites increased from around £5.8
million to £7 million between 1998/99 and 2000/01 – with an average
funding increase of £52k. Additional resources had sometimes resulted in
significant growth in the numbers employed; in one agency the number of
staff employed had tripled in the last two years.
EXHIBIT 7
Funding sources for street agencies (2000/01)
Street agencies are funded by a wide variety of bodies, although around two-thirds of their budget is derived from health
authorities and local authorities.
Source: Audit Commission data returns from 22 agencies in 11 study sites
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The role of GPs and primary care
GPs and primary care staff can play an important role in supporting
drug misusers in the community. GP surgeries are often the first port of
call for help. One survey of drug misusers found that 70 per cent of
respondents who had contacted a service had first sought help from a GP
(Ref.48). GPs can give information and advice as well as providing a
number of services including general medical services, substitute
prescribing, such as methadone, and guidance on harm reduction. Some
GPs also work with specialist services in shared care schemes. These
arrangements allow specialist treatment services to focus on more
challenging clients and to use their resources more effectively. Many drug
misusers also prefer to receive treatment through their GPs, often because
it offers them a more accessible service and easier access to medical
support, without the stigma of going to a specialist service (Ref.33).
Detoxification services
Detoxification services offer drug misusers help to eliminate physical
dependence safely and provide support during withdrawal. Detoxification
can be carried out on a supervised basis in a number of settings:I
• as an outpatient or a day patient at either a general practice, street
agency or community drug service (usually known as ‘community
detoxification’);
• as a patient in hospital; and
• in a residential rehabilitation unit or crisis intervention service.
The Department of Health effectiveness review suggested that choice
of setting should usually depend on the degree of motivation and
preferences of the patient, the severity of dependence, the degree of
multiple drug use, accompanying medical and psychological problems, as
well as the accessibility of local services (Ref.8). Where people have
relatively uncomplicated needs, they can usually be detoxified at home or
in an outpatient setting so long as professional support is available. Those
with a long history of addiction, or high levels of pre-treatment needs, or
previous unsuccessful attempts at community detoxification, may require
admission to an inpatient or residential setting (Ref.8).
I Some drug misusers may also try to detoxify themselves at home without medical supervision,
usually by reducing their dose over a period of time.
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GP surgeries are often
the first port of call
for help.
Social services department substance misuse
services 
Local authority social services departments have a statutory duty to
assess the community care needs of drug misusers and, where
appropriate, purchase services on their behalf.I These may include
placements in residential rehabilitation services or structured daycare
programmes. Different authorities have established different
organisational arrangements to meet these responsibilities. Across the
study sites, some social services departments had established substance
misuse teams of between 5 and 20 staff, while others had rested
responsibility with a single social worker, often based in a specialist
mental health team. In two sites, the authority had formal arrangements
with an independent provider to undertake assessments on their behalf.
Other services participating in treatment
A wide range of generic services come into contact with drug
misusers, including accident and emergency departments, maternity
services, mental health services and pharmacists. Many of these services
can be a major source of referrals to specialist drug agencies. Increasingly,
criminal justice services also play an important role both in referring drug
misusers into treatment and providing treatment programmes themselves,
usually in partnership with specialist treatment services.
Numbers in contact with treatment services
Recent figures estimate that in 2000/01 around 128,000 drug misusers
were in contact with treatment services in England and Wales, with the
majority attending community-based drug servicesII [EXHIBIT 8]. About one-
third of those reported were under 25 years of age. Routine data from the
Regional Drug Misuse Databases for the period ending September 2000
show that in both England and Wales the ratio of males to females
presenting to drug services was three to one (Ref.49). The proportion of
people presenting for treatment by main drug of use varies across England
and Wales. Heroin is the main drug of use for 64 per cent of clients in
England, compared with only 45 per cent in Wales. Welsh services report
larger proportions of users presenting with cannabis, amphetamines or
benzodiazepines as their main drug of misuse [EXHIBIT 9].
I Prior to the NHS and Community Care Act 1990 the costs of financing residential placements
were often met by central government through social security payments.
II Three sources of information were used to provide an estimate of the number of drug
misusers in contact with treatment services: censuses carried out of all drug misusers in
treatment in England and Wales during April to September 2000 (Refs. 50, 51), and routine
data from the Regional Drug Misuse Databases (RDMDs) for users presenting for treatment
during the period October 2000 to March 2001. As reporting to the database is voluntary
and some types of agencies are excluded (needle exchange schemes, social services, street
outreach work), the figures underestimate those in treatment. It is also likely that community-
based specialist services reported more completely than other groups – GP and residential
service returns are probably far less complete.
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EXHIBIT 8
Percentage of drug misusers in
contact with drug agencies by type
of service, 2000/01
The majority of users reported by the
census (86 per cent) were attending
community-based specialist services.
Source: Department of Health, Statistics
from the Regional Drug Misuse Databases
on drug misusers in treatment in England,
2000/01, Statistical Bulletin 2001/33
(Ref.51) Information from the Baseline
Census, Welsh Drug and Alcohol Unit,
2001 (Ref.52)
EXHIBIT 9
Main drug of misuse for users
starting agency episodes in the
period ending 30 September 2000,
in England and Wales
The proportion of clients presenting to
drug agencies with heroin as their main
drug of misuse is higher
in England than in Wales.
Source: Department of Health, Statistics
from the Regional Drug Misuse Databases
for six months ending September 2000.
London: Department of Health, Statistical
Bulletin 2001/18 (Ref.49)
Over the last twenty years, research has demonstrated that a wide
range of treatment interventions are effective in reducing drug use and the
criminal activity and health risks that are often associated with it
[APPENDIX 5, page 105]. NTORs reported improvements in the reduction in
drug taking and in the physical and psychological health of many clients
after one yearI (Ref.6). Abstinence rates for illicit opiate use increased from
22 per cent to 50 per cent in residential settings and from 5 per cent to 22
per cent in community settings. Significant reductions were recorded in
injecting, sharing of equipment and frequency of drug use. Self-reported
criminal activity also fell markedly. Shoplifting crimes fell by 67 per cent
and burglary came down by 77 per cent. Improvements in drug use were
largely maintained 4/5 years after treatment,II with 47 per cent of
residential clients and 35 per cent of those treated in community settings
reporting abstinence from illicit opiate use (Ref.52).
Despite research such as this, there are still many gaps in
understanding what interventions work best for whom, and why. This is
largely because the outcome of treatment for any one individual is
affected by their personal circumstances and motivation, as well as the
severity of their problem. Some drug misusers may respond to a brief
community-based intervention, such as a programme of counselling;
others may require more intensive long-term treatment. Some people may
be fully committed to achieving abstinence from all drugs from the start
of treatment, while others may initially only be prepared to make more
limited behavioural changes. The intervention and approach that works
for one person will not necessarily work for another. 
Nevertheless, some agencies are achieving better treatment gains than
others. For example, the NTORs study found wide variations in the
degree of improvement shown by clients receiving the same intervention
at different agencies. Clients in the ‘best’ performing agencies showed
reductions in heroin use which were three times greater than those of the
‘worst’ performing agencies (Ref.6). This may in part reflect a failure to
apply accepted good practice. Although the evidence base for some types
of intervention is weak, there is an emerging consensus about the factors
most likely to lead to positive treatment outcomes [BOX E].
Using these factors as a starting point, the following chapter explores
how well treatment services meet the needs of problem drug users.
I The study follows the progress of 1,075 clients (the majority of whom have been opiate
dependent for many years) in treatment, in both residential and community settings. The
community approaches are: methadone maintenance and methadone reduction programmes,
largely with a harm reduction philosophy. The residential treatments are abstinence-based,
specialist inpatient and rehabilitation programmes. One-year follow-up results were based on
interviews with 769 clients (72 per cent of the sample).
II A randomly stratified sample of 650 clients (drawn from 894 clients who the research team
had contacted during the first year of the study) were tracked at 2 and 4/5 year follow-up
points. Results at 4/5 year follow-up are based upon interviews with 496 clients from the
reduced sample (76 per cent).
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What is effective
drug treatment?
...some agencies are
achieving better
treatment gains than
others.
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BOX E
Factors promoting effective treatment
Research evidence suggests that a number of factors contribute to
successful treatment outcomes:
Rapid access – Many drug misusers present to treatment services in crisis
when they are extremely vulnerable. However, as they can quickly lose
motivation to address their problems, services need to get clients into
treatment without delay (Ref.8).
Systematic assessment and treatment matching – Treatment interventions
must be carefully matched to the needs of individual clients. It is
impossible to conclude that a drug misuser who improved in a residential
setting would necessarily have made the same gains in a community-based
programme (Ref.6). Good assessment procedures and access to a balanced
range of treatment interventions are essential to ensure an optimum
match between a client’s needs, treatment settings and interventions.
A comprehensive approach to care management – In most cases,
pharmacological interventions alone will not help to break a pattern of
drug dependency. Drug problems are often closely associated with many
other problems such as unemployment, family breakdown and crime.
Although there is limited evidence in this area, the Department of Health
effectiveness review concluded that failure to address wider life context
issues ‘may slow down or reverse progress in addressing drug misuse itself’
(Ref.8). This underlines the need for a comprehensive care management
approach that attends to the individual’s multiple needs.
Retention – Keeping drug misusers in treatment has been shown to
increase their chances of success. NTORs found that clients in short-stay
residential programmes who remained in treatment for 28 days, and those
who remained in long-stay residential rehabilitation programmes for 90
days, achieved better outcomes than those who stayed for shorter periods
(Ref.53). A number of factors contribute to poor retention, including
prolonged assessment procedures, inflexible approaches to dosage policy
in methadone programmes, the lack of ancillary services (such as
counselling, legal support and general medical services) and poor rapport
between clients and programme counsellors (Refs.54,55,56,57). Conversely,
delivering treatment within a positive and supportive environment
encourages people to stay in treatment.
Co-ordination – The complex nature of drug dependency means a client
may require varying combinations of services and treatment interventions
during the course of treatment and recovery. In practice, this may involve
a wide range of specialist treatment services and generic services working
together to support individual clients. Close interagency co-operation and
an effective system of care management are crucial, in order to prevent
clients falling between services, to avoid the duplication or omission of
interventions and to ensure continuity of care.
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Problems with Drug Treatment
Services
Drug misusers need rapid access to treatment, with support
carefully matched to their individual needs. But many drug
misusers struggle to get timely and appropriate help.
A picture emerges of limited treatment options, lengthy
delays and under-developed care management that allows
too many people to ‘fall through the net’. Some of the
problems stem from constrained resources, but poor service
planning, different views about ‘what works’ and poor
collaboration between treatment services, GPs, mental health
services and prisons do not help.
The complex nature of drug misuse and dependency means that drug
misusers often require different combinations of treatment interventions
over time and need to be supported along a ‘treatment pathway’. Many
also have multiple needs. Some have a mental health or an alcohol
problem and a proportion have difficulties with their social networks and
accommodation. This means that treatment options and support must be
carefully matched to different needs. It is crucial that different treatment
services are effectively co-ordinated and appropriate support marshalled
from a wide range of other agencies, such as housing and mental health
services.
This chapter examines how well drug treatment services respond to
these challenges at a local level. While Audit Commission fieldwork
identified a number of innovative and effective approaches, it also found
a common set of problems that can reduce the scope and quality of care
for individual clients. These include:
• Difficulties accessing drug treatment. Weak assessment procedures,
the uneven availability of treatment services and lengthy delays often
make it hard for drug misusers to get the help they need.
• Care often fails to meet individual needs. Some clients receive a poor
service because their care is not well managed and different treatment
interventions are poorly co-ordinated. Joint working arrangements are
underdeveloped.
• Weaknesses in commissioning and resource allocation. Poor service
planning, low levels of commissioning expertise and the funding
framework make it difficult to improve current performance and to
ensure that local provision is ‘fit for purpose’.
Multiple referral routes, unco-ordinated
assessment
In most areas, there are many routes into treatment and lots of
professionals involved in making onward referrals to specialist treatment
services. People can usually refer themselves to street agencies, community
drug services and social services departments or visit their GP. Each of
these agencies may either provide or arrange a treatment intervention
directly or make an onward referral to another service better placed to
meet people’s needs. Potentially, this type of multiple entry system can
allow rapid access to services and afford people a degree of choice over
the type of agency they approach. However, to operate effectively,
systematic screening and assessment systems need to be in place to ensure
a client is placed with the most suitable provider, irrespective of their
point of entry.
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Difficulties
accessing drug
treatment
But current assessment practices often do little to secure either rapid
access or appropriate treatment. Multiple assessment is common, as few
areas have developed a common screening and assessment framework or
arrangements for passing information between providers. This not only
leads to increased costs and delays but also means that many clients face
unnecessary repetition of a lengthy, and often personally distressing,
process. In many cases, assessments are undertaken by a single member of
staff and may be focused narrowly on a client’s suitability for one specific
intervention – such as maintenance prescribing or residential
rehabilitation [EXHIBIT 10]. This means that the client’s options may be
limited by the personal preferences or treatment philosophy of the
individual undertaking the assessment and/or the eligibility criteria for a
particular type of service. For example, some social services departments
will not consider a residential placement until a drug misuser has tried
(and failed) treatment in the community.
EXHIBIT 10
Multiple routes into treatment
Point of entry may influence the type of service offered to clients.
Source: Audit Commission
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Existing systems rarely have safeguards to prevent mismatches
between clients’ needs and the service offered. Few services use validated
tools to diagnose the degree and severity of drug dependence,I and many
lack clear eligibility criteria setting out the type of client who they are
most likely to be able to help. In combination, these deficiencies increase
the number of inappropriate referrals and reduce the likelihood that
people’s needs will be met effectively. Some psychiatrists interviewed for
this study, for example, considered that some of their current clients
would have benefited from earlier referral instead of receiving
inappropriate treatments elsewhere in the meantime. Current systems may
also fail to minimise risk, both to individuals and to the wider
community, since there is little guarantee that those with high level needs
receive more intensive support.
Limited treatment options
Strengthening referral and assessment procedures should help to
reduce any mismatch between clients’ needs and the services they receive.
However, this would not in itself guarantee a suitable service – client
choice in a particular locality may be limited to what is on offer rather
than what is needed.
The availability of different services varies widely across England and
Wales. For example, the numbers of street agencies – often the first port
of call for someone seeking help – varied widely between fieldwork sites.
While overall need in the underlying population makes direct
comparisons difficult, three areas had no street agencies at all. Anyone
seeking help in those areas would not have this option open to them. A
similar pattern was visible in inpatient detoxification services
[EXHIBIT 11, overleaf]. In one site, a county DAT straddled two health
authorities; one had 16 beds for drug and alcohol misusers, while the
other had none. This presented a problem where identified high level
needs were not met by alternative services such as community
detoxification.
I There are two official international diagnostic classifications based on the consideration of
both drug use (intoxication) and harmful use and dependence: the World Health
Organisation’s International Classification of Disease (ICD-10) and the American Psychiatric
Association’s Diagnostic and Statistical Manual of Mental Disorders (DMS-IV).
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The availability of
different services
varies widely across
England and Wales.
EXHIBIT 11
Inpatient provision in study sites
The level and type of inpatient provision varied from area to area.
* Inpatient provision in site 11 was spot-purchased on a bed-by-bed basis.
Source: Audit Commission fieldwork in 11 study sites
The range of interventions offered by the same type of services also
varied. For example, some social services departments provided a wider
range of support including structured daycare and home care, but others
focused resources almost entirely on residential rehabilitation programmes
– leaving gaps not filled by other agencies [EXHIBIT 12]. Some services were
only provided in one area: one social services department had
commissioned an independent agency to visit clients at home on a weekly
or daily basis to provide a range of practical and social support.
EXHIBIT 12
Percentage of social services
expenditure on different
interventions (1999/2000)*
Analysis of social services expenditure
shows marked variation in what is
being purchased. 
* Site 1 was unable to provide data.
Source: Audit Commission data returns
from 11 study sites
49.
36
N A T I O N A L  R E P O R T • C H A N G I N G  H A B I T S
Similarly, CDTs offered very different levels of support to drug
misusers who had completed detoxification and stayed in the community.
In one area, ex-users attended a structured daycare programme for up to
seven weeks following detoxification and could join local relapse
prevention groups, run by ex-users with the support of a local street
agency. Elsewhere, daycare programmes following detoxification lasted
just two weeks. In some cases, professionals felt such structured
interventions offered clients very little. Consequently, no further support
was offered after detoxification.
Generally, the type of support offered by community drug services
reflected the staff mix. Some CDTs mainly employed medical staff and
placed a strong emphasis on specialist substitute prescribing, general
healthcare and needle exchange services. Other CDTs employed a broader
range of staff, such as social workers, probation officers, counsellors and
generic drug workers, and therefore offered a wider menu of options,
including structured day programmes, aftercare programmes, counselling,
complementary therapy and support groups, as well as clinical support
[EXHIBIT 13]. The staff mix of some CDTs also influenced local shared care
arrangements. Where consultant-led CDTs conformed to a medical model,
access to shared care tended to be more limited. Conversely, nurse-led
services relied on GPs to provide all necessary clinical support. Neither of
these models appeared to be without its difficulties. Some GPs were
reluctant to prescribe to drug misusers or manage complex cases without
support from a local consultant. But areas that were heavily reliant on
specialist support frequently struggled to meet demand.
EXHIBIT 13
Different services provided by
community drug teams
Community drug teams provided a
range of services in most fieldwork
sites, though the range varied from
place to place.
Source: Audit Commission fieldwork in 16
CDTs in 11 study sites
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Special needs
Even where the right service exists in an area, the style of the service
may fail to cater for groups with special needs. In most fieldwork areas,
little emphasis has yet been placed on systematically reviewing the needs
of crack users, black and ethnic users and women, or developing new
services to promote their engagement more effectively. As most
community drug services have evolved in response to the needs of white
male opiate users, what they offer may be out of step with these groups’
own perceptions of need. Research among crack users, for example, has
shown that many fail to approach treatment services because what they
want is a less formal, open access service, offering a broader range of
psychosocial support and staffed in part by ex-users (Ref.58). Community
drug services that operate rigid appointment systems, offer limited access
to counselling, have little user involvement and continue to view
prescribing of methadone to counter opiates as their core business are
unlikely to meet this demand. Other research suggests that services do not
always respond effectively to the needs of people with drug and alcohol
problems. The NTORs study found that clients treated in community
settings reported no change in drinking patterns after one year (Ref. 59).
Other access problems
Drug users in receipt of substitute prescriptions need to be able to get
to dispensing facilities and their local clinic, sometimes on a daily basis.
Some may also want to visit drop-in services or other unstructured
services on a regular basis; or they may be required to attend structured
day programmes, sometimes as part of a community sentence or DTTO
programme. Yet getting there can be a problem. In some areas, services –
such as structured daycare programmes – were only available to a small
number of clients in the immediate catchment area, often due to lack of
transport or tight geographical eligibility criteria. In other areas –
especially large rural areas – access to prescribing services was limited,
due to low levels of participation by GPs and community pharmacists.
But the provision of special transport arrangements was rare and only one
site issued bus passes to enable clients to reach local services.
Services must also be available at the right time. The Department of
Health review of effectiveness stressed that ‘any service that aims to
provide ‘low threshold’ access to treatment must be available when its
target population needs it’ (Ref.8). Yet few street agencies operated outside
office hours. Only 7 of the 22 street agencies within the study sites
opened outside 9 to 6pm and only 5 provided a service at weekends.
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...little emphasis has
yet been placed on
systematically
reviewing the needs of
crack users, black and
ethnic users and
women...
Lengthy waiting times
Users surveyed by the Commission reported how long waiting times
and allocation processes which involved repeat appointments and further
delays stopped them engaging with a service [BOX F]. But many areas
struggled to respond quickly to new referrals. Among those CDTs able to
provide information (and not all could), the median waiting time for
prescribing services at 31 March 2000 was 35 days, although in three
areas the average wait was over 100 days. There were also lengthy delays
for community and inpatient detoxification services [EXHIBIT 14, overleaf].
Social services also took various amounts of time to respond to referrals:
while most undertook assessments within 14 days, one site took almost
80 days to respond, partly because of staff shortages. There were also
marked variations in the time taken to complete assessments and place
people in residential services. Of the six sites that could supply these data,
the average time taken ranged from 7 to 115 days, giving a median
response time of around 8 weeks. 
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BOX F
User comments on assessment/treatment waiting times
They don’t care. You’re put on a list and then they’ll call you up so many
months later and what are you supposed to do in that time? When you
want to come off drugs, it’s then, not 4 or 5 months down the line.
Male, heroin user, aged 40
The only problem with drug services is the length of time you have to wait
for a script…
Male, heroin and crack cocaine user, aged 21
They referred me to the service and I waited roughly 2 or 3 months for the
appointment. So that morning I was really positive, I’d gone down, I’d had
no gear, I thought, right I’m going to start my methadone script today and
that’s it. So I’ve gone in there and they’ve said, “You’ll have a two hour
interview and fill all these forms in,” and I’m withdrawing at this time. So I
thought I better do it. So long as I get my methadone at the end of it. And
then he said, “When you’ve filled this in, we’ll send you an appointment for
the doctor.” I went, “Eh? I thought this all happens today. This is why I’ve
waited this long”. And he goes, “No, we then refer you to the doctor,
which can take anything from 2 to six weeks.” So I said “You want me to sit
here 2 hours after waiting 3 months, rattling, and then wait another 6
weeks in the same situation and then come in.” I said, “Just stick it, forget
it.”
Male, heroin user, aged 38
Source: Audit Commission user research, 2001
EXHIBIT 14
Waiting times for prescribing and detoxification
Lengthy delays were evident in many CDTs for prescribing and detoxification services.
Source: Audit Commission data returns from 16 CDTs in 11 study sites
Lengthy waiting lists can drive clients away: in one area where
prospective clients routinely waited five months for an appointment at the
community drug service, only one in every three clients offered an
appointment ever attended. But long waits also have other adverse
consequences. They increase the risk that service choice will become
driven by availability rather than need. For example, in one site, some
users were encouraged to go for detoxification rather than wait for
vacancies to arise for methadone maintenance. Local agencies can be
deterred from making onward referrals, concealing unmet demand. A
number of street agencies reported that they rarely referred people to
prescribing services or social services departments because they knew they
would simply be put on a waiting list. Lengthy waiting times also
jeopardise the potential success of national drug initiatives, such as arrest
referral schemes. Clients with lower priority health needs picked up by
these schemes may have little chance of receiving a service quickly. 
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There are a number of reasons for lengthy waiting lists. The first is a
national one – as drug problems have increased, mainstream services have
not expanded quickly enough to keep pace. But there are two additional
problems that community drug teams need to address: inefficient,
bureaucratic procedures and inflexible, resource-intensive treatment
regimes.
Inefficient, bureaucratic procedures. Many drug services fail to
allocate people to services efficiently and effectively, leading to logjams
and delays. In some cases, the allocation process is overly reliant on the
involvement of senior clinical staff. For example, in one service, delays
occurred partly because a consultant insisted upon personally prioritising
every written referral before cases could be allocated to other team
members. In another, the allocation process was lengthened by the
involvement of many staff from different professional backgrounds, all of
whom assessed each client individually at separately arranged
appointments. As a result, clients seeking maintenance prescribing needed
to attend three separate appointments on different days before a
prescription could be issued. 
Inflexible treatment regimes. Some services apply standard treatment
‘conditions’ to all clients irrespective of their needs and record of
therapeutic compliance. For example, one service insisted that 95 per cent
of all clients on substitute scripts should be on supervised consumption
arrangements.I Another required each client to take a weekly urine test
and receive fortnightly key worker sessions. These sorts of treatment
‘conditions’ may be appropriate for some clients. However, their blanket
application increases the cost per client and hence reduces the number of
clients who can be treated. If regular reviews are not carried out,
provision may also become blocked by people whose needs are no longer
urgent. Waiting lists grow and high priority clients struggle to get the
support they need.
Once drug misusers have gained access to treatment, their care must
be carefully managed. It should be adjusted as people’s needs and
circumstances change. In some cases, care from a range of different
services may need to be co-ordinated. However, fieldwork for this study
found:
• some drug treatments were delivered poorly or not in accordance with
the evidence base;
• some clients received inadequate support due to poor care
management;
• services were often poorly co-ordinated – both drug treatment services
and other services; and
• shared care arrangements were underdeveloped.
I To ensure compliance and minimise diversion, prescriptions of substitute drugs such as
methadone are sometimes taken under the supervision of a pharmacist or a member of staff
at the prescribing service. This is known as ‘supervised consumption’.
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Care fails to meet
individual needs
Treatments delivered poorly or inconsistently
There are many gaps in understanding about the effectiveness of
different types of treatment. But even where evidence does exist, it does
not always influence practice. For example, research has shown that
inpatient treatment in a psychiatric ward produces fewer positive
outcomes than treatment in drug dependency units (Ref. 60). Users
interviewed on behalf of the Commission also identified the problems of
being accommodated in psychiatric beds [BOX G]. However, such beds were
still used in some areas, often irrespective of CDT concerns about the
limited expertise of ward staff, the poor quality of the treatment
environment and the ready availability of illicit drugs hampering
treatment outcomes. Some areas also opted for short inpatient stays of 10
days or less, despite research evidence showing better outcomes for those
who remained in treatment for 28 days.
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BOX G
User views of inpatient detoxification in psychiatric settings
It’s soul destroying, being mixed with all those with a mental illness…it’s
like you have been labelled…
Male, cocaine user, aged 40
I had three detoxes an’ each time I was sent to a psychiatric hospital and
put on a psychiatric ward. It’s hard enough to do a detox anyway, but when
you are thrown in with patients who’ve got their own issues, it doesn’t help
when you’re detoxing; it certainly doesn’t help them either. Twice I walked
out; I couldn’t cope with the havoc that was going on around the ward. It
was madness because people were ill at the time. You think – what am I
doing here?
Female, heroin user, aged 29
Source: Audit Commission user research, 2001
...where evidence does
exist, it does not
always influence
practice.
Inconsistent approaches to substitute prescribing can pose further
problems. While some areas placed a strong emphasis on tight control of
methadone programmes – generally, involving supervised consumption,
regular urine testing and the use of sanctions to address non-compliance –
others ran ‘low threshold’ programmes with far fewer controls. Users
confirmed the existence of variable approaches, with varying degrees of
satisfaction (or dissatisfaction) [BOX H].
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BOX H
User experience of prescribing
They wanted to refer me to a place in my area, but they said that my dose
was too high. Therefore I’m stuck in a service quite a way from where I live,
because the only place that will give me an adequate dose is the X hospital.
The area I live in has a policy of never giving doses that high. I am very
happy with the treatment I get from hospital, because they let me come
every six weeks and they give me tablets* rather than liquid which is more
convenient for me to travel with. They don’t sanction people if they use on
top, so you feel you can be honest with the people that you’re talking to.
Male, long-term opiate user, aged 46
There was two lads that I can think of who gave positive samples, and they
were on the three strikes and you’re out arrangement. One of the chaps I
spoke to said that if they’d just given him a little longer on the dose he was
on, he was just beginning to level out and get some sort of order. Then
they were hitting him with a reduction, then they kicked him off.
Male, long-term opiate user, aged 46
I was under a large Drug Dependency Unit in London. I moved out of
London two years ago and was referred to a Community Drug and Alcohol
and Resource Centre in X. I immediately encountered problems. I was on a
long-term maintenance script and had been for many years. They
immediately forced me onto a reduction dose, which I was extremely
unhappy about. I found it destabilising.
Male, long-term opiate user, early 40s
Everyone in this room has been told at some time during the course of their
treatment ‘It’s against the rules’. But they never produce these rules, they
never show these rules. They have nothing to do with the Orange Book
(Clinical Guidelines). Its totally arbitrary.
Male long-term opiate user, early 40s
* The Advisory Council on the Misuse of Drugs has advised ‘absolutely against the prescription
of methadone tablets to opioid misusers because of the potential dangers of tablets being
ground up and injected. In our view any doctor who despite warnings persists in
irresponsible practice should be reported to the GMC’. (Ref.3)
Source: Audit Commission user survey, 2001
Different approaches to prescribing in part reflect different (and quite
appropriate) clinical judgements. But they also highlight very different
views about the purpose of prescribing. Those running low threshold
programmes often argue that it is the only way to attract more ‘hard to
reach’ clients and minimise the harms caused by misuse. Others feel more
structured programmes better motivate clients, promote change and
reduce the risks of leakage into the wider community or of client
overdose. 
Clinical Guidelines produced by the Department of Health have done
little to resolve these differences. Most practitioners claim the Guidelines
support their approach irrespective of the rigidity or flexibility of their
regime. There are also differences between the approach recommended by
the Guidelines and the one recommended by the ACMD in their recent
report on drug-related deaths (Ref. 3). For example, while the Guidelines
suggest that most new patients should be on supervised doses for ‘at least
three months’, the ACMD recommends daily supervision for ‘at least six
months and often longer’ (Ref. 3). Other research has also pointed to wide
variations in prescribing practice across the UK, largely because of its
‘lack of formal structures or treatment protocols’ (Ref. 61).
The quality of support offered by some treatment services can also be
poor: community detoxification is a good example. An increasing number
of community drug services and street agencies offer community
detoxification, sometimes in partnership with a GP. But the support
offered to clients can be variable. One community drug service arranged
for a nurse to visit each client up to three times daily but others provided
far less support. Lack of support emerged as an important issue among
some users interviewed by the Commission [BOX I].
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BOX I
Negative user experience of community detoxification
A small number of clients reported undertaking a home detoxification
either via a GP or a community drug team. Several considered it to be a
negative experience:
I just felt abandoned.
Female, heroin user, aged 31
After two days I went from having my methadone and my heroin as well to
having nothing. I just couldn’t move off the couch. I stuck it for 48 hours,
which is a long time when you’re withdrawing. They just gave me some
tablets and that was it. Somebody came to see me once and that was it.
Female, heroin user, aged 32 with small child
Source: Audit Commission user research, 2001
Variable staff expertise 
Some of the problems with the ‘delivery’ of treatment may reflect low
levels of staff training and expertise. Staff in drug treatment services are
drawn from a wide variety of professional backgrounds. A mapping
exercise of the drug and alcohol sector undertaken by Healthworks UKI
in 2001 found many staff to be well qualified but ‘often their
qualifications are not specifically relevant to the specialised substance
misuse work they are undertaking’ (Ref.39). In the absence of any overall
framework of training and qualifications for the sector as a whole, many
workers in the field were also ‘still receiving little or no training relevant
to their needs’(Ref.39). The result is wide variations in practice and
standards of service. For example, several agencies did not employ British
Association of Counselling (BAC) accredited counsellors or provide staff
with supervision and were essentially offering a service more akin to
‘advice and support’. Elsewhere, qualified counsellors offered a more
structured service that aimed to achieve specific goals over a fixed period
of time.
Recruiting and retaining staff with suitable experience is a national
problem, largely due to overall shortages across the health and social care
professions. This partially explained the absence of consultant support in
some sites. But lack of key staff can hamper the development of new
approaches to service delivery. Some fieldwork sites struggled to secure
the participation of GPs in shared care arrangements due to the absence
of consultant support. Others failed to meet new demands arising from
arrest referral schemes because of the pressures faced by under-resourced
community drug services.
The rapid development of the drug treatment sector – with new
criminal justice interventions developing alongside the expansion of drugs
commissioning and policy – has exacerbated these pressures. Many
agencies reported difficulties retaining staff due to new opportunities
elsewhere. Such pressures are unlikely to diminish. Youth offending
teams, for example, are also now recruiting large numbers of drugs
workers. Estimates suggest that the number of drug treatment specialists
will need to increase by up to 50 per cent in the next five years to meet
demand (Ref.39).
I Healthworks UK, the National Training Organisation for the health sector, is currently
developing national occupational standards for people working in the drugs and alcohol
sector. As part of this work, it has produced a UK-wide occupational and functional map,
which sets out the role of people working in this area and identifies their education and
training requirements and existing qualifications.
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Recruiting and
retaining staff with
suitable experience is a
national problem...
Care management within community drug
services
Good care planning increases the likelihood that drug misusers will
remain in treatment and achieve a positive outcome. It also helps to
ensure that individual clients receive an integrated package of care that
offers a holistic response to their problems. Clear care plans can promote
effective co-ordination between services, taking account of each client’s
changing needs over time. Ideally, the plan should reflect the
contributions of all relevant agencies and copies of individual plans
should be given to users. Clear treatment goals – both short-term and
longer-term goals – should be included and reviewed on a regular basis at
meetings with a key worker. However, a review of treatment case files
showed that care planning within CDTs did not always reflect this good
practice [EXHIBIT 15]. A review of 52 case files across six community drug
teams found that around one-half of clients did not have a care plan and
that only one-half of the reviews involved other agencies. User interviews
also pointed to weaknesses in care management: ‘Until recently, they’d
kept me on 10mg methadone about 7 years, never speaking to me, never
asking me anything’ (male, long-term opiate user, late 30s).
EXHIBIT 15
Review of case files
Of 52 case files examined by the Audit
Commission, only half contained care
plans.
Source: Audit Commission casefile review
in 6 CDTs in 5 study sites
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Why is care management inconsistent? One explanation is that CDTs
have differing views about the role of the service and the way drug
treatment should be managed. Some CDTs interpret their role narrowly –
simply as prescribing services – and therefore do not consider wider needs
or actively organise contributions from other services. In one site, the
CDT simply suggested clients visit another agency if they needed help
with housing or benefits advice. Overemphasis on therapeutic compliance
can also have an adverse impact on care management. For example,
although some CDTs held regular care management meetings, these often
focused exclusively on compliance rather than the achievement of any
broader goals. Concerns about clients ‘topping up’ prescriptions with
illicit drugs are understandable and do need to be addressed within care
management arrangements. But failure to balance ‘policing’ with the
achievement of wider goals risks driving clients away and generating an
atmosphere of mistrust.
In other cases, effective care management can be impeded by negative
views about the client’s ability to change. For example, one CDT manager
argued that ‘we can’t set long-term goals for this group – they are too
chaotic’. Such negativity also appeared to lead to insufficient emphasis on
follow-up. Non-attendance was simply assumed to reflect lack of
motivation to change. Most CDTs made little attempt to follow up people
who had dropped out or missed appointments. Often follow-up was
limited to sending a letter offering a further appointment, although most
services made more effort to chase those considered to be a risk to others
or themselves. The existence of waiting lists was often used to justify this
approach; why follow up a non-attendee when there are more motivated
clients waiting for the service?
Different views about the nature of ‘treatment’ can also lead to
insufficient emphasis on moving a client along a treatment pathway. In
some cases, substitute prescribing and retention are seen as the primary
goals of treatment. This may be appropriate for some clients who need
several years of support. But if retention becomes the overriding service
philosophy, it risks holding back those who may be able to move on given
other support, such as help to gain qualifications and skills or to develop
new social networks. Conversely, if services define treatment to include a
range of social support, when does treatment end? More carefully tailored
care management approaches are required to secure a pathway approach.
However, few CDTs routinely set long-term goals for clients that relate
interventions to expected outcomes, or specify a treatment duration for
those who want to ‘move on’. These factors may help to explain why
clients in ‘methadone reduction’ and ‘methadone maintenance’
programmes appear to achieve very similar results. NTORs found that
after one year there were no significant differences in doses, treatment
retention rates, mean time in treatment or changes in substance misuse
(Ref.62).
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...failure to balance
‘policing’ with the
achievement of wider
goals risks driving
clients away...
Poor co-ordination and joint working
Most drug misusers have complex problems that cannot be solved by
one agency acting alone. However, many clients fail to receive a seamless
service due to:
• lack of co-ordination between different treatment services; and
• poor joint working with other services, such as mental health.
Some clients need to move along a pathway between treatment
services – in particular from detoxification to rehabilitation. Several sites
reported difficulties achieving a seamless transition from inpatient
detoxification to a residential placement. Some CDTs did not routinely
contact social services before a client was admitted for inpatient
detoxification. This resulted in them spending longer than necessary in
hospital awaiting the outcome of their community care assessment. In
some cases, there was no follow-up care for those leaving hospital. These
problems occurred more frequently when budgets for inpatient treatment
and residential care were held separately by CDTs and social services
departments. Difficulties were not limited to inpatient care. Those
undergoing detoxification in the community were not always linked into
other services, increasing their chances of relapse. Continuity of care can
also be poor where residential treatment is provided ‘out of area’. It is
usually the responsibility of the service provider to support the clients
following treatment, but if they do return ‘home’, local services rarely
attempt to check their progress. 
Co-ordination of care for ex-prisoners is particularly poor. Recent
research, tracking 112 prisoners who had undergone some form of
treatment in prison, found that only half were offered help to obtain
treatment on release and only 11 per cent were fixed with an
appointment at a drug agency. Four months after release, 86 per cent said
that they had used some form of drugs and one-half were using daily.
About one-half had nowhere to live and only 16 per cent were employed.
The tracking project estimated that 8,000 people may be released each
year with a serious dependency on drugs and that they account for five
million crimes per year (Ref.63). High levels of Government investment in
the CARATs programme have dramatically expanded prisoners’ access to
treatment, but inadequate follow-up on release remains a problem. Many
fieldwork sites reported that there was still little co-ordination between
CARATs workers and local treatment services. This was partly because
funding for aftercare included in CARAT contracts has often not been
invested in follow-up services in the community and partly because many
prisoners returned to a different geographical area on release, making co-
ordination difficult to achieve. These failings undermine the value for
money offered by CARATs.
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Co-ordination of care
for ex-prisoners is
particularly poor.
Drug dependency is often closely associated with many other
problems such as unemployment, family breakdown and crime. Clients of
other agencies may also need help from drug treatment services. For
example, recent studies of mental health team caseloads in inner city areas
found that around a third of clients with some form of psychosis also had
a substance misuse problem, giving them a ‘dual diagnosis’. 
But, despite research that demonstrates the importance of good joint
working across agencies, and the existence of local protocols in many
areas, joint working remains patchy. In some cases, joint relations are
good at a senior level but not translated into practice at an operational
level (or vice versa). As a result, some clients fail to get the service they
need. Drug misusers with mental health problems sometimes fall between
services because the necessary agencies are not involved in their
assessment and case review meetings, or agencies disagree on who should
take the lead. Some of these clients present high levels of risk. For
example, a review of 17 independent inquiries into homicides by mentally
ill people between 1993 and 1996 found evidence of either problem drug
or alcohol use in 13 cases (Ref.64). In around half it was thought to be a
major cause of the homicide. Drug misusers with children can also
experience problems. Interagency disputes about how the children should
be cared for sometimes lead to delays in residential placement for the
client. 
Poor joint working tends to have two main causes: different
philosophies or priorities across different services; and budgetary disputes.
For example, in some study sites, mental health services felt unable to
offer a diagnosis before a client was drug-free. Where diagnosis was
given, clients with a substance misuse problem were often diagnosed as
having a personality disorder – thus deeming them untreatable and
beyond help. Conversely, some mental health services reported difficulties
securing support for their clients from treatment services. Drug treatment
services can be reluctant to treat people who do not appear motivated.
But this can prove a formidable hurdle to people with ‘dual diagnosis’
who often have poor compliance and a chaotic lifestyle. Different views
about what constitutes a ‘serious’ drug or mental health problem, high
workloads and the absence of systematic joint training frequently
compound these problems.
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For non-drug services, drug misusers are only one of many client
groups – and one that presents particular challenges. For example, some
housing departments – especially in the south east – face an overall
shortage of stock for non-priority households and therefore struggle to
house drug misusers who are single. Where they do manage to do so, they
may face considerable pressure from other residents, concerned about
anti-social behaviour such as discarded needles, threatening behaviour,
and late night comings and goings. More generally, housing departments
are often unsure how best to house drug misusers. Should they be offered
accommodation in a familiar area, close to support from friends or
family, or moved out of the area, away from drug-dependent friends?
Should recovering misusers be housed together in close proximity so that
they can offer each other mutual support, or will this increase the danger
of ‘domino’ relapse or make them a target for dealers?
Joint working is also frequently hampered by arguments about who
should pay for what. It is not uncommon for drug services and specialist
mental health services to disagree on the proportion of treatment costs
that each should meet. Disputes arise even within social services: for
example about the proportion of funding to be met from the substance
misuse and children’s services budgets when children need to be supported
while a parent is in residential rehabilitation. Delays inevitably arise while
these problems are resolved – some social services departments
acknowledged that the assessment process can grind to a halt until
agreement is reached. Interagency relationships may also be strained by
confidentiality protocols. For example, while the police funded arrest
referral schemes, some CDTs felt bound by client confidentiality not to
reveal personal details of those subsequently receiving services.
Underdeveloped shared care arrangements
Good joint working between CDTs and GPs is critical. GPs can play
an important role in the day-to-day management of a drug misuser’s
medical needs and can help to reduce referrals to specialist services. Many
clients also prefer to receive care in a primary care setting in the
community wherever possible (Ref. 33). In response, some areas have
developed ‘shared care’ arrangements, whereby GPs and specialist services
work in partnership to support clients. But shared care is underdeveloped,
meaning that most drug misusers continue to be heavily reliant upon
specialist services. Only six of the eleven fieldwork sites visited by the
Commission had a formal shared care arrangement in place. In around
half of the areas fewer than 10 per cent of GPs were involved in local
arrangements, below the Department of Health’s target of 20 per cent
[EXHIBIT 16].
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...housing departments
are often unsure how
best to house drug
misusers.
EXHIBIT 16
GP and GP practice involvement in
shared care arrangements 
Many areas had very low levels of
participation in shared care
arrangements.
Source: Audit Commission data returns
from 11 study sites
The absence of any shared care arrangements sometimes reflects
specialists’ reluctance to encourage wider GP involvement, partly as they
feel the quality of support may diminish. However, when local schemes
are established, securing wider GP involvement is often a struggle. Some
GPs have negative attitudes towards drug misusers and have concerns
about client overdose, the potential impact on other patients and surgery
staff or increases in their workload [BOX J, overleaf]. Many still view
activities such as prescribing and dose assessment as the preserve of
specialist services. The results of an Audit Commission survey of GPs
across 10 study sites confirmed this problem.I Although the vast majority
of respondents agreed that they should provide general medical services to
opiate misusers, one-half did not consider prescribing methadone for
maintenance to be an appropriate activity for general practice; 77 per cent
felt it was inappropriate for them to perform dose assessment prior to
prescribing. Lack of training and expertise may partly explain this
response. Most GPs still receive very little training in drug misuse as part
of their undergraduate and postgraduate medical educationII and few feel
confident about meeting drug misusers’ needs [EXHIBIT 17, overleaf].
I 1,574 GPs in ten of the eleven fieldwork sites responded to an Audit Commission survey
focusing on the treatment of opiate users, a response rate of 43 per cent.
II In 1990 the Advisory Council on the Misuse of Drugs recommended that substance misuse
should form a core part of undergraduate and postgraduate medical training for GP
registrars. Although the recommendation was accepted by central Government, it was never
acted upon.
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EXHIBIT 17
GP attitudes towards drug
misusers
Only one-quarter of GPs felt
confident working with opiate
misusers.
* 1 per cent of respondents did not
complete this section of the survey
Source: Audit Commission survey of 3653
GPs, 2001
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BOX J
Negative GP attitudes to providing specialist support for drug misusers
Although around two-thirds of GPs who responded to the Commission
survey felt that it was highly appropriate to provide general medical
services to drug misusers, some expressed reservations about providing
specialist support.
Treatment of drug misusers requires protected time. I cannot treat them
within my contractual hours because they require three times the usual
consultation time. They are also often violent, manipulative, rude and
demanding.
[We need] specialist clinics for illicit opiate misusers, shorter waiting times,
more support and counselling and easier accessibility in the community.
I feel methadone prescription is not part of services that could be provided
from normal GP accommodation – GPs can provide these services sessionally
outside their practice premises with training.
The key to successful detoxification and maintenance is a high level of
monitoring and support, which GPs do not have time or resources to carry
out. Their general medical care remains very much our responsibility.
Our practice does not prescribe methadone any more due to a receptionist
and our practice manager being assaulted on two separate occasions.
Audit Commission survey of GPs, 2001
Poor support from specialist treatment services makes it difficult to
address these barriers or guarantee that those GPs who work with drug
misusers can offer a good quality service. Almost two-thirds of GPs who
responded to the Commission survey did not feel they had easy access to
specialist support when working with opiate misusers. Around a third of
those who prescribed methadone for maintenance also felt they had not
received sufficient training and did not have easy access to specialist
services. In some cases, such findings may be explained by the absence of
local shared care arrangements or GPs’ own concerns about the quality of
support in the absence of a local consultant. But some shared care
arrangements also fail to address GPs’ training and support needs
adequately. Audit Commission fieldwork found that some areas did not
provide training for those GPs participating in shared care and do not
consider their training requirements or the dissemination of good practice
within their local policy [EXHIBIT 18]. Without adequate training or support,
the service that clients receive can be poor: I don’t think GPs know
enough about heroin use. It’s hard to explain to them what you’re going
through, how you feel. Their answer is diazepam, temazepam or 80ml of
methadone – which makes you twice as worse at the end of the day
(male, heroin user, aged 34).
EXHIBIT 18
GP training 
Some areas have yet to address GP training or the dissemination of good practice within shared care schemes.
Source: Audit Commission fieldwork in 11 study sites
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Another reason for low levels of GP expertise and involvement is the
way in which shared care arrangements are set up and managed. Clinical
Guidelines produced by the Department of Health recognise that
‘specialists’ and ‘generalists’ should play distinct roles relative to their
degree of expertise [BOX K]. However, as there is no agreed model of
‘shared care’, many different models have evolved, each with their own
strengths and weaknesses [BOX L].
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BOX K
The role of medical practitioners in the treatment of drug misuse
Clinical guidelines produced by the Department of Health recognise three levels of expertise among medical
practitioners involved in the treatment of drug misuse:
Level 1: The Generalist
Level 2: The Specialised Generalist
Level 3: The Specialist
Source: Adapted from Drug Misuse and Dependence – Guidelines on Clinical Management, Department of Health (Ref.33)
Generalists are medical practitioners
who may be involved in the
treatment of drug misuse, although
this is not their main area of work.
They should be able to demonstrate
relevant competence to underpin
their practice and care for a number
of drug misusers, usually on a
shared care basis. Services to be
provided would be expected to
include the assessment of drug
misusers and, where appropriate,
the prescribing of substitute
medication.
A specialised generalist is a
practitioner whose work is
essentially generic or, if a specialist,
is not primarily concerned with drug
misuse treatment, but who has a
special interest in treating drug
misusers. Such practitioners would
have expertise and competence to
provide assessment of most cases
with complex needs. 
Examples of a specialised generalist
would be a general practitioner or a
prison medical officer who deals
with large numbers of drug misusers
in their practice and who, with
other professionals and agencies,
provides many of the services that
are necessary. Their drug misuse
practice would possibly involve the
prescription of specialised drug
regimens. Additionally they can
potentially act as an expert resource
in shared care arrangements for
general practitioners and
professional staff operating at Level
One.
A specialist is a practitioner who
provides expertise, training and
competence in drug misuse
treatment as their main clinical
activity. Such a practitioner works in
a specialist multidisciplinary team,
can carry out assessment of any case
with complex needs and provides a
full range of treatment and access
to rehabilitation options.
Most specialists would normally (but
not always) be a consultant
psychiatrist who holds a Certificate
of Completion of Specialist Training
(CCST) in psychiatry, and is therefore
able to provide expertise, training
and competence in drug misuse
training as their main clinical
activity. Their practice would
probably involve prescription of
injectable and other specialised
forms of prescribing, which will
require Home Office licences. They
can act as an expert resource in
shared care arrangements for other
practitioners, professionals and
staff.
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BOX L
Different approaches to shared care
The balance of responsibilities between specialist services and GP practices varied immensely across different shared
care schemes. However, three broad models could be identified, each with different strengths and weaknesses:
Source: Audit Commission
The specialist community drug service provides the majority
of client support, including dose assessment and key worker
sessions, and undertakes all urine testing. The GP role is
limited to signing scripts, usually on the basis of guidance
from the specialist service, following key worker sessions.
Contact between GPs and clients is limited.
Strengths
May encourage GP
participation and offers
clients access to support
from specialists with
expertise in drug misuse.
Weaknesses
May do little to increase
the confidence and
expertise of the wider GP
population or reduce
pressures on specialist
services and delays for
drug misusers.
GPs with special interest and expertise in drug misuse run
separate clinics for drug misusers, usually in parallel to a
specialist service. They usually offer substitute prescribing,
although a patient’s own GP may address their general
health needs. Alternatively, workers from the specialist
service may hold regular clinics in local GP practices. Usually,
the workers offer GPs guidance on dose assessment and
prescribing. GP involvement with the patient varies. Some
limit their involvement to signing scripts and addressing the
patient’s general healthcare needs. In others, they formally
review the client’s progress with the satellite service. Some
schemes have introduced contracts, setting out the role and
responsibilities of the patient, specialist service and GP.
Strengths
Provides patient with
more choice and can
reduce pressures on
specialist services.
Weaknesses
Can evolve into another
specialist service, which
then ’silts up’. Some
primary care-led models
may have poor links with
specialist services and/or
only offer clients medical
support. May discourage
wider GP involvement.
GPs provide drug misusers with health and medical support,
in partnership with a nurse-led specialist service. The
specialist service assesses all patients and offers GPs advice
on dose assessment and dispensing arrangements. GPs see
clients regularly and are usually involved in case review
meetings with the specialist service. Some schemes have
introduced contracts, setting out the role and
responsibilities of the patient, specialist service and GP.
Strengths
GPs fully involved in
patient care and support.
Can reduce pressures on
specialist services. In rural
areas, patient access to
prescribing services may
be improved.
Weaknesses
Some GPs are reluctant
to provide services
without access to
consultant support.
Where GPs are unwilling
to prescribe, clients may
be unable to access
appropriate support.
’Centralist’ models
’Satellite’ models
’GP-led’ models
In practice, few existing models seem to have achieved an effective
balance between general and specialist care. For example, if one or two
GPs in an area act as ‘specialised generalists’ but fail to engage the wider
GP population, they may evolve into yet another specialist service, which
then ‘silts up’. Similarly, some schemes continue to rely heavily on the
involvement of specialists, limiting the GP role to the ‘rubber stamping’ of
prescriptions. Such schemes do little to build the expertise and confidence
of GPs working with drug misusers. One area, which had set up this sort
of model, involved 89 per cent of local GPs, but only 37 per cent of GP
respondents from this area felt confident about working with drug
misusers. The bureaucratic nature of some central arrangements may also
increase pressures on specialist services [BOX M].
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BOX M
Bureaucratic, centralised, shared care arrangements
One consultant-led community drug service, with two specialist registrars
and nursing staff, relies upon local GPs to undertake all prescribing for
clients under its ’shared care’ scheme. However, medical staff at the
specialist service assess all clients and advise GPs on the type, and dose, of
substitute drugs to prescribe. When GPs prescribe substitute drugs, all
clients have a weekly or fortnightly session with their key worker in the
specialist service. Urine testing is also undertaken weekly by the specialist
service. Key workers recommend changes in dosage to GPs, notifying them
of proposed changes by fax. Prescriptions are printed by the specialist
service and sent to the GP for their signature each fortnight. Signed scripts
are then returned to the drugs service and taken to the dispensing
pharmacy by one of the staff. 
On average, GPs see their clients every three months, unless complications
arise. There is a five-month waiting list for appointments to the specialist
service.
Source: Audit Commission fieldwork
Lack of additional reimbursements is often felt to discourage
participation in shared care. Two-thirds of GPs who responded to the
Commission survey, for example, agreed that they should receive an
enhanced capitation fee for prescribing methadone. However, while there
is widespread recognition that treating drug misusers can be time-
consuming and raise prescription costs, several areas offered no additional
payments. Where payments were offered, rates varied [EXHIBIT 19]. The
impact of payments as an incentive was also unclear, suggesting that small
amounts of money alone did not greatly influence GP behaviour. The two
areas with the highest levels of GP participation in shared care, for
example, did not offer any separate payments. Some attempts to
introduce new payment schemes had also been poorly managed. In one
area, local GPs who had traditionally played an important role through
well-established shared care arrangements without any additional
payments became reluctant to continue once a new GP ‘satellite’ service
was introduced and reimbursed to support drug misusers. 
EXHIBIT 19
Patterns of reimbursement to GPs
in shared care arrangements
In those sites where shared care
arrangements are in place, payments to
GPs vary widely.
Source: Audit Commission fieldwork in 11
study sites
86.
3 • P R O B L E M S  W I T H  D R U G  T R E A T M E N T  S E R V I C E S
57
If all of the problems described above are to be addressed
systematically, services need to be commissioned carefully. Drug treatment
services are purchased primarily by health authorities, but local
authorities, probation and prison services and the police are also
commissioners. Local authority social service departments may pay for
services for drug misusers following community care assessments. The
police and probation and prison services fund arrest referral schemes,
drug treatment and testing order programmes and throughcare for
ex-prisoners. Local commissioners therefore need to come together to
address many of the problems with the management of drug treatment
services identified in this chapter. However, they are often hampered by a
lack of information about needs and services, and uncertainty about the
relative effectiveness of different treatment interventions. Complex
commissioning and funding arrangements compound these problems.
Poor service planning
To plan effectively, commissioners need good information about both
the needs in their locality and also the level and nature of current services.
However, in most cases, public health departments afford a low priority
to any ongoing analyses of drug problems. As a result, local needs were
identified from one-off studies, based largely on information about
national prevalence and trends, rather than local data, and were often out
of date. Attempts to identify latent demand or consider future trends in
drug misuse and their impact upon demand for services were rare. Where
commissioners adopted more systematic approaches, it was often unclear
what difference they had made to purchasing decisions. One of the
fieldwork sites had commissioned a needs assessment using ‘capture-
recapture’ techniques, but the results had not been used to inform local
service planning. 
In addition to problems identifying ‘demand’ for drug treatment
services, local commissioners often lack detailed knowledge of ‘supply’.
This is partly because some health authorities do not have service
agreements or contracts with providers that specify requirements for
information about their levels of service or their performance. Moreover,
many health authorities and social services departments struggle to
identify precisely what they are spending on drug treatment or levels of
activity. In many cases, expenditure is combined with alcohol treatment,
and in some health authorities it is lost in the overall block contract for
community mental health services. Simple disaggregation is rarely
possible, raising questions about the validity of information that has so
far been returned to central Government in DAT templates.
Commissioners are also often unable to identify the costs of particular
types of treatment interventions purchased from different services. Where
monitoring does take place, the effort is usually inversely related to
expenditure – large NHS trust contracts are often left to roll over year
after year, whilst smaller agencies are scrutinised much more closely. 
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Even where drug treatment commissioners can identify the unit costs
of different interventions, value for money is virtually impossible to
determine. This is mainly due to a lack of comparative data that can offer
a benchmark for comparisons. Where services have attempted to monitor
the effectiveness of their interventions, performance measurement is often
a problem, not least because the interpretation of ‘success’ can be
variable. One area, for example, decided to shift expenditure away from
residential care on the grounds that 50 per cent of people dropped out,
but struggled to explain why a success rate which was better than that
achieved in the NTOR study was considered so poor. Statistical reliability
of the information presents further difficulties. A common complaint is
that it is meaningless to judge a service by the outcomes of a small
number of individual clients. It is also not economically viable for small
drug services to become ‘mini-research’ projects.
In the absence of good local information, commissioning decisions
tend to be heavily influenced either by nationally determined priorities or
by the judgement of local providers. While providers may have first-hand
experience of drug misuse problems, there is a danger that existing
patterns of service will be replicated unquestioningly or that local
prejudices will determine purchasing priorities, rather than a sound
appreciation of the evidence base. Alternatively, purchasing decisions can
be driven solely by cost. For example, local commissioners in one study
site had jointly agreed to reduce the use of residential placements in order
to minimise costs and reinvest in community-based services that they felt
offered better value for money. However, the shift to community-based
provision left insufficient funds for those with higher needs. Another
study site put an arbitrary ceiling of £500 per week on residential
placements, making it difficult to place people with high needs.
Disjointed commissioning and funding
arrangements
Commissioning drug treatment services tends to be a low priority for
each of the agencies involved. Drug treatment accounts for only 1-2 per
cent of most health authority budgets and the ‘costs’ of drug problems
fall largely on other agencies. As a result, most health authorities have
insufficient drug treatment commissioning expertise. There is rarely a
whole-time post dedicated to drugs and frequent structural changes in the
NHS have shunted the responsibility from one person to another. The
move to PCT commissioning presents new opportunities but, without
careful management, risks exacerbating this problem. Attempts are being
made to introduce joint approaches to commissioning, bringing together
all funders to strengthen expertise and ensure effective co-ordination
between specialist services and criminal justice initiatives. But, while many
areas have already appointed joint commissioning managers and
established joint commissioning groups, these developments have not yet
had a significant influence upon purchasing decisions for mainstream
services. Some joint arrangements also face difficulties balancing the
differing priorities of different funders [EXHIBIT 20, overleaf].
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EXHIBIT 20
Different treatment objectives
Commissioning agencies may have a number of different treatment objectives.
Source: Audit Commission
Certain aspects of the funding framework for drug treatment services
also hamper effective commissioning (and therefore service delivery), with
most criticism being directed at the way the introduction of new criminal
justice initiatives had been managed. For example, in some areas, arrest
referral schemes and CARATs increased the numbers of drug misusers
referred for treatment before commissioners were able to increase service
capacity. As a result, some local treatment providers struggled to meet
new demands. These problems, which often fuelled friction between local
partners, are partly rooted in the national funding framework. Since the
introduction of the new drugs strategy, the bulk of new funding has been
targeted at criminal justice initiatives while investment in mainstream
drug treatment services has been much smaller. 
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Many providers were also highly critical of funding regimes that
promoted ‘new initiatives’ but failed to address the ongoing difficulties in
securing finance for core activities, such as drop-in centres, which can
play a vital role in attracting new clients (but are hard to evaluate). In
Wales, new monies allocated for drug and alcohol treatment and
vulnerable young people as part of a package of measures in a Social
Inclusion Fund were primarily targeted at new schemes, leaving
commissioners little scope to address shortfalls in mainstream services.
Problems presented by multiple funding streams were another source of
complaint, with many providers reporting difficulties due to the short-
term nature of the funding and the increased administrative burden that
resulted from their management. Long-term strategic planning can also
suffer. One DAT co-ordinator, for example, pointed to the difficulty of
developing a coherent approach when individual agencies bid for funds
opportunistically, resulting in duplication of services or new initiatives
that were not highly prioritised by the DAT. The need for health
authorities to spend monies allocated within a single year equally
increased the risk that money was allocated to areas where it could be
spent, rather than where it was needed
DATs should have a key role in the development and commissioning
of services. But their wide strategic agenda, combined with limited
specialist expertise, means that some have not yet grappled with the more
complex aspects of treatment. Their focus has tended to be on new
money and specific funding schemes rather than the effectiveness of
current performance. For example, one DAT had spent several meetings
discussing how to allocate £100,000 from a Health Action Zone
initiative, but had never reviewed the performance of mainstream drug
services costing around £2.4 million. National planning and reporting
arrangements for DATs also encourage a short-term planning horizon. At
present, DATs report details of activity in templates and treatment plans
on an annual basis, focusing primarily on actions in the last year and
identified priorities for the year ahead. This does little to encourage the
development of a strategic approach, which is usually characterised by
long-term goals and objectives, with actions implemented incrementally
according to a clear plan. Treatment plans appear to recognise the need
for a longer-term approach.
Drug misusers face a number of problems accessing treatment services
and getting the type of help they need. They may experience long waits to
get treatment, which is often insufficiently comprehensive or poorly
co-ordinated. This may contribute to higher than necessary drop-out
rates, causing problems for the client and increasing costs for the wider
community. But although drug problems are inherently difficult to
unravel and treat, some treatment services are performing better than
others. Drawing upon Audit Commission fieldwork, the next chapter
suggests how services could be improved, using case studies.
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Conclusion
One DAT
co-ordinator...pointed
to the difficulty of
developing a coherent
approach when
individual agencies bid
for funds
opportunistically...
4
Improving Performance
Increased funding offers local agencies new opportunities to
review the quality and range of drug treatment services. The
starting point is better intelligence about local needs and the
performance of existing services. Developing more flexible
approaches and improving care co-ordination and joint
working are likely to be priorities in many areas. The efforts
of local agencies need to be supported by parallel
improvements in the national framework. Raising the
standard of support could prove difficult without a better
understanding of ‘what works’ and a national focus on
performance measurement and staff training and
development.
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Commissioners, DATs and service providers need to work together to
improve drug treatment services. As already outlined, extra funds are
being provided, and these offer an ideal opportunity for areas to start to
tackle the problems described in the previous chapter. These findings –
along with the factors promoting effective treatment identified in Box E –
suggest that the efforts of local agencies will need to focus on five key
tasks:
• Strengthening partnership working and commissioning – DATs need
to establish a joint infrastructure to undertake commissioning and
ensure that key decisions are reflected in partners’ own policies and
resource allocation processes.
• Reviewing the quality and range of treatment services –
Commissioners and service managers need better intelligence about
their target population and the resources, activity and performance of
drug treatment services. Working together, they can assess how well
resources are currently being deployed and consider options for
change. 
• Promoting better care co-ordination and joint working –
Commissioners should ensure that care pathways across these services
are well managed and promote good continuity of care as drug
misusers move between services and agencies.
• Developing more flexible approaches – Many areas need to promote
more integrated approaches that marshal the support of other key
agencies effectively, including housing and mental health.
• Improving support to primary care – Areas need to review local
shared care arrangements and ensure that GPs have access to
appropriate support.
As some of the problems that local areas encounter in the successful
delivery of treatment must be addressed at a national level, the new
National Treatment Agency in England should help local stakeholders to
tackle this agenda. With a remit to improve ‘the capacity, quality and
effectiveness of drug treatment services’ (Ref.65), it is now well placed to
promote parallel improvements in the national framework and develop a
more coherent model of service standards and good practice. In Wales,
the new Substance Misuse Intervention Branch (SMIB) in the National
Assembly should play a similar role. Accordingly, this chapter sets out
some initial proposals for both local and national action.
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Promoting an effective strategy to secure improvements in drug
treatment services will depend upon an effective partnership between local
agencies with commissioning responsibilities. In practice, this means that
local DATs should aim to:
• establish a joint infrastructure to undertake commissioning of local
services; 
• ensure that there are effective links with other partnerships and
agencies, such as housing authorities and employment services; and
• link the work of the group to partners’ mainstream activities and
budget making processes.
Setting up a joint group to oversee the commissioning of drug
treatment services can promote better co-ordination and many DATs have
already established such groups: those that have not should do so. The
membership of such groups should be comprehensive and their remit
should include all investment in drug treatment services, rather than
simply the new pooled budget. Support for such groups will be key. As
treatment services are not the sole priority of any one member, there is a
danger that the development of a coherent purchasing strategy will be lost
amongst competing priorities. To avoid this, local areas should consider
appointing a joint commissioning officer to take forward key areas of
work, such as the development of key contracts and service specifications. 
Good links between commissioning groups and other local
partnerships will help to prevent duplication and ensure a coherent
approach to what are often overlapping problems. The development of
Local Strategic Partnerships (LSPs) and recent proposalsI to bring together
the work of DATs and Crime and Disorder Reduction Partnerships
(CDRPs) provide a new opportunity to review local arrangements. But
achieving effective co-ordination is not easy and new arrangements will
need to be closely tailored to local circumstances. One county DAT, for
instance, covers 16 district councils, each of which has a CDRP and a
Youth Offending Team. A number of DATs have already experimented
with ways to achieve better co-ordination. In one area with coterminous
boundaries, the same person chairs the drugs, crime and youth offending
partnerships, making it easier to recognise links between the three
agendas. In two-tier areas, some DATs have set up district-level drug
reference groups to plan tactical action and work with CDRPs to
implement the Communities Against Drugs initiative, leaving DATs to
focus on strategic matters (Ref.66).
I The White Paper on Police Reform, 'Policing a New Century', published in December 2001,
outlines plans to create a new community-based partnership by bringing together the work
of Drug Action Teams (DATs) and Crime and Disorder Reduction Partnerships (CDRPs) (Ref.40).
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Joint commissioning groups must also be linked to each partner’s
mainstream activities and budget processes. Strengthening service delivery
and realigning mainstream budgets, for example, will require strong links
between each agency at all levels of their organisation: strategic,
managerial and operational. Careful planning of proposed changes will be
key. In practice, the complexity of getting different organisations to agree
on a common change of direction can be a cumbersome process, requiring
each agency to go through their own decision-making processes and
canvass broader support. However, the involvement and support of
strategic players within the DAT – who have the authority to commit
their organisations and to endorse new models of service – can help this
process run more smoothly. Equally, an effective Chair can help to build
trust and commitment between local partners and encourage individual
agencies to consider changes in spending priorities.
While effective partnership working at a local level can help to drive
through change, the Government could usefully review certain aspects of
the national framework to promote a stronger emphasis on long-term
funding and planning for treatment services and ensure better continuity
in service development. More flexibility in the funding framework could
equally afford DATs more opportunity to respond to local needs. Some
areas, for example, need to make substantial investment in mainstream
treatment services and follow-up support, to fully realise the benefits of
new criminal justice initiatives. But although some DATs may ideally have
chosen to prioritise resources in this way, the initial ringfencing of new
treatment monies for drug treatment and testing orders militated against
this approach.
A number of existing models could provide the basis for allowing
DATs greater discretion over the use of funds. The move towards Public
Service Agreements (PSAs) with local authorities, for example, is
indicative of a longer-term approach, with funding tied to agreed
performance measures that reflect local objectives. A similar model could
be used to allocate pooled treatment monies, though the Government may
be understandably reluctant to do so until the weaknesses in performance
measurement highlighted in this report are addressed. Other types of
funding and planning flexibilities could also be explored. These could
include:
• allowing DATs more flexibility to set local targets and develop
initiatives that respond to local circumstances;
• relaxation of NHS rules which require annual allocations of treatment
monies to be spent within the year for which they are allocated; and 
• a greater emphasis on long-term planning and funding cycles that
allow greater synergy with other partnership activities. 
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The Government could further assist local areas by ensuring that the
future management of drugs policy is well co-ordinated. A number of
Government departments play a key role in policy development and the
NTA has already put together an ambitious business plan to guide the
further development of drug treatment services. However, without careful
management, there is a danger that local stakeholders will be
overwhelmed by the pace of change and could struggle to prioritise their
local agenda. Clarity around expectations and a clear statement of the
responsibilities and priorities of each department would be welcomed by
all working in the drug treatment sector and ensure more effective service
delivery. Ensuring that new Government initiatives have been allocated
sufficient time to deliver results (and are properly evaluated) would also
help. 
DATs need to develop a clear strategy to guide the development of
treatment services. This should reflect the needs of current and emergent
problem drug misusers within their area. More fundamental service
reviews will also be needed to improve the quality of local provision and
determine local priorities. 
Assessing local needs
To be effective, local strategies for drug treatment services should be
informed by up-to-date information on:
• drug-using patterns and the socio-demographic characteristics of drug
misusers identified in the area;
• different patterns of use by age, gender and ethnicity; and
• any distinct geographical patterns or ‘hotspots’.
A number of sophisticated approaches have been proposed, based on
epidemiological models. But few areas have the capacity to use these
approaches successfully, at least in the short term. However, qualitative
approaches can be used locally to build up a picture quickly, and at little
cost. 
Current service providers and key agencies – such as the police and
probation – will all have views on the accessibility and quality of existing
provision and can help to identify any shortfalls and unmet needs.
Gathering information about existing clients’ satisfaction with the content
and impact of the treatment they receive can also be helpful, perhaps
through the establishment of service user forums. A drug misuse
treatment satisfaction questionnaire recently developed in the UK for the
drug misuse population could be used to solicit views (Ref.67). Feedback
from outreach workers and street agencies can provide early indications
of new trends, possibly supplemented by the insights of key staff brought
together in more formal monitoring groups [CASE STUDY 1].
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Reviewing the
quality and range
of treatment
services: local
action
Where new problems are identified, local research can be
commissioned to find out more about their scale and nature and the way
that services will need to adapt to meet emergent needs. As gaining access
to ‘hidden’ populations of drug misusers can prove difficult, some areas
have employed drug misusers known to services to carry out research on
their behalf and used the results to shape future patterns of provision
[CASE STUDY 2, overleaf].
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CASE STUDY 1
Leicestershire illegal drug monitoring group
In Leicestershire DAT a group consisting of representatives from the LEA,
two drug agencies, the health service, the police and other services meets
three times a year to report on recent developments and observations from
the perspective of service providers. Police report on seizures and arrests,
agency workers on the profile of their clients. To provide a basis for
comparison, the group strives to provide information on the availability of
particular drugs (up or down) and the prices of key drugs. This information
allows the DAT to get an updated picture of drug related trends in the
area, and to build up trends and target interventions accordingly.
Source: ‘Local Drug Action Team Information Systems’, Drugscope, 2001 (Ref.68)
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CASE STUDY 2
Peer research to identify the needs of crack cocaine users, Trafford
Probation Service and Trafford Substance Misuse Services
In 1994 Trafford Probation Service funded a research project that aimed to
gauge the extent of crack cocaine use in their district and to find out about
the needs of users. A detached drug worker at Trafford Community Drug
Team managed the project.
Drug users with recent experience of using crack cocaine were employed as
fieldworkers, with volunteers recruited on the basis that they had credibility
and access to the target group. Fieldworkers made contact with drug
misusers by ’snowballing’. To help penetrate ’hidden’ populations, initial
contacts were asked if they knew other crack cocaine users who would be
prepared to be interviewed. A total of 231 crack users were interviewed
during March and April 1994. 
The research found that almost half (48 per cent) of those interviewed had
never been in contact with a treatment service. And the vast majority of
those who had contacted a service had sought help with a co-existent
heroin dependency rather than their use of crack cocaine. Those who had
contacted a service specifically for their crack cocaine use (13 per cent) were
often disappointed with the service they received, with over half of this
group rating it as ’useless’ or of ’little use’. Many of those who had never
contacted a service felt treatment providers offered very little to meet their
needs or were unaware of local services.
A clearer picture of the ’style’ of service that crack users wanted emerged
from the research: essentially an informal drop-in service, staffed partly by
ex-users, and targeted specifically at crack cocaine users. Confidentiality,
rapid access and better information about crack cocaine were also
identified as key issues. The results of the research have helped to shape
Trafford’s approach to service development. A crack cocaine project – The
Piper Project – now provides an informal drop-in service for crack cocaine
users and has succeeded in attracting a broader range of clients, including
cannabis users and alcohol users. 
Source: Adapted from Bottomley et al, ‘Crack cocaine users – tailoring services to user need’
(Ref.58), with support from the Piper Project, Trafford.
Reviewing existing provision
Alongside needs analysis, a review of existing provision will give
DATs a clearer picture of the capacity of services to meet local demands
and, equally importantly, help to identify pressure points and shortfalls.
Information contained in DAT treatment plans provides a starting point
for such reviews, providing information on current capacity, waiting lists
and estimates of projected demand. Such information is useful but needs
strengthening to provide a firm basis for judging how services should be
adjusted. 
Initially, better information about costs and performance should be
collected routinely to inform local reviews and provide sound
management information for service providers and commissioners. For
some health authorities, the first steps will be to identify their expenditure
on specialist treatment services, clarify the range of interventions provided
and set out current practices in separate service agreements or contracts.
These should include some meaningful reporting requirements to identify
the levels of activity and outcomes achieved within existing resources.
Social services should also review their information systems, ensuring that
any provision commissioned is carefully monitored. Where services are
commissioned jointly, a standard framework for performance monitoring
can help to reduce pressures on providers.
For trusts, this is likely to require a shift away from current opaque
reporting methods (which tend to focus on input data such as occupied
bed days, outpatient attendances and finished consultant episodes)
towards a more client-centred approach. A number of ‘process’ measures
based on those factors known to influence treatment outcome – such as
retention, treatment completions and effective care planning – potentially
offer commissioners more useful insights into service performance
[BOX N, overleaf].
Any new information systems designed locally must fit with the
National Drug Treatment Monitoring System (NDTMS), not least to
reduce the burden on staff within reporting agencies. Under new
reporting arrangements, the NDTMS can potentially provide profiles of
all clients in treatment, identify those registered with more than one
agency and the type of treatment interventions provided. However, under-
reporting reduces the value of this information and continues to be a
serious problem, especially among GPs. The most effective way to get
people to return accurate figures is to use the information locally for
management purposes. At a local level, commissioners could help by
including compliance requirements in local contracts, service
specifications and formal shared care arrangements. 
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BOX N
Measuring activity and performance of drug treatment services
As the range of interventions provided by different services will vary,
activity and performance measures need to be carefully tailored to each
agency. However, the following ideas would help commissioners to begin to
gauge how well community drug services and street agencies are
performing:
Waiting times
• Average waiting time for assessment.
• Average waiting time for a service (for example, methadone treatment
slot, residential placement).
• The number of people waiting to begin treatment at the end of the
reporting period.
Referrals
• The number of new referrals seen by each service, by source, age,
gender, ethnicity and main problem drugs.
• Percentage of new referrals completing assessment process.
• Percentage of new referrals admitted to service and interventions
provided.
• Percentage of new referrals referred to other agencies.
Care management
• Percentage of clients with a care plan.
• Percentage of missed appointments and key worker sessions.
• Percentage of clients re-contacted after missed appointments and key
worker sessions.
• Percentage of clients jointly managed with other agencies.
• Percentage of clients completing treatment and leaving the service.
• Percentage of clients leaving treatment early/dropping out.
• Percentage of clients asked to leave the service.
GP registration and shared care
• Percentage of clients registered with a GP.
• Percentage of GPs and GP practices participating in shared care
arrangements.
Hepatitis B vaccinations
• Percentage of clients offered Hepatitis B vaccinations.
• Percentage of Hepatitis B vaccinations completed.
Source: Audit Commission
Outcome monitoring can be undertaken to supplement routine
information collection. Increased pressure from commissioners has led to
a proliferation of different approaches including customer satisfaction
questionnaires and the use of instruments like the Maudsley Addiction
Profile (MAP) and the Christo Inventory for Substance Misuse Services
(CISS) [BOX O]. However, commissioners need to consider carefully the
added value of such exercises and the reporting burden placed on
provider agencies. They should also be alert to potential problems. Where
sample sizes are small, changes in the severity of clients admitted to a
service can lead to large random variations in the apparent ‘performance’
of individual agencies. Equally, the reliability of information collected by
some instruments may be variable. For example, the CISS depends upon
workers’ own assessment of the ‘severity’ of clients’ problems so
interpretations may differ. Self-report data can also be questionable,
especially where clients may fear that some information may jeopardise
their treatment.
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BOX O
Outcome monitoring tools
Two outcome monitoring tools are increasingly used to assess the impact of treatment interventions in local
services:
Outcome or milestone management can be used alongside clinical
outcome tools to encourage both commissioners and providers to focus
on results rather than activities and to promote continuous improvement.
The approach involves commissioners and providers agreeing the
outcomes that their services are expected to achieve. Milestones are then
identified, showing the different stages that clients should pass through to
get results [EXHIBIT 21]. Throughput targets are then set for the numbers of
clients expected to pass through each milestone. Providers monitor how
far these targets have been met. On the basis of the monitoring data
collected, commissioners and providers may modify the contract or
change the ways that services currently work. This sort of approach can
allow workers to see if what they are doing is having a positive effect and
offer clients concrete evidence of their progress (Ref.71). It can also help to
ensure that services avoid pursuing ineffective activities. However, its
success depends upon commissioners and providers allocating sufficient
time to review activities and set meaningful targets: without this, there is
a danger that provision will ossify and fail to meet emerging needs.
EXHIBIT 21
Outcome management approaches
A street agency working with drug users might agree the following client milestones with commissioners.
Source: Audit Commission, adapted from ‘Outcome Funding: An overview and early experience for commissioners and providers of health and
social care’, Dr Chrissie Pickin, Salford and Trafford Health Authority (Ref.72)
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Another approach is to encourage services to conduct self-assessment
procedures and monitor and improve their own services. Some areas have
already developed peer audit projects that have led to local
improvements, using both the Quality in Alcohol and Drug Services
(QuADS) improvement standards and locally determined standards as a
benchmark [CASE STUDY 3]. Such approaches can be an effective way of
encouraging local agencies to learn from each other and build ownership
for change. However, such a step requires strong partnerships in which
the commissioner trusts the provider (and vice versa). Equally, providers
need to trust each other and manage the process in a way that promotes
(rather than damages) good interagency relations. In an environment
where agencies routinely compete for resources, this can be a tall order.
117.
73
4 • I M P R O V I N G  P E R F O R M A N C E
CASE STUDY 3
The South West Drug Services Audit Project
Source: Audit Commission fieldwork
The South West Drug Services Audit
Project was set up in 1991 and is
currently managed with the
Regional Drug Advisory Service. Its
aim is to help improve the quality of
local drug treatment services using
both local and national standards to
inform an annual cycle of peer
audit. It is currently funded by 6
health authorities and carries out
regular reviews across 19 statutory
and independent agencies in the
south west of England. 
A full-time Project Co-ordinator has
responsibility for organising audits
and ensuring consistency across the
various audits. But the services
themselves are largely responsible
for steering the project on behalf of
their health authority funders. The
Project follows an audit
methodology that encourages drug
service staff from both sectors to
work together to:
• reflect upon their work
systematically, critically and
openly;
• set new ’South West Audit
Project standards’ of good
practice;
• agree on improvements that
need to be made;
• check that improvements occur;
and
• work towards compliance with
national standards (QuADS).
Teams of three experienced workers
from the field plus the Project Co-
ordinator conduct the audits. A user
group representative has also been
included on an audit team on a trial
basis and the Project hopes to
develop this role in the future. Each
audit lasts one day and covers one
compulsory standard agreed by
Project members, and two optional
standards nominated by the service
itself from an agreed list of South
West Audit Project standards and
QuADS standards. 
Currently, audit reports and any
follow-up reports are confidential to
the individual services, with only the
overall results being reported in the
Project’s annual report. From April
2002, Drug Action Teams will also
choose one standard for the audit
and will receive a copy of the audit
report. Failure to meet the agreed
standards will result in an action
plan with action points and
timescales both for the service and,
where appropriate, the Drug Action
Team. These additional measures are
being introduced by the Project in
response to changes in the
commissioning structure and to
make the audit approach more
rigorous.
As a measure of success, between
1999/2000 and 2000/01 compliance
with standards has steadily
increased from 36 per cent to 81 per
cent. The Project has also built up a
directory of over 300 good practice
examples identified in the audits,
allowing local agencies to learn
from each other.
Strategic choice and priorities
On the basis of the information assembled, DATs and commissioners
should be in a better position to identify the priorities for addressing
unmet needs and for developing services. The indicators of needs and
service patterns identified through service review should start to trigger
discussions between agencies on key topics:
• Is the right range of services and interventions being provided to meet
the needs and tackle the risk situations?
• How do unit costs, take-up and retention compare between different
agencies? Can lessons be learned about more efficient methods of
delivery?
• Do funding and contracting mechanisms encourage high quality
services? For instance, is it a key objective to secure rapid access to
high quality residential provision? If so, the development of some
block or volume contracts may yield cost savings and reduce the
uncertainties many providers face, thereby allowing them to develop
more high quality services.
• Are the right numbers and type of staff employed in each agency? For
example, do their skills match the problems being tackled?
• Are services being provided in a timely and acceptable manner? 
• Are there specific barriers to access, and how could these be tackled?
For example, is there scope to improve signposting and develop new
links with mainstream services? 
• What role should specialist services play in supporting other agencies
in a more skilled and responsive approach?
For the most part, an incremental approach to change, concentrating
first on key blockages, such as long waiting times, is likely to be the best
way forward. But some areas have taken a more radical approach and
chosen to recommission all drug treatment services within their locality
[CASE STUDY 4]. Such approaches need to be carefully managed and
evaluated. For example, changing providers can be disruptive, and
continuity of service to existing clients must be assured. Potential
disadvantages – such as lack of GP support for emerging models,
difficulties securing new premises and the views of existing clients and key
stakeholders – must all be considered.
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CASE STUDY 4
Recommissioning drug treatment services in a London health authority
Source: Audit Commission fieldwork
Prior to 1997, a London health
authority contracted with a single
mental health NHS Trust to provide
community drug treatment.
However, despite expenditure of
almost £0.5m, the service was
unable to meet local demands and
was placing additional pressures on
local GPs, some of whom were
increasingly dealing with complex
clients with Hepatitis B and C. The
service was also poorly located,
offered no outreach provision for
crack cocaine users, and was
unwilling to develop shared care
arrangements.
Despite resistance from the specialist
service, the health authority decided
to re-tender its whole range of drug
and alcohol services. In partnership
with social services, new service
specifications were developed to
support the tendering process,
based on a tiered range of services.
Shared care arrangements were
developed in advance, partly as a
means of securing the wider support
of the GP population.
Following a high profile and
independent tendering exercise,
which included a consultant
psychiatrist from another service on
the selection panel, a community-
based independent agency was
awarded the contract, with
specialised generalist GPs providing
medical input. 
Over a period of 6 months leading
up to the cessation of the contract
with the specialist service, 110
clients were transferred to the new
community agency. Research into
the characteristics of 103 members
of this group found that:
• Their ethnic breakdown did not
reflect the local population,
with an under-representation of
black and asian clients. In
contrast, the new agency had
successfully attracted a much
higher percentage of these
groups.
• Over 80 per cent of those on
oral prescriptions at the time of
transfer reported continued
injection of illicit drugs, with
close to half admitting to using
heroin.
• 47 reported no discussion with
their former specialist worker
concerning Hepatitis and HIV, 28
not having been screened for
either Hepatitis B, Hepatitis C or
HIV.
• The rate of GP registration for
general medical services was low
at 32 per cent, with over three-
quarters of the sample reporting
there had been no discussion
with their former specialist
worker concerning the value of
GP registration.
• A high percentage (82.5 per
cent) had not discussed the
possibility of transferring their
care into the primary sector. 
Following the establishment of the
new agency, around half of the
clients who were transferred were
passed on to GPs and the number of
Hepatitis B vaccinations has
increased. The service has also
attracted a new cohort of clients –
young asian male heroin smokers –
and has introduced new services for
crack users. 
Adopting new strategies to attract ‘hard to reach’ groups is likely to
emerge as a priority in many areas, and a number of services have already
adopted approaches that others could follow. Some have already attracted
more crack cocaine users through the development of a targeted
recruitment strategy [CASE STUDY 5]. Others have sought to make services
more accessible to women. The Oasis Project in Brighton, for example, is
a women-only service offering crèche facilities for users. It also provides a
drug liaison midwife service, offering pregnant drug misusers more
intensive support. Post-natal support lasts up to six months as opposed to
the ten days usually offered by mainstream midwifery services. The
worker also accompanies service users to ante-natal appointments,
sometimes to ensure that more chaotic users actually attend and get the
support they need. Outreach support and personal safety courses are
provided for sex workers using drugs; potential clients are contacted via
their cards in telephone boxes or through local saunas and massage
parlours.
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CASE STUDY 5
Working with Black crack users in a crisis setting, City Roads, London
City Roads has provided a
residential crisis intervention service
in London since 1978. Due to
increasing numbers of crack cocaine
users and black drug users in the
capital, it secured a specific grant
from the Department of Health in
1994 to develop new responses to
the needs of this group.
The new project placed a strong
emphasis on making contact with
black crack cocaine users and
developed a recruitment strategy
with three components:
• a 24-hour crack telephone
helpline offering information,
advice, support and assessment
for users;
• advertising the service to
existing referrers to City Roads;
and
• advertising the service in a wide
range of outlets frequented by
the target group people,
including shops, newsagents,
solicitors’ offices, fast food
outlets, launderettes, barbers
and minicab firms.
In total, 20,000 cards and 8,000
leaflets advertising the crack
helpline were distributed to both
professional agencies and
commercial and other outlets.
The service also employed two black
crack-specific workers and made
two beds available solely for crack
cocaine users. Following assessment,
users could be admitted for up to
three weeks and receive a package
of care including medication and
support through the withdrawal
period, complementary therapies,
recreation and exercise and key
worker support. Workers also
helped users to consider options
open to them following discharge
and, where possible, organised
appropriate support. 
In the 34 months of its operation,
the project recorded a number of
positive outcomes:
• around 1034 calls were taken on
the crack helpline, around
one-half of which were from
clients in crisis;
• 248 individuals were admitted
to City Roads via the crack line.
219 of these used crack as their
drug of first choice and 70 per
cent were black. In contrast,
only 69 primary crack users were
admitted through other
admission routes over the same
period and only 28 per cent of
these were black; and
• on discharge, 44 per cent of
crack users were discharged to
residential or day programmes
offering intensive, structured
follow-up treatment. Only five
per cent left without an onward
referral to another agency.
This service has been subsequently
integrated into City Roads’
mainstream crisis service. In this way
it has continued to develop the
service and deliver successful
outcomes to black clients, including
those using crack-cocaine.
The efforts of local agencies must be supported by national action to
raise the quality of drug treatment services. While more rigorous reviews
can help local areas to provide the right services and deliver the
interventions in the right way, the NTA and SMIB could make an
important contribution by:
• improving the national collection of drugs data;
• developing a national framework for performance measurement;
• increasing understanding of ‘what works’; and 
• building the capacity and skills of staff within the drug treatment
sector.
Improving the collection of drugs data
Local quantitative estimates of prevalence and forecasts of future
trends could help DATs to respond more rapidly to emerging problems
and gauge the overall impact of their local drugs strategy. However, when
managed locally, such exercises take time and effort and their success can
easily be hampered by a lack of appropriate (often statistical) expertise
and concerns about confidentiality and data protection issues. Delays in
the release of key national data sets – such as drugs enforcement, seizures
and mortality statistics – can further reduce the value of such local
analyses.
An alternative option would be to strengthen national arrangements
to quantify and transmit accurate and more up-to-date local drugs data.
The Department of Health, for example, could examine the feasibility of
extending the role of the National Drug Treatment Monitoring System
(NDTMS) to provide estimates and forecasts for each DAT. This sort of
arrangement is normal practice in surveillance of communicable diseases,
such as HIV, where local health authorities receive estimates produced
nationally. Options need to be considered in parallel with new studies
that are being funded by the Home Office’s Drug and Alcohol Research
Unit to assist in providing new estimates of problem drug misusers and to
assess the feasibility of estimating prevalence at DAT level. 
Developing a national framework for
performance measurement
While local areas could do more to ensure that the performance of
services is measured effectively, the NTA and SMIB could take a lead in
developing a core national data set to capture key information in a
standard way. Ideally, this should move away from the current focus on
capacity and aim to include:
• input measures which show how resources are allocated in different
areas and by different agencies;
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• indicators of take up, timeliness and activity, which show the extent
to which services and interventions are accessed by target groups, the
speed of response and the effectiveness of care pathway management; 
• indicators of cost efficiency which judge the unit cost of an
intervention, such as cost per counselling hour delivered, or the
annual cost of a methadone maintenance treatment slot; and
• indicators of effectiveness and cost-effectiveness, which assess the
achievement of individual outcomes, and the unit costs involved.
Such an approach would be dependent upon appropriate investment
in computer support at a local level to facilitate data collection and
analysis. However, over time the data would provide a firmer basis for
assessing the performance of different agencies and enable comparison
and learning across different areas. Meaningful comparisons would be
dependent upon the identification of some standard categorisation of
interventions, such as structured day programmes and residential
programmes, many of which vary in length and content. Equally,
meaningful cost comparisons would depend on local arrangements for
disaggregating drug and alcohol expenditure and activity across services,
as well as the development of accounting rules which require treatment
costs in trusts to be managed consistently. 
Whatever information system is devised should seek to address the
information requirements of all relevant Government departments (DoH,
HO, HMT) and exclude re-reporting of any information already available
nationally. The Department of Health should also promote the potential
benefits of the new NDTMS system more widely and clarify issues that
may lead to under-reporting or incomplete data. Confusion about
‘informed consent’, for example, has recently led some psychiatrists to
refuse to provide patients’ initials to NDTMS, making it impossible to
identify where drug misusers are in contact with several agencies.
Increasing understanding of ’what works’
Many major difficulties within the drug treatment field stem from
uncertainty about ‘what works’. Although a growing body of research has
shown that many types of treatment interventions deliver positive
benefits, there remain some important gaps in knowledge. There is still no
strong evidence base for the treatment of stimulant dependency, or for
interventions such as outreach programmes, counselling or
complementary therapies. Moreover, while the effectiveness review
concluded that purchasers should have access ‘to a full range of well-
organised, properly monitored services’, little is known about the client
and organisational characteristics that reduce or prevent improvement.
Such gaps, combined with the lack of nationally agreed standards for the
delivery of key interventions and the absence of agreed service models or
accreditation schemes for community drug programmes, can mean that
local purchasers often struggle to address key issues:
127.
126.
125.
78
N A T I O N A L  R E P O R T • C H A N G I N G  H A B I T S
...meaningful cost
comparisons would
depend on local
arrangements for
disaggregating drug
and alcohol
expenditure and
activity across
services...
• Should they restrict investment to more proven interventions or
experiment with less proven approaches, such as structured daycare
programmes or new prescribing options, such as naltrexone? 
• What criteria should govern access to different types of interventions?
• What staff mix and interventions should community drug services
offer? What role should medical specialists play in local
arrangements? 
The NTA must help local areas to answer these sorts of questions.
This requires action on a number of fronts. One priority is to begin to
address research gaps around the effectiveness of specific interventions
and the treatment of non-opiate drug problems. In this context, recent
Government announcements to set up a group of key experts to tackle the
treatment of crack cocaine dependency and develop new guidance around
heroin prescribing, provide an important step forward. To guide
purchasing decisions, more research is also needed to accumulate evidence
about the cost-effectiveness of different interventions and the type of
services and staffing mixes that appear to work best. In the longer term,
the development of an accreditation scheme for community drug
programmes should also be considered. 
Ensuring that partnerships and commissioners can understand and
interpret the existing research base, learn from each other and critically
appraise any new local approaches is also important. This will require the
NTA to continue to support change on the following fronts to support a
‘learning culture’:
• ensuring that staff on the ground have the time and appropriate skills
to draw on research to inform strategic choices about drug treatment;
• promoting research findings in an accessible format that increases
local understanding of why and in what settings different approaches
can be most effective; and
• allowing local work to inform national level decision making by
giving partnerships scope to learn and experiment and feed back
results to the ‘centre’.
Steps must also be taken to promote greater agreement about the best
way to deliver interventions with a strong evidence base, such as
methadone prescribing. Learning from other clinical areas that have
sought to secure rapid improvements in practice and promote agreement
on the best way to provide care, may prove the best way forward.
Collaborative improvement approaches, for example, have already been
successfully used to promote improvements in both primary care and
cancer services. They have also helped to strengthen multidisciplinary
working, promote enthusiasm for change and, most importantly, improve
the patient’s experience of care [CASE STUDY 6, overleaf]. Critical success
factors include a central team with experience of collaborative
approaches, performance measurement and redesign skills, as well as a
clinical excellence team bringing together individuals with substantial
experience of promoting improvements in the topic area. 
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CASE STUDY 6
The Collaborative Improvement Model
The collaborative approach is based
on the premise that:
• A substantial gap exists between
knowledge and practice in
healthcare.
• Broad variation in practice is
pervasive.
• Examples of improved practices
and outcomes exist, but they
need to be described and
disseminated to other
organisations.
• Collaboration between
professionals working toward
clear aims enables improvement.
• Healthcare outcomes are the
results of processes / systems
• Understanding the science of
rapid cycle improvement can
accelerate demonstrable
improvement.
It relies on spread and adaptation of
best practice through multi-
disciplinary teams to accomplish a
common aim. The key ingredients of
the approach are:
• A practical review of current
processes, identifying key
constraints, delays and
bottlenecks.
• Permission to redesign and
streamline the current process.
• A flexible improvement model
for testing, and implementing
changes.
• Packaging of specific evidence-
based subject matter knowledge
(best practice).
• Small-scale testing to create
momentum for making big
changes to the system.
• Effective use of data for
learning.
• Collaboration with other teams
and experts in the subject
matter to share learning.
At the start of the project, three key
questions are addressed:
• What are we trying to
accomplish?
• How will we know that a
change is an improvement?
• What changes can we make that
will result in improvement?
A Plan, Do, Study, Act cycle (PDSA) is
used to test existing systems. The
cycle begins with a plan and ends
with action being taken based on
the learning gained from the Plan,
Do, and Study steps of the cycle. The
four steps in the cycle consist of
planning the details of the test and
making predictions about the
outcomes (Plan), conducting the test
and collecting data (Do), comparing
the predictions to the results of the
test (Study), and taking action based
on the new knowledge (Act).
I The collaborative improvement model is described in detail in an article entitled ‘A Framework
for Collaborative Improvement: Lessons from the Institute for Healthcare Improvement’s
Breakthrough Series’ written by Charles M Kilo and presented in ‘Quality Management in
Health Care’ 1998, 6(4), 1-13 © 1998 Aspen Publishers, Inc.
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* LS = Learning session
The Cancer Collaborative
Based on the results of the test, a
change, or some part of a change,
could be implemented, or it could
be modified and re-tested, or
abandoned. When the overall
desired improvements are achieved,
details are presented as good
practice to other services through a
combination of national
conferences, Service Improvement
Guides, conference calls and links to
professional bodies.
The Cancer Services Collaborative
(CSC) is a national programme that
seeks to improve the experience and
outcomes of care for people with
cancer. Phase one of the CSC
established 51 dedicated teams
within 9 cancer networks to improve
services over a 2-year period (1999-
2001), using a simple change
framework developed by Professor
Don Berwick at Harvard’s Institute
for Healthcare Improvement.I
Each network undertook a series of
projects with each project focusing
on patients with a specific cancer:
bowel, breast, lung, ovarian, and
prostate. The ideas for change were
developed from expert meetings,
discussions with leading
practitioners, and literature reviews.
During the CSC, doctors, nurses,
managers, clerical staff, porters,
technicians and staff from every part
of the healthcare system worked
together to examine the service that
they provide, to consider what could
be made better, and to make
improvements for patients. During
the term of the project many teams
achieved improvement rates of up
to 80 per cent against key targets.
These included:
• reducing the time from patient
referral for cancer to the first
definitive treatment;
• improving access to
investigations eg, a 13-week
wait for barium enemas cut to 1
week;
• increasing the capacity in out-
patient clinics eg. 3 visits over 4
weeks to get a diagnosis
reduced to 1 week and a single
visit; and
• procedural changes as a result
of new methods of canvassing
patient views and levels of
satisfaction.
A major strength of the CSC was
that it provided an important forum
for clinical teams from across the
country to come together and to
share how they deliver services.
Teams tested ideas out with each
other, learned from each other’s
failures, and developed mechanisms
to adopt the changes that worked.
Many of the improvements that
have been made are not due to
inventing new ideas but are due to
applying an existing idea that has
already been shown to work well.
This, coupled with the fact that the
collaborative change framework is a
practical approach which places
great emphasis on doing rather than
reviewing, and with timescales
leading to improvement measured
in days and weeks rather than
months and years, created
widespread enthusiasm and an
extremely positive environment for
change.
Applying such a model to the delivery of methadone treatment may
lead to clearer standards for prescribing services. But much variation
currently stems from different interpretations of risk. Some stakeholders
adopt a relatively narrow, clinical approach – focusing on the risks arising
from leakage and the danger of methadone-related deaths – which points
to the need for close supervision and compliance. Others take a broader
approach – taking into account other ‘risks’ associated with continued use
of illicit, and often contaminated, substances and the wider impact on
crime levels – leading to more emphasis on engagement. Less variable
practice may consequently hinge upon clearer agreement about the
appropriate balance of risk to adopt. 
Building the capacity and skills of staff
Many drug misusers interviewed by the Commission reported that
staff in the drug treatment sector were supportive, highly motivated and
provided them with a lifeline:
I have a good relationship – I tell him everything – and honestly!
Female, heroin user, aged 31.
They really care, really, really wanted to help, you could see how
motivated people are...how caring they are!
Female, heroin user, aged 28.
My support worker is marvellous, she would bend over backwards for
you!
Male, heroin user, aged 21
But lack of appropriate staff or the absence of appropriate skills among
the existing workforce must be managed by the NTA and SMIB. The
current development of occupational standards for the drug treatment
sector, and a new qualifications and curriculum framework, are important
starting points and should increase professional status and career
development opportunities within the field. However, the introduction of
these new arrangements will take time. In the short term, emphasis needs
to be placed on the development of initiatives to:
• strengthen the knowledge base and expertise of those involved in the
commissioning of local services;
• develop the leadership and management skills of service managers;
• promote the development of effective team working within
multidisciplinary services; and
• improve workforce planning to address shortfalls in key staff and
identify short-term measures that commissioners and service managers
can take to bridge gaps.
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lack of appropriate
staff or the absence of
appropriate skills
among the existing
workforce must be
managed by the NTA
and SMIB.
A critical area for improvement is the capacity to offer drug misusers
well co-ordinated, tailored packages of care that can bring together
appropriate support from a range of agencies. At present there is little
guarantee that the services provided will match a client’s level of need or
that they will be provided in a ‘seamless’ way. This increases the risk of a
‘revolving door’ syndrome, as those people who ‘fall’ between different
providers, or fail to get appropriate help after treatment, resume their
habit and re-enter services a number of times. The nature of drug misuse
means that such cases cannot always be avoided. However, better
management of the initial referral process and the subsequent care
pathway offers an opportunity to achieve better results.
The recent development of the Department of Health Models of Care
(MOC) Project has already begun to examine how these issues will be
addressed. This recognises that in most DAT areas better pathway
management will depend on the establishment of more systematic
processes of care for: 
• screening and assessing to identify the actions required in a care plan
agreed with the user;
• managing and organising care, in accordance with the goals identified
in the care plan;
• ensuring continuity of care; and
• promoting ongoing monitoring and review.
This agenda provides a significant challenge for the drug treatment
sector. First, it requires the development of a common screening and
assessment framework and care management practices to underpin
effective co-ordination across local agencies: many have evolved, and are
committed to, their own procedures and practices. Different services also
have different philosophies of care. Some CDTs see their role largely in
clinical terms – with an emphasis on treating a specific condition, rather
than on managing care. Equally, some social services departments have
placed strong emphasis on providing continuity of care, while others see
themselves primarily as ‘local purchasers’. A further challenge stems from
the need to manage care co-ordination and pathways across a large
number of agencies. Some DATs in England, for example, rely on services
from up to three CDTs, while DAATs in Wales may cover up to six
separate social services departments. Concerns over the resource
implications of new arrangements and the proposed timescale for
implementation may pose further barriers to change, especially during a
period of rapid change within the NHS.
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Promoting better
care co-ordination
and joint working:
local action
These sorts of difficulties underline the need for an incremental, well-
planned approach. In most areas, the first step will be to identify who will
take lead responsibility for driving forward the introduction of new care-
planning arrangements and build ownership for proposed changes.
Working together, commissioners and local providers will then need to:
• better define the roles and responsibilities of different services and
their objectives;
• develop a shared understanding of what needs to be done locally to
improve care management and co-ordination; 
• establish and agree clear criteria for referrals between services and
how they will be dealt with;
• agree clear criteria and common procedures for assessment to ensure
that the plans for future care reflect a multidisciplinary, integrated
approach; 
• agree how training and development needs arising from the
introduction of new arrangements will be addressed; and
• consider how users could be involved in developing the new
approach.
More effective care co-ordination will be the cornerstone of successful
approaches, addressing many of the difficulties clients currently face in
finding their way through a maze of local services. In recent years, a
range of approaches has emerged in related fields that can provide models
to follow. The Care Programme Approach (CPA), for example, is used in
mental health to achieve better co-ordination, with specialist mental
health teams, including both health and social service staff, taking the
lead [EXHIBIT 22]. A single plan is devised which sets out the contributions
from each service and a single worker keeps in touch with the client and
makes sure that all the necessary elements of care are delivered. Clear
criteria are established to determine those who are entitled to receive a
care programme; where resources are very limited, those with severe
mental illness are the first to receive care programmes. When care
management programmes are operating fully, users have said how much
they value access to a named worker who knows them and can be
contacted about their needs, regardless of which agency is involved (Ref.73).
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EXHIBIT 22
The care programme approach in practice
Recent proposals to modernise the Care Programme Approach emphasise the role of the care co-ordinator.
Source: Adapted from: ‘Modernising the Care Programme Approach: A Policy Booklet’, London: Department of Health (Ref.74)
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Each local area will need to decide how such systematic approaches to
care co-ordination can best be implemented in their area and identify
which agency should take the lead. Decisions will need to take into
account the skills and capacity of existing agencies, as well as their ability
to marshal support from a wide range of statutory and independent
providers. In practice, a team that brings together social and health
professionals may prove to be the best option, allowing both medical and
social care needs to be addressed together in multidisciplinary assessment
and care planning processes. Such teams offer clients a more streamlined
service, with one person responsible for driving their case through. In
some areas, teams could be built around existing CDT structures,
especially where these already include a broad mix of different
professional groups within local teams. However, such teams would need
to be carefully managed to ensure that different professional disciplines
made a full contribution to patient-centred care. 
Where CDTs are unwilling (or felt to be unsuitable) to take on a
broader role, other options could be considered. The care co-ordination
function could be located with either a well-established street agency or
social services, given the latter’s growing experience of care management.
However, in most cases, medical input would be lacking and the problems
of multiple assessment would persist. A more radical approach could be
to locate the care management function outside the provider network
altogether. In some parts of America, for example, separate care
management projects provide a single point of referral for people with
drug misuse problems who are on welfare. Projects, which generally
include a mix of treatment professionals, undertake assessments, refer
people to other services and manage their progress until they are ready to
return to work. Such arrangements help to ensure that assessment is
standardised and could provide an incentive for quality outcomes, as care
co-ordinators can choose which providers to use. On the other hand,
developing effective relationships with providers can prove problematic.
Doctors providing treatment would need to make their own assessments.
In the longer term, the NTA and the Home Office Drugs Strategy
Directorate should consider giving clear guidance to local agencies on
effective care management models, based upon the outcomes of the
Enhancing Treatment Outcomes initiative (which is piloting arrangements
for improving care co-ordination in eight DAT areas in line with the
Models of Care Project) and an evaluation of approaches adopted outside
the UK.
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Promoting better
care co-ordination
and joint working:
national action
...a team that brings
together social and
health professionals
may prove to be the
best option, allowing
both medical and
social care needs to be
addressed together...
Whatever local models are developed to improve care co-ordination,
developing more flexible approaches that are closely tailored to the needs
of individual clients will be key. Many areas need to strengthen the
support they provide to people following treatment, particularly those
with more complex ongoing problems and ex-prisoners. Some agencies
have already started to develop imaginative approaches to support ex-
prisoners using link workers based in voluntary agencies [CASE STUDY 7].
Others have recognised that the need for assistance with housing and
other practical support is often not time-limited and developed long-term
projects to help drug misusers with complex needs [CASE STUDY 8, overleaf].
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Developing more
flexible
approaches: local
action
CASE STUDY 7
Revolving Doors – providing link workers for ex-prisoners with complex needs
Revolving Doors Agency is the UK’s
only charity concerned exclusively
with mental health and the criminal
justice system. It runs practical
schemes in police stations, prisons
and courts to support people with
mental illness, multiple needs and a
history of offending. This is a
vulnerable and often chaotic group
who have ’fallen through the net’ of
mainstream service provision and
have little or no support in gaining
access to the services they need.
Since March 1993, Revolving Doors
has worked in partnership with the
police, health, housing, probation
and social services in London to
research the needs of this group.
Having identified the demand for a
service, it set up experimental Link
Worker schemes to offer support
and to identify new ways of
improving access to housing, health
and social care.
There are now four teams operating
in Ealing, Tower Hamlets, Islington
and southern Buckinghamshire. The
teams work across the criminal
justice system, with people leaving
Wormwood Scrubs, Pentonville,
Holloway and Woodhill prisons as
well as those in local police stations
and courts. The service was
extended to prisons in October 2000
and received 332 referrals in the
first six months of operation. It is
expected that the four schemes will
receive 1000 new referrals from
across the criminal justice system.
Substance misuse is a common
problem for the client group, with
75 per cent having a drug or alcohol
dependency, rising to 95 per cent of
long-term clients leaving prison.
Many are some way off being able
to benefit from specialist substance
misuse services. Harm reduction is
the top priority in the short term,
together with social and practical
support .
The teams tackle substance misuse
within a multidisciplinary
framework. They help clients to link
into a range of other services to
improve related aspects of their
lives, such as gaining meaningful
daytime activities and a secure
tenancy. The aim of the approach is
to increase stability and support for
clients with a view to engaging with
specialist services later and with
greater success. Recent measures of
the impact that the Ealing scheme
has had on its long-term clients have
shown that:
• 30 per cent experienced
improved access to
detoxification services, with
access being declined to just 6
per cent of cases;
• 23 per cent gained improved
access to mental health services,
with less than 2 per cent being
refused; and
• 34 per cent experienced
improved access to a GP either
through permanent or
temporary registration with just
5 per cent refused. 
The prevalence of substance misuse
among the client group requires
Link Workers to be trained to deal
with both drug and alcohol
dependency as well as mental
health problems. The composition of
the team also enables them to work
across boundaries to pursue
multidisciplinary solutions to
problems. Link Worker teams
comprise nurses, probation officers,
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Source: Revolving Doors
voluntary sector workers, social
workers and occupational therapists,
ensuring a range of skills are
available to meet clients’ needs.
Each scheme has successfully
brought together expertise from
other sectors through multi-agency
advisory groups that monitor and
advise on the development of their
work.
The Link Worker approach is based
on the findings of thorough
research. Anonymised records are
kept of drug and alcohol
dependency, tenancy arrangements,
conviction history and other
relevant factors, while outcomes
such as registration with a GP or
receipt of benefits are analysed to
assess where the schemes are most
successful and where they can
improve. The aim is to use the
evidence collected to establish a
successful model for supporting this
group effectively – and within
budget – so that other agencies can
develop and run schemes in their
local areas.
Of central importance is the training
of prison, court and police officers
on mental health issues –
particularly where mental illness can
be masked by the effects of drugs
and alcohol. Link Workers run a
rolling training programme to help
officers identify and refer prisoners
with mental health problems and to
improve their knowledge of what is
available in the community. 
Case History
Bill is a 35-year-old man of Irish
descent with a long history of drug
and alcohol use. Between the ages
of 21 and 30, Bill was unemployed,
spending long periods sleeping
rough and committing petty
offences to fund his growing drug
habit. During this time, Bill was
involved in a series of abusive
relationships and was charged
several times with assault. On his
30th birthday, Bill took an overdose
following the breakdown of his
long-term relationship, and was
found face down in a pub car park.
He continued to sleep rough and
take drugs. Aged 33, he was
arrested for assault following a fight
in a pub and served one-half of an
8-month sentence. 
While in prison, he completed a
10-day detox programme. When he
self-harmed on the Wing he was
referred to the Revolving Doors Link
Worker Team. Bill had no fixed
abode, and the vast majority of
hostels were barred to him because
of his drug problem. He was not
registered with a GP and was still
dependent on drugs. 
Before his release, the Team and Bill
planned how to link him into the
services that he would require on
release. He identified housing as a
priority. Without accommodation,
he told Link Workers that he felt his
only option was to squat with
friends where drugs were easily
available. However, he wanted to
stop using drugs and was
enthusiastic about getting a place
on a drug-detox programme.
Prior to release, Link Workers liaised
with the Community Drugs Team
(CDT) and arranged for an
assessment of need for Bill which
took place on the day of his release.
Following his assessment he saw the
CDT frequently for 4 weeks. Also
before release, the Team referred
him to a local direct-access hostel.
He was successfully assessed and
accepted for a place. This meant
that he had accommodation during
the 4-week period before joining
the detox programme. 
Throughout this time, Bill
maintained contact with the Link
Worker Team who were able to
support him with his depression and
other mental health issues. This
included registering him with a GP
who prescribed him some
antidepressants. He completed the
detox programme and then went
into rehabilitation, which lasted 18
months. Bill no longer uses the Link
Worker service but he is free to re-
access the service at any point
because the Team do not operate a
system of case closure.
The current development of Supporting People, the new policy
framework for supported housing, provides new opportunities for DATs
and commissioners to extend these types of schemes and establish (or
review) policies in relation to drugs and homeless drug misusers. Policies
should recognise that poor housing, or lack of access to housing, is often
a contributory factor in drug misuse and try to avoid concentrating drug
misusers in particular areas. Proposals for dealing with any ‘nuisance’
arising from a drug misuser’s behaviour should also seek to minimise the
revolving door syndrome by treating eviction as a last resort. Taking steps
to avert tenancy crises through practical support, ‘early warning systems’
and resettlement services are likely to prove more cost effective in the
long run. 
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CASE STUDY 8
Intensive support programmes for high needs clients, Focus Housing Group, Birmingham
Source: Audit Commission fieldwork
This supported accommodation
project is aimed at men in the age
group 25–45 who are homeless and
who have a history of serial
exclusion from all other direct access
hostels in Birmingham. It has
provision for fifteen individuals to
reside at the project for up to four
years in purpose-built flats. Annual
revenue costs of £297,000 (2000/01)
are funded by the health authority
(35 per cent), Social Housing
Management Grant (4 per cent),
and rents made up of housing
benefit and personal contributions
(61 per cent).
Many of the residents have
combinations of mental health, self-
harm, behavioural, alcohol misuse
and substance misuse problems. The
project works with these issues to a
greater degree than in standard
provision and provides:
• support on a 24-hour basis;
• intensive housing support;
• welfare rights advice;
• help in accessing primary
healthcare and specialist
services; and
• advice and support with basic
life skills.
All the support services are intended
to enable individuals to stabilise
their lifestyle and maintain
accommodation and there is an
emphasis on joint working with
other agencies so that this can be
achieved successfully.
Referrals to the project are
identified by the Community
Homeless Mental Health Team, the
Rough Sleeper’s Initiative Contact
and Assessment Team, and by local
authority departments involved in
mental health and homeless
services. Every referral has to be
submitted for approval by an
allocations panel and the project
manager. The project does not
accommodate people whose
behaviour/lifestyle is such that they
should be dealt with through the
criminal justice service or as an
inpatient in community care
services.
In many cases, flexible support will only be achieved where partners
in key services areas – such as housing, social services, mental health and
substance misuse – work closely together. This requires a clear
understanding of each agency’s respective responsibilities and scope of
involvement in assessing care and support needs. Distinctive statutory
remits, cultures and accountability procedures can make this difficult to
achieve. But shared guidelines, protocols and procedures can help to
clarify who is to do what. Other approaches include changing the way
that services are organised and the style of operation to allow for a more
preventive, multidisciplinary approach. In one authority, for example,
local panels have brought together key professionals to promote a more
co-ordinated approach to the care management of high risk clients with
complex needs [CASE STUDY 9]. More effective liaison could also be secured
through joint training, allowing different agencies to develop shared
knowledge and skills, agree common objectives and establish regular
communication channels. 
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CASE STUDY 9
Jointly managing high risk clients with complex needs, Surrey Social Services
Source: Audit Commission fieldwork
Surrey Social Services recognises that
substance misusers with personality
disorders or mental health problems
(‘dual diagnosis’ clients) can
represent a very high risk group. In
order to protect both individual
clients and the community, it has
agreed that rehabilitation should be
easily available to this group and
that social services has a
responsibility to re-engage high risk
clients as soon as possible. Two main
measures have been introduced to
achieve this:
• Five specialist substance misuse
social work/care managers,
attached to local substance
misuse teams, are employed to
assess and manage clients and
refer more complex cases to a
local ’substance misuse panel’.
• Two localised ’substance misuse
panels’ have been introduced to
oversee and co-ordinate the
care of identified individuals.
Membership of the substance
misuse panels includes social
services, NHS mental health trusts,
criminal justice and housing
representatives. The relevant
substance misuse social work/care
manager also attends. Managers
from the assertive outreach team
and a local assessment centre (which
provides respite beds for drug
misusers) attend in an advisory
capacity. 
Workers from partner agencies who
are involved in cases coming before
the panel are also invited to attend
for discussion of their client. The
structure ensures:
• long-term, co-ordinated
oversight of contact and
engagement with identified
high risk/vulnerable clients;
• co-ordinated care of clients with
dual diagnosis to avoid barriers
between mental health and
substance misuse services;
• information exchange about
these clients with relevant
agencies; and
• reduction and containment of
risky behaviours through
co-ordinated community
support and assertive outreach.
‘I’m confident that my GP is doing the best for me...My doctor
doesn’t speak down to me, doesn’t think she’s better than me and she’s
always willing to help and when you go back to see her she remembers
what happened last time...not all the doctors have been like that.’
Male heroin user, aged 21
Irrespective of the configuration and focus of specialist services, GPs will
continue to be a key resource in the treatment of drug misuse. The
current shift towards primary care and many drug misusers’ preference
for treatment in a primary care setting mean that new partnerships with
specialist services make good sense. And while not all GPs are willing to
play a more active role, some may be prepared to do more [BOX P]. The
Audit Commission survey of GPs, for example, found that 27 per cent of
respondents would be prepared to work with more opiate users if they
had access to specialist support. Results from NTORs also show that
treatment in a GP setting can be successful, finding no differences in rates
of improvement between clients receiving methadone treatment in
specialist clinics and general practice settings (Ref.75).
Shared care arrangements that focus on those GPs who are willing to
participate, build up their expertise, and ensure an effective balance
between the roles of specialists and generalists, are likely to be the most
promising approach [CASE STUDY 10, overleaf]. However, the strengths and
weaknesses of different models need to be carefully considered, with
options carefully matched to local circumstances and agreed with local
medical committees and primary care trusts. Dorset Health Authority, for
example, has sought to address local GPs’ concerns about the lack of
consultant support in West Dorset by purchasing a specialist consultant
service from an adjacent NHS Trust. Under a 12-month fixed-price
contract, the neighbouring Trust agrees to provide the local nurse-led
specialist service and local GPs with: 
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Improving support
to primary care:
local action
B0X P
Positive GP attitudes to working with drug misusers
Some GPs reported that they found
working with drug misusers a
positive experience and some would
do more if training and support
were available:
No protocols or training have been
offered at all. I could only make an
informed choice of treating, or not,
after that.
Willing GPs should get protected
time for proper training, and
updating their skills in managing
this group of patients. They should
be remunerated appropriately.
Locally agreed guidance is needed
for a consistent approach to
management, and closer liaison
with local GP services.
When I have got involved it has
actually been very rewarding.
Difficult, interesting, challenging
and worthwhile!
• specialist consultant outpatient sessions for five clients with complex
needs (up to three appointments per client);
• up to four ‘surgeries’ at the drug service offices for GPs who need
advice on how to manage patients with complex substance misuse
needs;
• input to the local GP training programme; and 
• a weekday telephone helpline service for GPs within the West Dorset
area. 
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CASE STUDY 10
The Consultancy Liaison Addiction Service – an integrated, primary care-based community drug and alcohol team
Source: Audit Commission fieldwork
The Consultancy Liaison Addiction
Service (CLAS) has been operating in
south-east London since 1995. The
service comprises a team of three
drug and alcohol community
psychiatric nurses, supported and
managed by a principal in general
practice. All staff in the CLAS team
have specialist training in
addictions, with the GP consultant
having psychiatric training to senior
registrar level. As the service is
approved to provide the psychiatric
component for general practice
vocational training, a Senior House
Officer is also attached to the team. 
The key aims of the service are to:
• enable drug and alcohol
misusers to access primary
healthcare services. The team
works with 72 neighbouring
general practices and local
street agencies, supporting the
treatment of alcohol misusing
and drug misusing patients. A
menu of possible services is
offered to each practice,
including the provision of a
weekly or bimonthly
consultation and assessment
service, one-off advice, brief
intervention therapies,
establishment of a practice-
controlled drug register,
community detoxification and
liaison with other services where
appropriate. 
• improve the skills of GPs and
primary care nurses in
identifying and managing
patients with alcohol and drug-
related problems. In-house
training is offered to practice
receptionists, managers and
administrators in all local
practices and specific courses
have been organised for
primary care nurses. To date, 17
different training sessions have
been run, involving 123 practice
staff. The team also provides
training to all GPs on local
vocational training schemes,
following this up with a session
during their GP practice
attachment. 
• enhance the quality of care
these patients receive by
developing clinical guidelines,
practice protocols and policies.
The team is closely integrated
into the secondary specialist
addiction service based at the
South London and Maudsley
Trust. CLAS offers specialist
primary care expertise and
advice to the specialist provider
and health authority and has
been actively involved in
drawing up local shared care
guidelines and payment
schemes for GPs involved in the
care of drug misusers.
Since the service was established,
the number of local GPs prepared to
see alcohol and drug misusing
patients has increased, although the
majority of patients are still seen by
a minority of GPs. Over the years,
the team has tended to focus its
efforts on those GPs willing to work
with substance misusing patients,
while encouraging others to take on
some patients and countering their
reluctance.
Whatever model is agreed, critical success factors will include: 
• the production of locally agreed management guidelines that define
the roles and responsibilities of both GPs and the specialist service;
• good joint working relations between specialist and primary care
services;
• a comprehensive training strategy for GPs, preferably supported by
locum cover that will help to release GPs from their surgeries; and
• clear arrangements for monitoring and evaluation.
The appointment of a shared care facilitator, who can oversee the
development and management of local arrangements and provide a point
of contact for GPs, may also be helpful. Camden drug action team, for
example, appointed a facilitator to increase the number of GPs
participating in shared care arrangements and to ensure they work within
the clinical guidelines.
Local schemes should also address the needs of other primary care
staff, many of whom have high levels of day-to-day contact with drug
misusers. Community pharmacists, for example, can play an important
role in the management of drug misusers, including dispensing drugs as
part of supervised consumption arrangements and offering needle
exchange services. However, research has shown that many are an
underused point of contact for the drug misusing population and would
benefit from a closer relationship with prescribing services and improved
training (Ref.76).
Funding flexibilities introduced by section 36 of the NHS Primary
Care Act 1997 provide opportunities to offer GPs additional payments to
recognise increases in workload and expertise. Drug misusers generally
consult their GP more than other patients, they require more prescribed
items and generate specific costs related to methadone prescribing, such
as toxicology charges. One study estimated these costs at around £2,030
per year in 1994 [BOX Q, overleaf], though others have put the cost closer to
£1,000 per annum. The financing of individual GPs would need to be
considered carefully to reflect the extent of their responsibilities and
should only be considered alongside other measures that seek to enhance
support to GPs – payments alone are unlikely to secure greater
participation. The development of Personal Medical Services pilots also
gives health authorities scope to negotiate new salaried contracts with
GPs to meet specific local needs, such as providing care for drug misusers. 
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The appointment of a
shared care facilitator,
who can oversee the
development and
management of local
arrangements...may
also be helpful.
The Department of Health has already taken steps to improve training
and support to GPs, in partnership with the Royal College of General
Practitioners (RCGP). An accredited Certificate course has already been
developed for those GPs with a special interest in drug misuse and a
Diploma-level qualification is under development. However, there is
currently no training scheme or accredited qualification for the increasing
number of GPs who lead multidisciplinary drug teams and often act as
the local ‘expert’ in the absence of a more traditional specialist service.
This gap needs to be addressed and will require clarification of the core
skills and competencies of GPs working in this capacity, as well as
agreement on remuneration and clinical governance arrangements.
Developing an undergraduate curriculum designed to promote training in
drug misuse in nursing, medical and pharmacy schools and considering
the role that emerging ‘nurse consultants’ could play in supporting drug
misusers could equally lead to an expansion of expertise and clinical
resources within the sector. Key stakeholders, including the relevant Royal
Colleges, RCGP, NTA and Department of Health, should work together
to oversee this agenda.
149.
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Improving support
to primary care:
national action
BOX Q
Estimated annual costs of methadone prescribing
Research based on 46 drug misusers receiving methadone maintenance
during an 18-month period at clinics run by general practitioners in
Glasgow identified the following estimated annual costs, based on 60mg
dispensed daily at a local pharmacy:
Cost per patient (£) *
General practitioner and practice time
(3 minutes weekly) 208
Counsellor time (20 minutes weekly) 173
Dispensing fees 806
Methadone 323
Toxicology (fortnightly urine analysis) 520
Total 2030
* Based on prices in 1994
Source: Philip Wilson et al ‘Methadone Maintenance in General Practice: Patients,
Workload, and Outcomes’, 1994 (Ref.77)
‘I can see the future and it looks bright’.
Male, crack cocaine user, aged 32.
People who become problem drug misusers often face myriad
problems; for Government, local agencies and communities, the problems
caused by drug misuse in turn pose a significant challenge. Effective
treatment services provide a major way of helping drug misusers return to
a healthier life in the community and can help to reduce
drug-related crime and social exclusion. Many of the weaknesses in
current provision can be remedied where local agencies strive to make
services more accessible and responsive to the needs of the user, improve
care co-ordination and joint working, and develop more effective links
with primary care. Better strategic planning, bringing together
information on local needs and service performance, must also underpin
new ways of working. 
The time is ripe for change in drug treatment services:
• New proposals to bring together the work of DATs and CDRPs
provide a new impetus to strengthen joint working.
• The NTA in England and SMIB in Wales can improve the national
framework – providing better guidance on service models,
strengthening the research base and promoting agreement upon best
practice.
• New investment can be used to expand and improve local services.
Securing improvement will take time, but the potential gains are immense.
If the opportunity is missed, the losers will be some of the most
vulnerable people and communities in the country.
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Changing Habits
Recommendations for drug action teams and key local agencies
Establish clear arrangements for joint commissioning drug treatment services
within the DAT area, ensuring that any joint arrangements are linked to each
partner’s mainstream activities and budget processes [paragraphs 100-102].
Promote effective links between DATs, key local partnerships (Crime and Disorder
Reduction Partnerships, Youth Offending Teams and Local Strategic Partnerships)
and other mainstream services to ensure a coherent approach to drug-related
problems [paragraph 101].
Identify the needs and profile of all problem drug misusers within the DAT area,
taking into account existing clients’ satisfaction with the content and impact of
the treatment that they receive [paragraphs 107-110].
Establish information systems to collect better information about the costs and
performance of drug treatment services in order to inform purchasing decisions
and more fundamental service reviews [paragraphs 112-117].
Consider the development of new strategies to promote the engagement of
’hard to reach’ groups and improve access where problems are apparent, for
example, through new recruitment strategies or women-only services
[paragraph 120].
Develop more effective assessment, care planning and co-ordination
arrangements to ensure that the services provided match a client’s level of need,
promote a multidisciplinary approach and minimise the risk of ’revolving door’
syndrome [paragraphs 133-139].
Improve the quality of support provided to drug misusers following treatment,
especially for ex-prisoners and those with complex, ongoing problems
[paragraph 141].
Establish (or review) policies in relation to drugs and homeless drug misusers and
consider new opportunities to strengthen joint working arising from the
development of the Supporting People policy [paragraphs 142-143].
Review the effectiveness of shared care arrangements, taking into account the
strengths and weaknesses of different models, new funding flexibilities and the
views of key stakeholders (GPs and practice staff, community pharmacists,
primary care trusts and local medical committees) [paragraphs 145-148].
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R E C O M M E N D A T I O N S
Changing Habits
Recommendations for central Government
The Home Office Drugs Strategy Directorate (DSD) should review the funding
framework for drug treatment services to promote a stronger emphasis on
long-term funding and review [paragraphs 103-104].
The Home Office DSD should consider whether new funding flexibilities
identified for the public sector (such as Public Service Agreements) could be
extended to the drug treatment sector [paragraph 104].
The Home Office DSD should ensure that drug treatment policy is well co-
ordinated and that the responsibilities and priorities of each Government
department are clearly stated [paragraph 105].
The Department of Health/NTA/SMIB/Home Office DSD should examine the
feasibility of using national drug treatment monitoring systems to provide
forecasts and estimates of drug trends for each DAT [paragraphs 122-123].
The Home Office/Department of Health/NTA/SMIB should address key research
gaps around the effectiveness of specific treatment interventions and their cost
effectiveness [paragraphs 127-128].
The NTA/SMIB should promote existing research findings in an accessible format
to increase understanding of ‘what treatment works’ [paragraph 129].
The Department of Health/NTA/SMIB should assess the feasibility of using
collaborative improvement approaches to promote improvements and greater
consistency in the quality of treatment offered by specialist treatment services,
focusing initially on community prescribing services [paragraphs 130-131].
The Department of Health/NTA/SMIB should improve workforce planning to
address shortfalls in key staff and build the expertise of all those working in the
drug treatment field [paragraph 132].
The Home Office DSD and the NTA should give clear guidance to local agencies
on effective care management models, based on the Enhancing Treatment
Outcomes initiative and approaches adopted overseas [paragraph 140].
The Department of Health/NTA/SMIB should agree the core skills and
competencies of specialist or consultant GPs and develop an accredited
qualification and training scheme for practitioners working in this capacity
[paragraph 149].
The Department of Health/NTA/SMIB should develop an undergraduate
curriculum for medical, pharmacy and nursing schools, in partnership with the
Royal College of General Practitioners (RCGP) and relevant Royal Colleges, and
consider the role that nurse consultants could play in supporting drug misusers
[paragraph 149].
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Checklist for action:
Improving services at a
local level
Strengthening partnership working and commissioning
 Set up an inter-agency group to oversee the commissioning of drug treatment services
 Make an officer responsible for developing key treatment contracts and specifications
 Ensure joint commissioning arrangements are linked to each partner's mainstream activities and budget processes
 Establish effective links between the DAT, joint commissioning group and other key strategic partnerships
Reviewing the quality and range of treatment services
 Canvass the views of current service providers, commissioners and key staff on the quality and accessibility of
existing provision and new trends
 Gather information about existing clients' satisfaction with the content and impact of the treatment they receive
 Identify expenditure on specialist drug treatment services and clarify the range of interventions provided by each
service
 Develop separate contracts or service level agreements with each treatment provider
 Ensure that performance monitoring arrangements collect robust information on costs and performance of services
 Consider the use of outcome monitoring and outcome funding models to promote continuous improvement
 Review current provision using information collected on needs and service patterns to identify service priorities
and options for change
 Consider new strategies to attract 'hard to reach' groups, such as women drug misusers and crack cocaine misusers
Promoting better care co-ordination and joint working
 Develop a shared understanding of what needs to be done to improve care co-ordination locally
 Define the roles and responsibilities of the different services and identify who will take the lead in driving forward
new care planning arrangements
 Establish and agree clear criteria for referrals between services and how they will be dealt with
 Set clear criteria and common procedures for assessment to reflect a multi-disciplinary, integrated approach
 Agree how training and development needs arising from the introduction of new arrangements will be addressed
 Consider how users could be involved in developing the new approach
Developing more flexible approaches
 Strengthen support provided to people following treatment particularly those with more complex problems and
ex-prisoners
 Introduce shared guidelines, protocols and procedures with partners in housing, children's services and mental health
Improving support to primary care
 Assess the strengths and weaknesses of the different shared care models and match the options to local circumstances
 Take account of the views of GPs and stakeholders, including the LMC and PCT, on the introduction of a shared
care scheme
 Introduce a local shared care policy in line with Departments of Health guidelines
 Consider including care for drug misusers in any new salaried contracts with GPs and offering additional payments
to other GPs supporting drug misusers
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Strengthening partnership working and commissioning
 Promote greater emphasis on long-term planning and funding cycles to promote better continuity in local service
development
 Allow DATs more flexibility to set local targets and develop initiatives that respond to local circumstances
 Consider a relaxation of NHS rules that require treatment monies to be spent within the year for which they are
allocated
 Provide clarity around expectations and a clear statement of the responsibilities and priorities of each Government
department
 Ensure that all new Government initiatives to strengthen and expand treatment services are properly evaluated
Reviewing the quality and range of treatment services
 Strengthen national arrangements to quantify and transmit accurate and more up-to-date local drugs data
on both prevalence and future trends
 Promote the potential benefits of the new NDTMS reporting arrangements more widely and issue guidance
on issues that lead to under-reporting
 Develop a core national database to capture information on the cost and performance of drug services more
effectively
 Address research gaps around the effectiveness of specific interventions and the treatment of non-opiate
drug problems
 Promote research findings in an accessible format that increases local understanding of what works and why
 Accumulate evidence about the cost-effectiveness of different interventions and types of service
 Consider a collaborative improvement approach to promote agreement on the best way to deliver key interventions
such as community prescribing
 Consider the development of an accreditation scheme for community drug programmes
 Strengthen the knowledge base and expertise of both commissioners and service managers through training and
development
 Promote the development of effective team working within multi-disciplinary services
 Improve workforce planning to address shortfalls in key staff and identify short-term measures to bridge any gaps
Promoting better care co-ordination and joint working
 Give clear guidance to local agencies on effective care management models, based on the outcomes of local pilot
projects and approaches adopted overseas
Improving support to primary care
 Develop an accredited qualification for those GPs who act as 'the local expert' and often lead multi-disciplinary
drug teams
 Develop an undergraduate curriculum to promote training in drug misuse in nursing, medical and pharmacy schools
 Consider the role that emerging 'nurse consultants' could play in supporting drug misusers
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I Or the Substance Misuse Intervention Branch (SMIB) in Wales
Checklist for action:
Improving the national
framework
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Main types of illicit
drugs
DRUG NAME STREET NAMES
WHAT DOES IT LOOK LIKE AND
HOW IS IT TAKEN?
Amphetamines • speed, whizz, uppers, amph, billy, sulphate • grey or white powder that can be snorted,
swallowed, smoked, injected or dissolved in a
drink
• tablets that are swallowed
Benzodiazepines • includes drugs such as Valium, Mogadon
(’moggies’) and temazepam (’mazzies’)
• tablets or capsules that are swallowed
Cannabis • marijuana, draw, blow, weed, puff, shit, hash,
ganja, spliff, wacky backy
• a solid, dark ‘resin’
• leaves, stalks and seeds (‘grass’)
• a sticky dark oil
• can be rolled (usually with tobacco) in a spliff
or joint, smoked on its own in a special pipe,
or cooked and eaten in food
Cocaine • coke, charlie, snow, C • white powder that is snorted up the nose;
sometimes dissolved and injected
Crack • rock wash, stone • small raisin-sized crystals that are smoked
Ecstasy (MDMA) • E, doves, XTC, disco biscuits, echoes, hug
drug, burgers, fantasy
• tablets of different shapes, sizes and colours
(but often white) that are swallowed
Heroin • smack, brown, horse, gear, junk, H, jack, scag • brownish-white powder that is smoked,
snorted or dissolved and injected
LSD • acid, trips, tabs, blotters, microdots, dots • ¼ inch squares of paper, often with a picture
on one side, that are swallowed. Microdots
and dots are tiny tablets
Methadone • Physeptone is the most common brand name • white crystalline powder that is dissolved in
fluid and swallowed
• also available in tablets, that can be
swallowed, or crushed and injected
• methadone in ampoule form can be injected
A P P E N D I X  2
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WHAT ARE THE EFFECTS? WHAT ARE THE RISKS?
• gives the user a ’buzz’ of extra alertness, energy and confidence • can impair judgement and concentration
• may lead to depression and anxiety after use
• long-term use places strain on the heart and can lead to mental
illness
• calms user and slows them down mentally
• relieves tension and anxiety
• high doses can make user drowsy and forgetful
• physical dependence can develop with withdrawal leading to
nausea, headaches and irritability
• overdoses can cause coma and impaired breathing
• user feels relaxed and talkative
• may bring on a craving for food (’the munchies’)
• smoking cannabis with tobacco may lead to users becoming
addicted to cigarettes
• can leave user tired and lacking energy
• can make user paranoid and anxious
• smoking joints over a long period can lead to respiratory
disorders, including lung cancer
• sense of well-being, alertness, confidence
• effects last roughly 30 minutes
• user is often left craving more
• cocaine is addictive; regular use can be expensive and hard to
control
• leaves user feeling tired and depressed for a couple of days
• can cause chest pain and heart problems that can be fatal
• crack has the same effects as cocaine, but causes a more
intense and shorter ’high’
• crack and cocaine carry the same risks, but crack use can be
even harder to control
• users experience enhanced feelings of alertness, well-being and
sociability
• sound, colour and emotions seem more intense
• users may dance for hours
• users can feel tired and depressed for days
• risks of overheating and dehydration if user dances excessively
without taking breaks or drinking enough fluids
• has been linked to liver and kidney problems
• some suggest use may be linked to brain damage, causing
depression in later life
• produces euphoria and pain relief, and gives the user a sense of
warmth and well-being
• larger doses may make the user relaxed and drowsy
• heroin is highly addictive, and requires increasing amounts to
achieve the same high
• sudden withdrawal produces symptoms of nausea, muscle
pains, diarrhoea and goose flesh
• overdose can cause coma and in some cases death
• injecting can damage veins, and sharing injecting equipment
puts users at risk of blood-borne infections
• effects (a ‘trip’) can last for 8 to 12 hours
• users will experience their environment in a different way
• objects, colours and sounds may be distorted
• users may experience a ‘bad trip’
• ‘flashbacks’ may be experienced where parts of a ‘trip’ are
re-lived some time after the event
• use can complicate mental health problems
• commonly prescribed as a substitute for heroin 
• causes a high/mood change that is less intense but longer
lasting than with heroin
• may cause drowsiness
• can cause unpleasant side effects such as itching, constipation
or reduced sexual desire
• overdose can result in over-sedation or death
• using heroin, alcohol or other sedatives on top of methadone
can easily cause overdose
• can cause vein damage if tablets or concentrated ampoules are
injected
Source: © Health Education Authority, 1998.
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Appendix 4
For most of the nineteenth century, drugs such as opium and cocaine
could be bought over the counter in local pharmacies. The first serious
restrictive framework for regulating the sale of opium and other
substances was introduced under the Poisons and Pharmacy Act 1868.
Possession of cocaine and opiates first became an offence under the
Defence of the Realm Act 1916.
Through the twentieth century most British drug law has been passed to
meet obligations arising from United Nation Conventions. For example,
the 1920 Dangerous Drugs Act was passed in order to ratify the Hague
Convention of 1912. The Convention required states to limit the
manufacture, trade and use of opiates for medical purposes; to close
opium dens; to penalise unauthorised possession of opiates; and to
prohibit their sale to unauthorised persons. The Act also placed controls
on the importation, exportation and manufacture of tincture of cannabis
and preparations containing dihydrocodeine. Between 1925 and 1967 the
Dangerous Drugs Act was amended a number of times, both to extend
the range of controlled substances and to implement Convention
protocol. 
Today, the main legislation controlling the misuse of drugs in Britain is
the Misuse of Drugs Act 1971. This replaced earlier Acts and brought all
controlled drugs under the same statutory framework. It also
incorporated: the relatively new system of licensing doctors to prescribe
heroin and cocaine to addicts; the requirement for all doctors to notify
addicts to the Home Office; regulations on the safe custody of drugs; and
national stop and search powers for the police. It also established the first
statutory advisory body, the Advisory Council on the Misuse of Drugs
(ACMD).I
The Misuse of Drugs Act 1971 divides controlled drugs into three
Classes, which are linked to maximum penalties in a descending order of
severity, from A to C. This three-tier classification was designed to make
it possible to control particular drugs according to their comparative
harmfulness, either to individuals or to society as a whole. For the offence
of possession, penalties for Class A drugs range from six months
imprisonment and/or a fine of £5,000, to 7 years in jail. For the same
offence with Class C drugs, the maximum penalty is 2 years in jail or an
unlimited fine.
I Drugs and the Law, Report of the Independent Inquiry into the Misuse of Drugs Act 1971,
The Police Foundation, 2000.
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The legal
framework
Current classifications, which incorporate changes and additions since
1971, are as follows:
• Class A includes cannabinol and cannabinol derivatives, cocaine
(including ‘crack’), dipipanone, ecstasy and related compounds,
heroin, LSD, magic mushrooms, methadone, morphine, opium,
pethidine and phenylcyclidine.
Class B drugs which are prepared for injection are classed as Class A.
• Class B includes amphetamines, barbiturates, cannabis (herbal),
cannabis (resin), codeine, dihydrocodeine and methylamphetamine.
• Class C includes anabolic steroids, benzodiazepines, buprenorphine,
diethylpropion, mazindol, pemoline and phentermine.
Between 1997 and 2000 the Police Foundation Inquiry into the Misuse of
Drugs Act 1971 reviewed current drug laws in the UK. The inquiry made
81 recommendations, including a number of proposed changes to the
classifications of drugs that they argued would better reflect up-to-date
medical and scientific knowledge. The report also recommended that the
penalties for possession of Class B and C drugs should not include prison,
and that the maximum sentence for possession of Class A drugs should be
reduced and imposed only when a community sentence and treatment
have failed or been rejected.
The Government’s official response to the Police Foundation Inquiry in
November 2000 rejected all the proposed reclassifications of drugs. The
only major recommendation of the report to be accepted was the
suggestion that charges of supplying drugs might be avoided if offenders
proved the drugs were only for use by a small group of friends. However,
in October 2001, the Home Secretary announced the reclassification of
cannabis from a Class B to a Class C drug, subject to evidence from the
Advisory Council on the Misuse of Drugs.
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Research on what
works to reduce
illegal drug
misuseI
Evaluating treatment outcomes
Any evaluation of what works in reducing illegal drug
misuse must focus on what each specified treatment is
designed to achieve. For most people presenting to a
service, tackling problem drug misuse is the main goal
and stopping or reducing use is the obvious indicator
of success (Ref. 1). There are also expectations that
treatment will lead to reductions in health problems
and improvements in the patient’s personal and social
situation. Consequently, most research studies evaluate
treatment on four problem ‘domains’:
• drug use involvement; 
• injection and sexual risk behaviours for blood-
borne infections; 
• physical and psychological health problems; and
• personal and social functioning (a broad set of
problems spanning family and relationships,
accommodation, employment, criminal
involvement and other public safety issues). 
It is important to recognise that treatment outcome
expectations and priorities may differ across
individual, family, community, service-related and
criminal justice perspectives.
The majority of people who have difficulties with their
use of illegal drugs encounter relatively mild and self-
limiting problems usually during their adolescence and
early adulthood. However, those presenting to
specialist treatment services tend to have chronic
problems in several areas and these are often
characterised by remissions and relapses. The
treatment of drug misuse can therefore be compared
with other chronic health conditions – such as adult
onset diabetes, hypertension and asthma. Treatment
outcomes for drug misuse are as good or better than
those achieved for these ‘mainstream’ debilitating
conditions (Ref. 2).
The nature of the evidence
Most of the evidence for the effectiveness of treatment
for drug misuse comes from two types of research
study:
(i) Naturalistic or ‘observational’ studies contrast
patients who access studied treatments on outcome
measures at one or more points following a
baseline intake assessment. These studies are very
useful for the evaluation of treatment systems
where patients often engage in different types of
service over time. There have been several major
multi-site studies of this kind, including the Drug
Abuse Treatment Outcome Study (DATOS) in the
United States and the National Treatment Outcome
Research study (NTORs), a cohort study of 1075
patients conducted in England and funded by the
Department of Health. These studies can show if
outcome expectations are achieved and how
changes observed vary across services and with the
amount or type of treatment that patients receive.
These research designs cannot unequivocally
attribute improvements to treatment in the absence
of a control group of patients randomly assigned to
receive no treatment. It is possible that patients
would have changed significantly over the same
period without treatment.
I This appendix is based on a review of the evidence base
commissioned by the Audit Commission. The review, undertaken
by Dr John Marsden and Dr Michael Farrell from the National
Addiction Centre, Institute of Psychiatry at the Maudsley
Hospital, focuses on research from the UK, as well as the USA,
Australia and a small number of other countries. All of the
summarised studies have been published in peer-reviewed
academic journals. References cited in this appendix are given on
pages 109–12.
(ii) Experimental, controlled trials usually involve
random assignment of patients to specific
treatment interventions and to comparison
interventions. No-treatment control conditions are
rarely used in this healthcare area. Where they are
feasible to conduct, experimental designs offer the
most convincing evidence on treatment efficacy,
but these sorts of study need to be carefully
conceived to maximise their usefulness in treatment
systems. Randomised trial studies of treatment for
young people and adults in the pharmacotherapy
and counselling arenas have been recently
commissioned in the UK.
Although much can be learned from overseas research
studies, it is sometimes difficult to judge whether the
findings can be fully applied to the UK culture and
service delivery context. There are often marked
differences in the types of people who take part in
outcome studies and the structure and operation of
the services studied.
The effectiveness of key treatment
interventions
In the UK, there are four main types of treatment for
drug misuse:
• inpatient programmes;
• community prescribing;
• care planned counselling, including structured day
programmes; and
• residential rehabilitation.
The characteristics and evidence base for each of these
interventions are summarised below.
Inpatient programmes 
Currently, most UK inpatient programmes care for
patients who are primarily dependent on heroin, and
many also have concurrent problems with use of
psychostimulants and benzodiazepines. The main goal
of hospital inpatient programmes is to help the patient
detoxify in as safe and as comfortable a manner as
possible. For heroin there is a choice from several
medications, including methadone, buprenorphine and
other drugs such as lofexidine or clonidine. On its
own, the detoxification phase of treatment may not be
effective in helping patients achieve lasting recovery.
Rather, detoxification is better seen as an important
first phase of those treatment programmes aimed at
abstinence (Ref. 3).
Completion of detoxification in an inpatient setting is
the main outcome indicator. Average completion rates
are generally good, being 75 per cent when
methadone is used, and 72 per cent when using non-
opioid drugs (mainly lofexidine) (Ref. 4). While
methadone remains the most commonly used
withdrawal medication, several randomised controlled
trials have contrasted between buprenorphine and
clonidine. These suggest that buprenorphine is better
at reducing the severity of withdrawal symptoms and
leads to fewer adverse effects (Ref. 5).
There is evidence that patient treatment acceptability,
completion and post-discharge outcomes are better
among those treated in specialist rather than general
psychiatry inpatient settings (Ref. 6). NTORs has
reported on the follow-up outcomes from inpatient
treatment in a sample of 95 patients interviewed six
months after discharge. The proportion using heroin
dropped from 70 per cent at intake to 40 per cent at
follow-up, while injecting reduced from 66 per cent to
39 per cent (Ref. 7). These improvements were
maintained at a one-year follow-up (Ref. 8).
Community prescribing
Two broad types of community substitution
prescribing programme are available for heroin users.
In maintenance programmes, a substitute (usually oral
methadone) is administered at a suitable and stable
level for a period of several months and sometimes
years. In reduction programmes, patients are first
stabilised on the substitute and then gradually
withdrawn over a period ranging from several weeks
to many months. Internationally, there is a well-
established research and clinical evidence-base for oral
methadone maintenance treatment (MMT). On
average, patients report a substantial reduction in
heroin use and improvements across the four problem
domains (Refs. 9, 10). NTORs results at six months, one
year and two years describe sustained patient
improvements across these follow-up points
(Refs. 7, 12, 13). At four to five year follow-up, 35 per
cent of the NTORs participants who had entered
methadone treatment reported being abstinent from
heroin (Ref. 14). Several studies have shown a dose
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response effect in MMT, with patients receiving doses
at 50mg per day and above being more likely to be
retained in treatment and less likely to continue to use
heroin (Refs. 15, 16, 17).
Outside of the specialist clinics, NTORs has also
reported on six-month follow-up outcomes for 155
patients treated in seven primary healthcare settings
(of which five had shared care arrangements with
specialist services). These GP-treated patients were
contrasted with a cohort of 297 patients treated in
specialist services and achieved comparable
improvements (Ref. 18).
Buprenorphine maintenance is generally as effective as
methadone maintenance in reducing illegal heroin use
and retaining patients in treatment, and also has a
better safety profile in overdose (Refs. 19, 20, 21). Further
research and development work may be needed in the
UK to assess the patient groups and delivery
arrangements best suited to buprenorphine
maintenance. Levo alpha acetyl methadol (LAAM), a
longer acting form of methadone, has currently been
withdrawn in Europe due to concern about
cardiovascular complications.
Since methadone reduction treatment programmes in
the UK contain a stabilisation or maintenance phase
prior to dose reduction, researchers have evaluated
outcomes using the same criteria as for MMT. In the
US, studies of shorter-term reduction programmes
have generally been negative, reporting high patient
attrition and poor rates of abstinence (Ref. 22). NTORs
has reported on the two-year follow-up outcomes
from reduction programmes. On average, patients
reported using heroin on 23 days in the previous three
months at this point (a reduction of 61 per cent on
pre-admission levels) (Ref. 12). However, the reduction
services had poorer retention rates than the MMT
programmes although this was still at reasonable
levels, with half of the patients sampled still receiving
a reduction programme after one year, and almost a
third remaining in treatment after two years. While
this suggests good retention, the study highlights a
need to review the operational goals and clinical
practices of UK reduction prescribing.
Other forms of community prescribing include: 
• Relapse prevention prescribing
Drugs such as naltrexone may be used to speed up
withdrawal and can help patients avoid relapse after
detoxification. A single maintenance dose of
naltrexone blocks the effects of any heroin taken for
the next day and this may also reduce heroin cravings.
However, the evaluation literature points to
considerable problems with naltrexone compliance
and high levels of patient dropout (Ref. 23). A recent
review of 11 evaluations noted that in four studies
only 3–49 per cent of subjects actually commenced
treatment. In a further five studies, 23–58 per cent of
participants left within the first week, and in another
four studies 39–74 per cent of participants left
treatment by the end of the second week (Ref. 24).
Collectively, patient retention in treatment varied from
43–240 days. However, among highly motivated or
compliant patients, naltrexone effectiveness is
generally high, suggesting a patient-treatment
assessment and matching effect (Refs. 25, 26).
• Community detoxification
In contrast to inpatient treatment, average completion
rates for community detoxification treatment are less
impressive, being 35 per cent for tapered methadone,
and 53 per cent for other drugs, such as lofexidine
(Ref. 3). The reason for lower performance appears to
be due to patients being unable to endure withdrawal
symptoms or losing their resolve to continue with
detoxification. This does not mean that all heroin
dependent patients seeking detoxification should be
treated in an inpatient programme, as there is some
evidence that patients with a stable, supportive home
environment are able to succeed in community settings
(Ref. 27). However, the literature points to a
considerable need to strengthen support and aftercare
arrangements for community detoxification services.
Care planned counselling
Most UK counsellors working with drug misusers
follow a client-centred, cognitive behavioural
framework. Treatment goals tend to be individually
determined and are developed from a motivational
interviewing style intended to help the patient to
increase understanding of their drug use behaviour
and encourage changes in harmful drug taking
patterns.
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Care planned counselling services usually offer a
planned programme of individual psychotherapy, with
treatment varying in duration from a few sessions to
several months. In some parts of the UK, structured
day programmes have been established that provide
fairly intensive individual and sometimes group
counselling. Patients may attend four or five days a
week, for several hours each day and for between two
and eight weeks. To date, there have been no
observational or experimental studies of counselling
and structured day services published in the UK.
However, there is a substantial international literature
on counselling and psychotherapy approaches in drug
misuse treatment and this has relevance for the
delivery of counselling programmes in this country. 
There is some outcome evidence for the impact of
motivational interviewing with drug users (Ref. 28).
Positive evaluations of interpersonal problem solving
approaches have also been reported (Refs. 29, 30). In the
US, brief and intensive cognitive behavioural coping
skills treatments have achieved positive results for
adults with cocaine dependence, as have behavioural
psychotherapies which use contingency reinforcement
methods to help patients maintain abstinence
(Refs. 31, 32, 33, 34).
Generalised counselling has been evaluated in a
variety of studies and as part of the US multi-site
observation studies. Results suggest that abstinence-
based counselling is associated with reductions in drug
use and crime involvement and improvements in
health and well-being (Refs. 36, 37). In DATOS, for
example, weekly or more frequent cocaine use among
patients attending outpatient drug-free counselling
services reduced from 41–18 per cent at one-year
follow-up while weekly heroin use fell from 6 to 3 per
cent (Ref. 38).
Residential rehabilitation
While the origins and underlying philosophy of
residential rehabilitation services differ, these services
share common features, including: communal living
with other drug users in recovery; group and
individual relapse prevention counselling; individual
key working; improved skills for daily living; training
and vocational experience; housing and resettlement
services, and aftercare support. Programmes can be
grouped by duration: short-term residential (STR)
programmes include a detoxification programme as
the first stage of a programme that lasts for six to 12
weeks; long-term residential (LTR) programmes
generally do not provide medically supervised
withdrawal and last for 12–52 weeks.
Residential rehabilitation programmes have been
evaluated in terms of completion rates and reductions
across the four problem domains. There is a strong
body of international research showing good
outcomes for patients treated (Refs. 39, 40, 41). However,
early drop-out appears to be a problem and studies
commonly show that 25 per cent of patients leave
within two weeks and 40 per cent by three months
(Ref. 42).
NTORs has reported on one-year follow-up outcomes
from patients admitted to 4 STR and 12 LTR
programmes. Reductions in rates of illegal drug use
between the 90 days before intake and follow-up were
as follows: heroin (75–50 per cent); crack cocaine
(37–18 per cent); other stimulants (71–32 per cent)
and benzodiazepines (57–28 per cent) (Ref. 43). Some 38
per cent of the patients treated in residential
programmes were abstinent from illegal drugs at 4–5
year follow-up and 47 per cent were abstinent from
heroin (Ref. 13).
Factors influencing treatment
effectiveness
Although the evidence base suggests that a wide range
of treatments can be effective, there is often
substantial variability in the outcomes achieved by
different patients. A number of factors may account
for this:
• Programme variation
Treatment agencies operating within the same
modality can vary quite widely in their operating
characteristics and specific therapeutic methods and
support services used (Refs. 44, 45). Treatment agencies
operating programmes of the same modality are not
equally effective and multi-site evaluations of
methadone prescribing, for example, have pointed to
marked differences in effectiveness in heroin use
outcomes between agencies (Refs. 15, 59). These
differences are likely to arise from a complex
interaction of patient differences and operational
efficiency and quality aspects of the programme itself.
For methadone prescribing, for example, the most
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effective types of programme use substitution
prescribing as a platform to deliver individual or
group counselling together with the provision of
medical and other support services (Ref. 46).
• Mental health problems
Many problem drug misusers have co-existing mental
health problems, including anxiety, affective, anti-
social and other personality disorders (Refs. 47, 48). For
example, many patients in NTORs had high levels of
psychological health problems at intake to treatment,
including thoughts of suicide (Ref. 49). While reports of
psychological symptoms were reduced at 1, 2 and 4–5
year follow-up, other studies have shown that those
who enter treatment with formal psychiatric disorders
are more likely to have poorer outcomes (Refs. 13, 50, 51).
Special assessment and care management
arrangements are required for these patients.
• Treatment motivation and therapeutic relationships
Several studies have looked at the extent of patients’
motivation and degree of engagement in treatment
(Refs. 52, 53). For example, patients who engage early
with LTR, community prescribing or community
counselling stay longer in treatment (Ref. 54). These
findings are supported by work that suggests that
improved outcome is generated by counsellors who
have strong interpersonal and organisational skills, see
their patients more frequently, refer to ancillary
services as needed and generally establish a practical
‘therapeutic alliance’ with their patients (Refs. 55, 56).
• Treatment duration
Longer stays in maintenance, rehabilitation and
counselling treatment are related to better outcomes
and retention is a fairly reliable proxy measure of
success for most programmes (Ref. 57). NTORs has
identified various ‘critical times’ for residential
treatment that are associated with increased levels of
abstinence from heroin at one-year follow-up. These
are 28 days for inpatient and STR programmes, and
90 days for LTR programmes (Ref. 41). A treatment
duration effect has also been identified for inpatient
and community detoxification programmes. When
detoxification extends for more than 21 days, the
mean completion rate is 31 per cent, compared to 58
per cent for treatment completed in 21 days or less
(Ref. 3).
• Social and environmental factors
Effective treatment must attend to a patient’s multiple
needs, including related social, vocational and legal
problems. Studies have shown that treatment benefits
can diminish rapidly if the patient has poor social and
familial supports (Refs. 58, 59). Social supports and
stresses should be an integral part of the assessment
process and programmes that seek to improve
patients’ integration and stability, address life
problems, family relationships and personal resources
will be valuable. 
Other issues
Economic evaluations 
Economic evaluations examine whether the
investment of treatment resources is effective in
tackling problems across the four problem domains
(Ref. 60). Studies that have looked at changes in crime
(largely acquisitive or property oriented) during and
after a treatment episode have pointed to reductions
in victim costs to individuals, retailers and insurers
(Refs. 61, 62, 63). Economic analyses in NTORs have
focused on the overall costs of providing treatment in
relation to the costs due to crime within the cohort.
Reductions in criminal behaviour at one year
represented cost savings worth around £5.2 million to
victims and the criminal justice system, leading to the
conclusion that for every extra £1 spent on treatment
there is a return of more than £3 in terms of cost
savings to victims and the criminal justice system
(Ref. 64). The impressive crime-related benefits of long-
term residential rehabilitation and outpatient drug-
free treatments for cocaine dependence have also been
reported by DATOS (Ref. 65).
Crime issues and treatment in the justice
system
In the NTORs cohort, 50 per cent of patients had
committed some form of acquisitive crime
(shoplifting, fraud, robbery or other theft) in the three
months before intake and a minority engaged
repeatedly in criminal behaviour to fund their habit.
There is now a substantial investment of resources in
the UK to tackle the problem in the criminal justice
system (Ref. 66). The research literature indicates that
drug users within the criminal justice system who are
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coerced into treatment achieve the same outcomes as
those seeking treatment on a voluntary basis
(Refs. 67, 68).
In terms of crime outcomes, US evaluations of drug
courts (which involve prison diversion through
mandatory treatment) and in-prison treatment suggest
that participants report more reduced drug use than
comparison groups (Refs. 69, 70, 71). Follow-up
assessments in NTORs showed a reduction of 67 per
cent in the number of crimes committed reported at 1
year and a maintenance of this effect at 2 and 4–5
year follow-ups (Refs. 72, 73). In the UK, there have been
no published outcome evaluations of specific criminal
justice referral and treatment interventions in peer-
reviewed journals, although outcome evaluations are
now in progress. 
HIV and AIDS
The sharing of injecting equipment is the main cause
of the HIV epidemic amongst drug injectors. Drug
treatment generally, and substitute prescribing in
particular, have been shown to be highly effective in
encouraging patients to change their injecting
behaviour and avoid or cease sharing injecting
equipment (Refs. 74, 75). The international research
evidence shows that on average MMT achieves
reductions in injecting behaviour and the sharing of
contaminated injecting equipment, and may reduce
the incidence of unprotected sexual activity (Ref. 76, 9).
NTORs has reported improvements in sharing of
needles and syringes and improvements in injecting in
several reports for inpatient, residential and
methadone prescribing programmes. At six-month
follow-up, there was a 40 per cent reduction in the
proportion of patients injecting and a 68 per cent
reduction in sharing (Ref. 6). Rates of injecting and
sharing remained low across the five-year follow-up
period. Injecting fell from 60 per cent at intake to 37
per cent at 4–5 years while the rate of sharing fell
from 14 to 5 per cent (Ref. 13).
Summary
There is a considerable international literature on the
effectiveness of treatment for illegal drug misuse
problems and a growing domestic evidence base for
the impact of community prescribing treatments and
residential care. But the picture is far from complete.
The impact of structured community counselling
programmes and the impact of psychotherapy and
counselling generally require further study in the
context of treatment service delivery in the UK. There
should be much to be gained from the detailed study
of links between programme variation factors and
patient outcome. There is also a growing need to
focus on the impact of treatment for specific
population groups, including younger people, people
with psychiatric co-morbidity and people within the
criminal justice system.
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Abstinence In absolute terms, abstinence refers to the complete absence of drug use,
including alcohol, tobacco, and medically prescribed medicines. More
pragmatically, heroin misusers may be considered to have achieved
abstinence if they have ceased all opioid drug use. 
Advisory Council on The Advisory Council on the Misuse of Drugs (ACMD) was set up under
the Misuse of Drugs Act 1971 to advise Government on all aspects of
drug misuse.
Its terms of reference are: 
‘to keep under review the situation in the United Kingdom with respect to
drugs which are being or appear to them likely to be misused and of
which the misuse is having or appears to them capable of having harmful
effects sufficient to constitute a social problem’.
Addiction See drug dependence.
Christian-based programmes These residential programmes either require clients to follow the Christian
faith, or use Christian teachings solely to motivate staff.
Complementary therapies A range of alternative medicine techniques are used in the treatment of
drug dependency. For example, auricular acupuncture (in the ear) is
believed by some to relieve cravings for crack.
Controlled drugs In the UK, controlled drugs are preparations subject to the requirements
of the Misuse of Drugs Regulations 1985. The regulations divide drugs
into five schedules, and for each of these covers import, export,
production, supply, possession, prescribing, and appropriate record
keeping.
Detoxification The way in which a drug such as heroin is eliminated from the drug user’s
body, often with the help of a doctor and/or specialist drug worker. This
is often a gradual process, and can involve the use of other drugs (e.g.
methadone) to help deal with withdrawal symptoms. 
Drop in A service, or part of a service, offering open access for drug misusers.
Typically, potential clients may receive initial help and advice without an
appointment.
Drug dependence Drug dependence is defined by the WHO (1993) as ‘a cluster of
physiological, behavioural and cognitive phenomena of variable intensity,
in which the use of a psychoactive drug (or drugs) takes on a high
priority’. The state is characterised by a ‘preoccupation with a desire to
obtain and take the drug and persistent drug seeking behaviour.
Determinants and the problematic consequences of drug dependence may
be biological, psychological or social and usually interact’. The degree of
psychological dependence may be approximated to the amount of
negative effect experienced in the absence of the desired drug.
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Glossary
the Misuse of Drugs
Repeated use of some drugs (for example, opioids) leads to physiological
changes in the drug taker, such that when the drug is not present a range
of physiological withdrawal symptoms result. These are rapidly relieved
by further use of the drug. This physical dependence is broadly equivalent
to ‘addiction’. Not all drug users are drug dependent.
Drug Dependency Unit Clinical teams, mostly consultant psychiatrist-led, that are able to offer
treatment to particularly complex or difficult cases. Many DDUs run
outpatient services and day programmes, and have access to specialist
hospital inpatient beds.
Drug misuse/abuse Drug use that is hazardous or harmful; often used to denote all illicit drug
taking, reflecting the legal problems users may incur.
Drug offence Offence involving controlled drugs. Offences under the Misuse of Drugs
Act 1971 include unlawful possession, unlawful production, unlawful
supply, possession with intent to supply unlawfully and permitting
premises to be used for unlawful purposes. Unlawful import or export of
controlled drugs are offences under the Customs and Excise Management
Act 1979.
Dual diagnosis This refers to co-existing diagnoses of mental illness and substance use.
Harm reduction/ Harm reduction initiatives concentrate on trying to reduce the harm that
people do to themselves, or other people, through their drug use (for
example, syringe exchange schemes).
Low threshold Low threshold refers to services or types of treatment that are relatively
easy to access, and require little commitment from the user (for example,
syringe exchange).
Methadone leakage The diversion of prescribed methadone into the illicit market.
Methadone maintenance The long term prescribing of methadone to heroin users to maximise
stability and encourage harm reduction. In the UK, some specialists view
a maintenance programme as a stage towards gradual reduction and
eventual abstinence.
Methadone reduction The prescribing of methadone to opiate users to control withdrawal
symptoms. The aim is to gradually reduce the quantity prescribed until
the user experiences no withdrawal complaints and is drug free. The
degree of reduction and length of time afforded to achieve abstinence can
vary greatly, depending on the requirements of the individual.
Naltrexone Naltrexone is a drug that blocks the effects of heroin and other opioids
by blocking the opioid receptors in the brain. It is used following
detoxification so that recovering patients know they will be unable to
achieve any ‘high’, even if they take heroin. 
Opiate/opioid Opiates are drugs derived from the opium poppy, and are known as
narcotic analgesics (for example, heroin, morphine and codeine). Opioid
is a generic term for the many synthetically produced narcotic analgesic
drugs (for example, methadone, pethidine, dihydrocodeine), but is
commonly used to refer to all narcotic analgesics.
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(DDUs)
minimisation
programme
programme
Outcome funding Grant funding where the funding is contingent upon specifically defined
targets and outcomes being met within a certain period. These would be
agreed by the agency and the funder, with regular monitoring of progress.
Outreach Services that target individuals and groups that are under-represented in
treatment either because they do not seek, or do not gain easy access to,
treatment.
Overdose Overdose refers to the use of any drug in such quantities that acute
adverse physical or mental effects occur. Overdose may result in death,
for example through heart, liver or respiratory failure.
Polydrug use Polydrug use describes drug misuse where two or more drugs are taken
concurrently. There is often a primary drug of use, with others taken less
frequently or in smaller quantities. Most problem drug misusers show
some degree of polydrug use.
Psychosis Drug misuse can result in the user experiencing a psychotic episode.
Psychosis can include a variety of symptoms, for example sensory
hallucinations, delusions or paranoia.
Psychosocial treatment Treatment techniques based on psychological and social principles and
functioning (for example, motivational interviewing, relationship
counselling).
Recreational drug use Drug use on an occasional and infrequent basis, often of cannabis, ecstasy
and amphetamines, as part of social recreation. The link between
recreational and problem drug misuse is unclear.
Rehabilitation Establishing a state in which individuals are physically, psychologically
and socially capable of coping with situations encountered, and able to
take advantage of opportunities that are available to other people in the
same age group in society.
Relapse prevention Relapse prevention programmes may be offered to drug users who have
completed detoxification. Issues addressed might include the recognition
of potential relapse situations, communication skills, job support,
relationship management, and assertiveness.
Risk behaviour Behaviour which carries significant health, social and legal risks. For
example, injecting a drug into veins carries risks beyond those of the
effect of the drug itself: local infection, tissue damage, etc.
Structured daycare Community-based structured programmes, which may include activities
such as one-to-one counselling, group therapy, relapse prevention,
workshops, lectures and seminars. Structured day care is usually designed
for people who have completed detoxification, as an aid to recovery and
rehabilitation into the community. Programmes often require participants
to be abstinent.
Structured methadone A pre-determined structure and plan of methadone dispensing coupled
with psychosocial interventions, regular testing, and frequent monitoring.
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Substitute prescribing The use of a drug substitute for a drug of dependence (for example, of
oral methadone for illegal heroin). The substitute will be legal, safer and
easier to manage clinically in effective treatment.
Supervised consumption The supervised consumption of methadone, by a pharmacist or
appropriate professional, is designed to ensure both that the patient
receives the correct dose and that the drug is not diverted onto the illegal
market.
Supported Arrangements whereby support is made available to vulnerable people, to
help them to continue living independently in the community. In the case
of an individual with drug misuse problems, the role of the support
worker might be to ensure the person retains a level of stability in day-to-
day living, including attendance at rehabilitation programmes. These
services may be provided alongside a more intensive programme of
rehabilitation or medication.
Therapeutic Communities (TCs) Residents of TCs are encouraged to support and constructively confront
each other in order to bring about behavioural change. Clients will also
engage in individual development, and may earn additional privileges
during their stay.
Twelve-step model Programmes of 12 steps can be used to aid recovery from addiction, and
are based upon the principles of Narcotics Anonymous (NA). Problem
drug misuse is viewed as a disease from which only incremental
improvements or ‘steps’ can be made, with abstinence being the ultimate
aim.
Withdrawal The body’s reaction to the absence of a drug to which the user has
become physically dependent.
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Box O (p71)
Medical practitioners, levels of
expertise Box K (p54)
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The Audit Commission has produced a number of reports covering
related issues.
Acute Hospitals Portfolio: Review
of National Findings for Accident
and Emergency
The second report in the Acute Hospital
Portfolio series reviews the national
findings of the Audit Commission's survey
on A&E services. It compares waiting times
across departments and against national
standards. It also examines the workloads
of nurses and doctors.
Contents:
Background; Measures of waiting time;
Waiting times between departments; The
trend in waiting times since 1996; Size of
department and geographical location;
Numbers of doctors and nurses; Measures
of quality of care; Availability of good
information to measure performance;
Conclusions
2001, ISBN 1862403090, Stock code HNR1877, £10
Hidden Talents: Education, Training
and Development for Healthcare
Staff in NHS Trusts
This report explores methods that trusts
can adopt to help them to proactively
manage education, training and
development for their staff, from creating
an organisation-wide training and learning
culture, through to setting up effective
support systems to make it a reality. The
study focuses on nurses, midwives, health
visitors, allied health professions, scientific
and technical staff and healthcare staff
without a professional qualification.
Contents:
Getting the best from training and
development; Identifying training needs;
Access to education, training and
development; Improving access; The way
forward.
2001, ISBN1862402701, Stock code HNR1519. £20
Misspent Youth: Young People and
Crime
With two out of every five offenders in
1994 being under 21, the subject of this
study is high on the public agenda.
Misspent Youth explores how effectively
£1 billion a year is distributed between
the police, youth justice services,
probation, legal aid, the Crown
Prosecution Service, youth court, crown
court and the prison service, and considers
how resources might be better used to
reduce offending. Useful for all those
involved in the area, including researchers
and students, this report is on the Open
University course reading list.
Contents:
Introduction; Tackling offending
behaviour; Preventing youth crime;
Developing a strategy; Appendices.
National Report, 1996, ISBN 1862400075, £20,
stock code LNR1172
Summary, 1996, ISBN 1862400067, £8,
stock code LEB1173
Misspent Youth 99: The challenge
for youth justice
This update reports on the results of an
audit exercise that took place in the
second half of 1998 in Wales and England,
which assessed improvements in local
criminal justice agencies and the progress
that has yet to be achieved.
Contents:
Introduction; The time taken for the
criminal justice process; Addressing
offending behaviour; Recommendations.
1999, ISBN 1862401586, £10, stock code LUP1331
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Audit Commission Publications, PO Box 99, Wetherby LS23 7JA
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1 Vincent Square, London SW1P 2PN
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Over the last 20 years, drug misuse has increased and become
more closely associated with social disadvantage. The impact
of drug problems often spreads to local communities who
face a rise in anti-social behaviour, crime and family
breakdown. Policing drug misuse and supporting those
affected by a drug habit also places additional burdens on
taxpayers, with recent estimates putting the cost to the public
purse at between £3-4 billion a year.
Drug treatment services can help drug misusers to overcome
their problems and Government policy recognises that caring
for this group should be a priority. But the uneven availability
of different types of treatment and lengthy delays often
make it hard for drug misusers to get the help they need,
when they need it. Many drug misusers also have multiple
problems, but poor co-ordination between different services
offers little guarantee that their care will be managed in a
'seamless' way. And lack of support for those completing
treatment increases the risk that people will resume their
habit and re-enter services a number of times.
Changing Habits makes a number of recommendations for
improving services at a local level, highlighting both good
practice and problems with current service delivery. It also
identifies the steps that central government could take to
strengthen the national framework of policy guidance and
performance monitoring. With drug treatment high on the
political agenda, the report is essential reading for all those
involved in the commissioning and delivery of drug treatment
services.
